<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Antibiotics (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Antibiotics (Basel)</journal-id><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title>Antibiotics</journal-title></journal-title-group><issn pub-type="epub">2079-6382</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27025527</article-id><article-id pub-id-type="pmc">4810414</article-id><article-id pub-id-type="doi">10.3390/antibiotics5010012</article-id><article-id pub-id-type="publisher-id">antibiotics-05-00012</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Glycosyltransferases and Transpeptidases/Penicillin-Binding Proteins: Valuable Targets for New Antibacterials</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sauvage</surname><given-names>Eric</given-names></name><xref ref-type="author-notes" rid="fn1-antibiotics-05-00012">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Terrak</surname><given-names>Mohammed</given-names></name><xref rid="c1-antibiotics-05-00012" ref-type="corresp">*</xref><xref ref-type="author-notes" rid="fn1-antibiotics-05-00012">&#x02020;</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Vollmer</surname><given-names>Waldemar</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-antibiotics-05-00012">Centre d&#x02019;Ing&#x000e9;nierie des Prot&#x000e9;ines, University of Li&#x000e8;ge, B6a, Quartier Agora, all&#x000e9;e du six Ao&#x000fb;t 11, 4000 Li&#x000e8;ge 1, Belgium; <email>eric.sauvage@ulg.ac.be</email></aff><author-notes><corresp id="c1-antibiotics-05-00012"><label>*</label>Correspondence: <email>mterrak@ulg.ac.be</email>; Tel.: +33-4366-3332; Fax: +33-4366-3364</corresp><fn id="fn1-antibiotics-05-00012"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>17</day><month>2</month><year>2016</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2016</year></pub-date><volume>5</volume><issue>1</issue><elocation-id>12</elocation-id><history><date date-type="received"><day>22</day><month>12</month><year>2015</year></date><date date-type="accepted"><day>03</day><month>2</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2016 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement><copyright-year>2016</copyright-year><license><license-p><!--CREATIVE COMMONS-->This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Peptidoglycan (PG) is an essential macromolecular sacculus surrounding most bacteria. It is assembled by the glycosyltransferase (GT) and transpeptidase (TP) activities of multimodular penicillin-binding proteins (PBPs) within multiprotein complex machineries. Both activities are essential for the synthesis of a functional stress-bearing PG shell. Although good progress has been made in terms of the functional and structural understanding of GT, finding a clinically useful antibiotic against them has been challenging until now. In contrast, the TP/PBP module has been successfully targeted by &#x003b2;-lactam derivatives, but the extensive use of these antibiotics has selected resistant bacterial strains that employ a wide variety of mechanisms to escape the lethal action of these antibiotics. In addition to traditional &#x003b2;-lactams, other classes of molecules (non-&#x003b2;-lactams) that inhibit PBPs are now emerging, opening new perspectives for tackling the resistance problem while taking advantage of these valuable targets, for which a wealth of structural and functional knowledge has been accumulated. The overall evidence shows that PBPs are part of multiprotein machineries whose activities are modulated by cofactors. Perturbation of these systems could lead to lethal effects. Developing screening strategies to take advantage of these mechanisms could lead to new inhibitors of PG assembly. In this paper, we present a general background on the GTs and TPs/PBPs, a survey of recent issues of bacterial resistance and a review of recent works describing new inhibitors of these enzymes.</p></abstract><kwd-group><kwd>peptidoglycan</kwd><kwd>glycosyltransferase</kwd><kwd>transpeptidase</kwd><kwd>penicillin-binding proteins</kwd><kwd>&#x003b2;-lactam</kwd><kwd>lipid II</kwd><kwd>antibiotics resistance</kwd></kwd-group></article-meta></front><body><sec id="sec1-antibiotics-05-00012"><title>1. Introduction</title><p>Peptidoglycan (PG) is an essential macromolecular sacculus surrounding most bacteria. PG determines the bacterium cell shape and provides protection from rupture under the high cytoplasmic osmotic pressure [<xref rid="B1-antibiotics-05-00012" ref-type="bibr">1</xref>]. The PG structure consists of glycan strands made of alternating &#x003b2;-1,4-linked <italic>N</italic>-acetylglucosamine (GlcNAc) and <italic>N</italic>-acetylmuramic acid (MurNAc) residues cross-linked by peptides [<xref rid="B1-antibiotics-05-00012" ref-type="bibr">1</xref>]. Nascent glycan strands are first polymerized by the glycosyltransferases (GTs) using the lipid II precursor (undecaprenyl-pyrophosphoryl-MurNAc-(pentapeptide)-GlcNAc) as a substrate [<xref rid="B2-antibiotics-05-00012" ref-type="bibr">2</xref>,<xref rid="B3-antibiotics-05-00012" ref-type="bibr">3</xref>], and cross-linked between them and with the pre-existing cell wall by the penicillin-binding proteins (PBPs)/transpeptidases (TPs) (<xref ref-type="fig" rid="antibiotics-05-00012-f001">Figure 1</xref>) [<xref rid="B4-antibiotics-05-00012" ref-type="bibr">4</xref>,<xref rid="B5-antibiotics-05-00012" ref-type="bibr">5</xref>]. The activities and regulation of GTs and TPs are coupled to provide a concerted knitting and enlargement of the PG sacculus [<xref rid="B6-antibiotics-05-00012" ref-type="bibr">6</xref>,<xref rid="B7-antibiotics-05-00012" ref-type="bibr">7</xref>,<xref rid="B8-antibiotics-05-00012" ref-type="bibr">8</xref>,<xref rid="B9-antibiotics-05-00012" ref-type="bibr">9</xref>,<xref rid="B10-antibiotics-05-00012" ref-type="bibr">10</xref>].</p><p>Most of the steps in the PG biosynthesis pathway (from uridine diphosphate (UDP)-GlcNAc to the polymeric sacculus) are essential and some of them have been exploited as antibacterial targets [<xref rid="B11-antibiotics-05-00012" ref-type="bibr">11</xref>], but the most successful of all and the most extensively targeted are the PBPs [<xref rid="B4-antibiotics-05-00012" ref-type="bibr">4</xref>], named after the &#x0201c;miraculous&#x0201d; penicillin antibiotic that inactivates these enzymes. Since the discovery of penicillin and its wide utilization in medicine in the 1940s, several new classes and generations of related &#x003b2;-lactam antibiotics have been developed to successfully fight the emerging resistant strains. However, the widespread resistance to most &#x003b2;-lactams, particularly that mediated by &#x003b2;-lactamases, limits their efficacy unless they are used in combination with &#x003b2;-lactamase inhibitors, the most recent of which are mostly non-&#x003b2;-lactams [<xref rid="B12-antibiotics-05-00012" ref-type="bibr">12</xref>,<xref rid="B13-antibiotics-05-00012" ref-type="bibr">13</xref>]. Resistance affects all antibiotic classes, and the emergence of multidrug resistant bacteria (MDR) has become a major public health crisis worldwide [<xref rid="B14-antibiotics-05-00012" ref-type="bibr">14</xref>]; therefore, the battle against MDR strains is a continuous endeavor that should explore all the present possibilities and develop new ones in order to identify new antibiotic classes with low resistance potential.</p><p>In addition to penicillin, several other antibiotics (glycopetides, lactibiotics, <italic>etc.</italic>) inhibit the last stage of peptidoglycan polymerization (GT and TP) by binding to the lipid II substrate, the last monomeric precursor of the peptidoglycan polymer, and preventing its use by the polymerases [<xref rid="B15-antibiotics-05-00012" ref-type="bibr">15</xref>,<xref rid="B16-antibiotics-05-00012" ref-type="bibr">16</xref>,<xref rid="B17-antibiotics-05-00012" ref-type="bibr">17</xref>]. More recently, a newly discovered natural product, teixobactin, isolated from an uncultured soil microorganism (related to <italic>Aquabacteria</italic>), was found to inhibit cell wall synthesis by binding to the cell wall precursors lipid II and lipid III [<xref rid="B18-antibiotics-05-00012" ref-type="bibr">18</xref>]. This mode of action will not be discussed further in this review and we refer the reader to recent reviews on the subject [<xref rid="B15-antibiotics-05-00012" ref-type="bibr">15</xref>,<xref rid="B17-antibiotics-05-00012" ref-type="bibr">17</xref>]. The examples cited here show that targeting PG synthesis by various modes of action is often used by microbes in the environment, and demonstrates once again that natural products are our best source of antibiotics [<xref rid="B19-antibiotics-05-00012" ref-type="bibr">19</xref>]. Only a small portion of the microorganisms have been isolated, showing their huge potential as a natural product reservoir whose analysis through innovative techniques has just begun [<xref rid="B18-antibiotics-05-00012" ref-type="bibr">18</xref>,<xref rid="B20-antibiotics-05-00012" ref-type="bibr">20</xref>].</p><p>A deep knowledge of peptidoglycan metabolism, particularly networks decryption, a better characterization of all the potential targets involved, and the use of this knowledge to develop innovative screening assays, not only based on the inhibition of the enzymatic activity of the PBPs and other enzymes but also on the targeting of regulatory mechanisms, protein-protein interactions and the lipid II substrate, could lead to the new generation of antibacterial agents with novel mechanisms of action. PG synthases (GTs and TPs) are central to the complex networks of PG synthesis machineries (elongasome and divisome). Inhibition of the late stage of PG polymerization (GT-TP) has the advantage that the target is located outside the cytoplasmic membrane and therefore is more easily accessible to antibacterial agents, particularly in Gram-positive bacteria; the structures of PG and the enzymes involved in its synthesis are unique to bacteria and this lowers the incidence of unwanted side effects on eukaryotic cells. This review is focused on recent progress in the characterization and targeting of the GT and TP activities of PBPs via direct interaction with their active sites rather than their substrate and emphasizes their great potential for the future of antibiotic discovery.</p></sec><sec id="sec2-antibiotics-05-00012"><title>2. Penicillin-Binding Proteins: Classification, Structure and Function</title><p>With the exception of bacteria lacking peptidoglycan (<italic>Mollicutes, Dehalococcoides, Rickettsia</italic>), which are also deprived of PBPs, and the particular case of <italic>Chlamydiae</italic>, which lack class A PBPs but contain a ring-like structure of peptidoglycan instead of the characteristic sacculus [<xref rid="B21-antibiotics-05-00012" ref-type="bibr">21</xref>,<xref rid="B22-antibiotics-05-00012" ref-type="bibr">22</xref>], all bacteria possess at least one PBP of each class and, in general, the PBP content correlates with bacterial morphology and cell cycle [<xref rid="B23-antibiotics-05-00012" ref-type="bibr">23</xref>]. Gram-negative cocci (e.g., <italic>Neisseria</italic>) generally have only one PG-synthesizing machinery, called the divisome, which is active at the septum. Gram-negative rod-shaped bacteria have a second PG-synthesizing machinery active during the elongation phase, and thus possess at least two class A and two class B PBPs. More complex situations exist in Gram-positive bacteria where the various forms of life may require additional PBPs. In major pathogenic Gram-positive bacteria (<italic>Staphylococcus aureus</italic>, <italic>Streptococcus pneumoniae</italic> and Enterococci) the occurrence of acquired or endogenous PBPs, very weakly sensitive to &#x003b2;-lactam antibiotics while maintaining functional transpeptidase activity in the presence of the antibiotic <italic>in vivo</italic>, confer to the bacterium a high level of resistance [<xref rid="B24-antibiotics-05-00012" ref-type="bibr">24</xref>]. The &#x003b2;-lactam-insensitive PBPs are only found in Firmicutes, mainly in <italic>Bacilli</italic> but also in some <italic>Clostridia</italic> (e.g., <italic>C. difficile</italic>). Antibiotherapy against clostridial infection is usually not based on &#x003b2;-lactams but infection with <italic>C. difficile</italic>, in which the existence of a &#x003b2;-lactam-insensitive PBP has not received the attention it deserves, and is induced by exposure to factors that disrupt gut microflora, including third generation cephalosporins [<xref rid="B25-antibiotics-05-00012" ref-type="bibr">25</xref>].</p><p>Penicillin-binding proteins represent a vast group of proteins that are traditionally divided into high and low molecular weight (HMW, LMW) PBPs. Bipartition of PBPs is not simply a matter of protein size but rather reflects the different functions of these proteins: the late stages of peptidoglycan synthesis are achieved by HMW-PBPs while LMW-PBPs are mainly involved in the maintenance, remodeling and recycling of PG [<xref rid="B4-antibiotics-05-00012" ref-type="bibr">4</xref>,<xref rid="B26-antibiotics-05-00012" ref-type="bibr">26</xref>,<xref rid="B27-antibiotics-05-00012" ref-type="bibr">27</xref>,<xref rid="B28-antibiotics-05-00012" ref-type="bibr">28</xref>]. Generally, two HMW-PBPs (one class A and one class B) are necessary for the bacterium to survive, whereas deletion of all LMW-PBPs (class C), although deleterious, is not fatal to the bacterium [<xref rid="B27-antibiotics-05-00012" ref-type="bibr">27</xref>]. As a result, HMW-PBPs are the primary targets of &#x003b2;-lactam antibiotics but LMW-PBPs may participate in the sensitization of the bacterium to these antibiotics [<xref rid="B29-antibiotics-05-00012" ref-type="bibr">29</xref>,<xref rid="B30-antibiotics-05-00012" ref-type="bibr">30</xref>] and simultaneous inhibition of HMW and LMW-PBPs may present an interesting synergistic effect.</p><p>PBPs are mostly multidomain enzymes divided in three classes (A, B and C) based on their domain organization and function (<xref ref-type="fig" rid="antibiotics-05-00012-f002">Figure 2</xref>). Subdivision of class B PBPs, based on their sequences, is of particular interest for understanding the problems of their inhibition and resistance. Subclass B1 (B1-PBPs) groups are the insensitive PBPs found in <italic>Firmicutes</italic> (e.g., <italic>S. aureus</italic> PBP2a). B2- and B3-PBPs are Gram-negative PBPs, respectively, active during elongation and division (e.g., <italic>E. coli</italic> PBP2 and PBP3). B4- and B5-PBPs are Gram-positive equivalents to B2- and B3-PBPs. In class A PBPs the transpeptidase domain is invariably linked to an N-terminal transglycosylase domain but additional domains can be encountered. The N-terminal module of class B PBPs has no enzymatic activity and was suggested to serve as a stalk, allowing the C-terminal TP domains to reach the peptidoglycan [<xref rid="B31-antibiotics-05-00012" ref-type="bibr">31</xref>]. The N-terminal module is made of small domains and could be important for protein-protein interactions in the PG synthesis complexes [<xref rid="B32-antibiotics-05-00012" ref-type="bibr">32</xref>]. The GT and TP activities are coupled within the same class A PBPs and also with their class B partners (e.g., PBP1a-PBP2, PBP1b-PBP3), showing regulated and synchronized PG synthesis [<xref rid="B6-antibiotics-05-00012" ref-type="bibr">6</xref>,<xref rid="B8-antibiotics-05-00012" ref-type="bibr">8</xref>,<xref rid="B33-antibiotics-05-00012" ref-type="bibr">33</xref>].</p><p>In addition to the catalytic GT and TP domains, some PBPs, such as the class A PBP1a and PBP1b of <italic>E. coli</italic>, exhibit a small domain called UB2H (<xref ref-type="fig" rid="antibiotics-05-00012-f002">Figure 2</xref>) located between the GT and the TP domains [<xref rid="B34-antibiotics-05-00012" ref-type="bibr">34</xref>]. They have been recently shown to function as the binding sites of regulatory lipoproteins LpoA and LpoB which stimulate the activities of PBP1a and PBP1b, respectively [<xref rid="B37-antibiotics-05-00012" ref-type="bibr">37</xref>,<xref rid="B38-antibiotics-05-00012" ref-type="bibr">38</xref>]. The Class B PBPs can also contain additional domains. B4-PBPS (e.g., PBP2x), for example, have two additional C-terminal PASTA domains (PBP And Serine/Threonine kinase Associated) [<xref rid="B39-antibiotics-05-00012" ref-type="bibr">39</xref>]. These domains have been found to play a role in &#x003b2;-lactam binding, protein stability and bacterial morphogenesis [<xref rid="B40-antibiotics-05-00012" ref-type="bibr">40</xref>,<xref rid="B41-antibiotics-05-00012" ref-type="bibr">41</xref>,<xref rid="B42-antibiotics-05-00012" ref-type="bibr">42</xref>].</p><p>The class C PBPs are found as single domains (type-7 PBPs; type AmpH) but an additional C- (type-5) or domains inserted in the PBP domain (type-4 PBPs) are also encountered. They have <sc>dd</sc>-carboxypeptidase and/or endopeptidase activity and are generally not essential for bacterial viability in laboratory conditions terminal domain but they play roles in the regulation of the degree of cross-linking in PG [<xref rid="B4-antibiotics-05-00012" ref-type="bibr">4</xref>,<xref rid="B28-antibiotics-05-00012" ref-type="bibr">28</xref>,<xref rid="B43-antibiotics-05-00012" ref-type="bibr">43</xref>].</p><p>The overall structure of the PBP/TP domain consists of one alpha-beta and one all-alpha subdomain, with the active site located between both [<xref rid="B4-antibiotics-05-00012" ref-type="bibr">4</xref>]. The transpeptidase activity relies on a few key residues of the three conserved motifs (SxxK, SxN, and KTGT) which decorate their active site [<xref rid="B4-antibiotics-05-00012" ref-type="bibr">4</xref>,<xref rid="B5-antibiotics-05-00012" ref-type="bibr">5</xref>]. The serine of the SxxK motif play an essential role in the two-step cross-linking reaction. Firstly, it performs a nucleophile attack on the CO of the terminal <sc>d</sc>-Ala-<sc>d</sc>-Ala amide bond of a pentapeptide which leads to the formation of an acylenzyme intermediate with departure of the terminal <sc>d</sc>-Ala; secondly, an amino group of a peptide from a neighboring glycan chain attacks this complex, resulting in the formation of the cross bridge and release of the free enzyme. Acylation of the active serine of PBPs by &#x003b2;-lactams blocks the enzyme in an inactive form for a long period of time. Modifications of the peptide side-chain of the peptidoglycan precursor, such as amidation or substitution, were found to be an important determinant of the specificity of the TP activity of some enzymes [<xref rid="B44-antibiotics-05-00012" ref-type="bibr">44</xref>,<xref rid="B45-antibiotics-05-00012" ref-type="bibr">45</xref>,<xref rid="B46-antibiotics-05-00012" ref-type="bibr">46</xref>] and the efficacy of some antibiotics that interact with the substrate such as vancomycin [<xref rid="B16-antibiotics-05-00012" ref-type="bibr">16</xref>,<xref rid="B47-antibiotics-05-00012" ref-type="bibr">47</xref>].</p><p>The TP domain of HMW PBPs requires a peptide attached to the polymeric PG as a donor substrate for the cross-linking reaction, and they are not active on short peptides ending with <sc>d</sc>-Ala-<sc>d</sc>-Ala [<xref rid="B3-antibiotics-05-00012" ref-type="bibr">3</xref>,<xref rid="B48-antibiotics-05-00012" ref-type="bibr">48</xref>]. However, some LMW PBPs are able to catalyze transpeptidase activity using simple peptide substrates [<xref rid="B49-antibiotics-05-00012" ref-type="bibr">49</xref>,<xref rid="B50-antibiotics-05-00012" ref-type="bibr">50</xref>]. <italic>S. aureus</italic> PBP4 (LMW PBP) was shown to use lipid I, lipid II and PG strands as donors [<xref rid="B48-antibiotics-05-00012" ref-type="bibr">48</xref>]. On the other hand, the TP reaction of almost all PBPs is less stringent for the acceptor substrate and can use various <sc>d</sc>-amino acids [<xref rid="B49-antibiotics-05-00012" ref-type="bibr">49</xref>,<xref rid="B51-antibiotics-05-00012" ref-type="bibr">51</xref>,<xref rid="B52-antibiotics-05-00012" ref-type="bibr">52</xref>,<xref rid="B53-antibiotics-05-00012" ref-type="bibr">53</xref>], allowing their incorporation (exchange) into PG, and in case of <italic>S. aureus</italic> PBP4 also into the lipid II and lipid II precursors. These properties have been exploited to label peptidoglycan and precursors by fluorescent <sc>d</sc>-amino acids in different organisms, providing a convenient tool to study peptidoglycan synthesis and bacterial morphogenesis in living cells [<xref rid="B54-antibiotics-05-00012" ref-type="bibr">54</xref>,<xref rid="B55-antibiotics-05-00012" ref-type="bibr">55</xref>].</p></sec><sec id="sec3-antibiotics-05-00012"><title>3. Recent Developments in Transpeptidase Inhibitors</title><sec id="sec3dot1-antibiotics-05-00012"><title>3.1. The &#x003b2;-Lactam Inhibitors of PBPs</title><p>Commercially available inhibitors of PBPs almost exclusively contain the four-membered &#x003b2;-lactam ring (<xref ref-type="fig" rid="antibiotics-05-00012-f003">Figure 3</xref>). Penicillins, cephalosporins, monobactams and carbapenems have been developed from natural representatives and, except for penicillin derivatives, research continues in an ongoing process to find new compounds active against the most harmful bacteria. The &#x003b2;-lactam antibiotics take advantage of their structural similarity to the <sc>d</sc>-Ala-<sc>d</sc>-Ala moiety of the natural substrate to lure the PBP [<xref rid="B56-antibiotics-05-00012" ref-type="bibr">56</xref>].</p><sec id="sec3dot1dot1-antibiotics-05-00012"><title>3.1.1. Cephalosporins</title><p>During the last decade, efforts in the development of new generation cephalosporins have culminated with the marketing of ceftaroline and ceftobiprole, two compounds active against methicillin-resistant <italic>S. aureus</italic> (MRSA). Ceftaroline has a broad-spectrum activity against Gram-positive pathogens and several Gram-negative pathogens, with the notable exceptions of <italic>P. aeruginosa</italic> and extended spectrum &#x003b2;-lactamase (ESBL)-producing Enterobacteriaceae [<xref rid="B57-antibiotics-05-00012" ref-type="bibr">57</xref>,<xref rid="B58-antibiotics-05-00012" ref-type="bibr">58</xref>]. Ceftobiprole is active against MRSA with broad spectrum activities against Gram-negative bacteria and other Gram-positive bacteria, in particular ceftriaxone-resistant streptococci [<xref rid="B59-antibiotics-05-00012" ref-type="bibr">59</xref>].</p><p>Both compounds have been shown to bind to PBP2a [<xref rid="B60-antibiotics-05-00012" ref-type="bibr">60</xref>,<xref rid="B61-antibiotics-05-00012" ref-type="bibr">61</xref>] and to <italic>E. faecium</italic> PBP5 but with less affinity than to PBP2a [<xref rid="B62-antibiotics-05-00012" ref-type="bibr">62</xref>,<xref rid="B63-antibiotics-05-00012" ref-type="bibr">63</xref>]. In <italic>S. pneumoniae</italic>, ceftaroline binds to PBP2x [<xref rid="B64-antibiotics-05-00012" ref-type="bibr">64</xref>], and ceftobiprole to all six PBPs, with a higher affinity for PBP2x [<xref rid="B65-antibiotics-05-00012" ref-type="bibr">65</xref>]. The X-ray structure of PBP2a in complex with ceftobiprole [<xref rid="B66-antibiotics-05-00012" ref-type="bibr">66</xref>] and with ceftaroline [<xref rid="B67-antibiotics-05-00012" ref-type="bibr">67</xref>] provided the molecular details of the interaction between the compounds and the MRSA-acquired enzyme. Binding of both compounds involves a structural rearrangement of the active site residues, mainly a shift in the &#x003b2;3 strand and a twist of the residue backbone and side-chain atoms. The binding of ceftaroline in the active site of PBP2a possibly involves an allosteric site located in the non-penicillin-binding domain [<xref rid="B68-antibiotics-05-00012" ref-type="bibr">68</xref>], but the existence of such an allosteric site was not reported upon binding of other &#x003b2;-lactams, either in PBP2a [<xref rid="B69-antibiotics-05-00012" ref-type="bibr">69</xref>] or in PBP5fm [<xref rid="B70-antibiotics-05-00012" ref-type="bibr">70</xref>].</p><p>Amino-acid mutations leading to resistance to ceftaroline in MRSA have rapidly emerged. In fact, moderately resistant strains predating the use of ceftobiprole have been reported [<xref rid="B71-antibiotics-05-00012" ref-type="bibr">71</xref>]. The Glu<sub>239</sub>Lys mutation, located in the aforementioned allosteric site of the non-penicillin-binding domain, gives rise to a slight MIC increase (MIC &#x0003e; 2 mg/L whereas ceftaroline-susceptible MRSA have MIC &#x02264; 1 mg/L ); four strains with MIC &#x0003e; 8 mg/L were found with the additional Glu<sub>447</sub>Lys mutation, located in the penicillin-binding domain, close to the ceftaroline binding site [<xref rid="B72-antibiotics-05-00012" ref-type="bibr">72</xref>]. Highly ceftaroline-resistant isolates (MIC &#x0003e; 32 mg/L) have been reported, bearing two mutations in the ceftaroline-binding pocket of the transpeptidase domain [<xref rid="B73-antibiotics-05-00012" ref-type="bibr">73</xref>]. From a study conducted with 184 MRSA isolates, Lahiri <italic>et al.</italic> conclude that high level MICs are only achieved with mutations in the penicillin-binding domain whereas mutations in the non-penicillin-binding domain have only a small impact on ceftaroline susceptibility, probably via destabilization of a protein-protein interface [<xref rid="B74-antibiotics-05-00012" ref-type="bibr">74</xref>].</p><p>The Glu<sub>447</sub>Lys mutation appears as crucial for reducing the sensitivity of PBP2a to ceftaroline. Interestingly, in <italic>E. faecium</italic> PBP5, a mutation in this region, consisting of the insertion of an additional serine after Ser<sub>466</sub>, leads to a highly insensitive PBP5 (MIC &#x0003e; 256 mg/L for ampicillin) [<xref rid="B75-antibiotics-05-00012" ref-type="bibr">75</xref>]. Direct alteration of residues surrounding the active site of B1-PBPs is thus the most straightforward mean for staphylococci and enterococci to increase the level of resistance against the &#x003b2;-lactam antibiotics that threaten their survival.</p><p>Beyond ceftaroline and ceftobiprole, the last years have not seen the emergence of novel cephalosporins, even at the academic level. Nonetheless, there was a considerable rise in our understanding of the interaction between &#x003b2;-lactam antibiotics and Gram-negative PBPs of subclass B3 (Gram-negative PBP3 including <italic>N. gonorrhoeae</italic> and <italic>N. meningitidis</italic> PBP2), resulting from the solution of several structures in apo or complex form [<xref rid="B32-antibiotics-05-00012" ref-type="bibr">32</xref>,<xref rid="B76-antibiotics-05-00012" ref-type="bibr">76</xref>,<xref rid="B77-antibiotics-05-00012" ref-type="bibr">77</xref>,<xref rid="B78-antibiotics-05-00012" ref-type="bibr">78</xref>,<xref rid="B79-antibiotics-05-00012" ref-type="bibr">79</xref>,<xref rid="B80-antibiotics-05-00012" ref-type="bibr">80</xref>].</p><p>Han and colleagues have solved the structure of <italic>P. aeruginosa</italic> PBP3 with various compounds. They showed that the affinity of ceftazidime for B3-PBPs results from the fit of its aminothiazole ring into a pocket made of several aromatic residues. The residues lining the aminothiazole affinity pocket are conserved in B3-PBPs and, thus, compounds bearing a side-chain with an aminothiazole ring have a good chance to be active against Gram-negative bacteria. The ceftazidime side-chain has a carboxypropyloxyimino moiety but the 2-amino-4-thiazolyl methoxyimino (ATMO) side-chain is common to many third-generation cephalosporins. It resists the deleterious effect of class C &#x003b2;-lactamases and can be used for development of new &#x003b2;-lactamase inhibitors [<xref rid="B81-antibiotics-05-00012" ref-type="bibr">81</xref>]. Unfortunately, the structure of a B3-PBP in complex with an ATMO side-chain-bearing compound (cefotaxime, ceftriaxone, &#x02026;) has not been solved and one does not know if the methoxyimino moiety could fit into the aminothiazole ring binding pocket.</p><p>The class B PBP involved in cell division (FtsI) is the relevant target of cephalosporins and resistance due to alterations of FtsI is found in many non-&#x003b2;-lactamase-producing Gram-negative pathogens. Deletion of the <italic>ftsI</italic> gene has even been seen in rare cases of resistance in <italic>Burkholderia pseudomallei</italic> [<xref rid="B82-antibiotics-05-00012" ref-type="bibr">82</xref>]. Mutations leading to resistant strains commonly occur close to the active site and, somewhat unexpectedly, mutations are specific to each bacterial species, <italic>i.e.</italic>, they do not overlap if the B3-PBPs structures of different species are superimposed. They are generally located in one of the two walls that border the active site entrance. On one side, the wall is made of the loop that acquires a stable conformation upon antibiotic binding (as discussed above), which covers &#x003b2;3 and &#x003b2;4 strands. Mutations conferring high &#x003b2;-lactam resistance are located in this loop (e.g., Glu545Ser in <italic>N. gonorrhoeae</italic>) or in contact with it (e.g., Arg517His and Asn526Lys in <italic>H. Influenzae</italic>). On the opposite side of the active site entrance, a long loop inserted between &#x003b1;4 and &#x003b1;5 helices covers the SxN motif. Reduced susceptibility to cephalosporins was recently reported in <italic>E. coli</italic> isolates as a result of the insertion of four residues in this loop [<xref rid="B83-antibiotics-05-00012" ref-type="bibr">83</xref>]. As well, the Asp345a insertion in the equivalent loop of <italic>N. gonorrhoeae</italic> is commonly observed in penicillin-resistant strains, reducing the penicillin acylation rate approximately six-fold [<xref rid="B84-antibiotics-05-00012" ref-type="bibr">84</xref>]. Interestingly, this insertion is located in the same region as the Ser466 insertion in PBP5 of highly resistant <italic>E. faecium</italic> strain.</p><p>Secondary mutations located in the penicillin-binding domain and sometimes in the non-penicillin-binding domain can reinforce the strain resistance. The subtle alterations that these mutations induce on the binding of antibiotics are not easy to explain. In transformable bacteria, especially <italic>Neisseria</italic> and Streptococci, target-mediated antibiotic resistance is exacerbated by the horizontal genetic exchange of fragments of chromosomal genes [<xref rid="B85-antibiotics-05-00012" ref-type="bibr">85</xref>].</p></sec><sec id="sec3dot1dot2-antibiotics-05-00012"><title>3.1.2. Carbapenems</title><p>Carbapenems are last resort &#x003b2;-lactam antibiotics. Their broad spectrum activity and their high potency as antimicrobial agents arise from their ability to bind B2-PBPs as well as B3-PBPs [<xref rid="B86-antibiotics-05-00012" ref-type="bibr">86</xref>,<xref rid="B87-antibiotics-05-00012" ref-type="bibr">87</xref>]. Of note is their ability to also inhibit <sc>ld</sc>-transpeptidases [<xref rid="B88-antibiotics-05-00012" ref-type="bibr">88</xref>,<xref rid="B89-antibiotics-05-00012" ref-type="bibr">89</xref>,<xref rid="B90-antibiotics-05-00012" ref-type="bibr">90</xref>]. <sc>ld</sc>-transpeptidases catalyze the formation of a 3,3 peptidoglycan cross-link instead of the classical 4,3 cross-link formed by <sc>dd</sc>-transpeptidases [<xref rid="B91-antibiotics-05-00012" ref-type="bibr">91</xref>,<xref rid="B92-antibiotics-05-00012" ref-type="bibr">92</xref>]. The 3,3 cross-link is predominant in the peptidoglycan of <italic>M. tuberculosis</italic> [<xref rid="B93-antibiotics-05-00012" ref-type="bibr">93</xref>] and, in combination with clavulanic acid, carbapenems are bactericidal against drug resistant <italic>M. tuberculosis</italic>.</p><p>Unfortunately, the latest news makes the future rather bleak. With the spread of resistance mediated by &#x003b2;-lactamase production and emergence of new mechanisms of resistance, bacteria are winning the battle against the developers&#x02019; ingenuity. Resistance affects all carbapenems and perspectives of new effective carbapenems are scarce. New derivatives, awaiting further experimental evidence, have been proposed as the result of <italic>in silico</italic> analysis [<xref rid="B94-antibiotics-05-00012" ref-type="bibr">94</xref>].</p><p>Resistance to carbapenems is essentially mediated by the production of &#x003b2;-lactamases. Carbapenemases were first found as metallo &#x003b2;-lactamases but all classes of &#x003b2;-lactamases are now found to contain carbapenemases [<xref rid="B13-antibiotics-05-00012" ref-type="bibr">13</xref>]. Until the last months, a carbapenem-resistance mechanism resulting from PBP2 mutations had only been seen in an experimentally mutS- and tolC-deficient <italic>E. coli</italic> strain [<xref rid="B95-antibiotics-05-00012" ref-type="bibr">95</xref>]. A recent paper reports a mutation in PBP2 as a new mechanism to render clinical isolates of <italic>E. coli</italic> non-susceptible to imipenem [<xref rid="B96-antibiotics-05-00012" ref-type="bibr">96</xref>]. In PBP2, the substitution of the second motif alanine by a serine probably disrupts the interaction between the imipenem hydroxyethyl group and the aspartic acid present in motif 2 of B2-PBPs, reducing the affinity of imipenem for PBP2.</p></sec><sec id="sec3dot1dot3-antibiotics-05-00012"><title>3.1.3. Monocyclic &#x003b2;-Lactams</title><p>Although many monobactams have been developed, the only FDA-approved monobactam is aztreonam, which shows high antibacterial activity against Gram-negative bacteria but not against their Gram-positive counterparts. Aztreonam binds to Gram-negative B3-PBPs and the solution of the structure of the aztreonam: <italic>P. aeruginosa</italic> PBP3 adduct shows that the enzyme pocket that tightly accommodates the aminothiazole ring of the ceftazidime side-chain accepts the aminothiazole ring of aztreonam in the same way.</p><p>The latest efforts in the design of new monocyclic &#x003b2;-lactams have involved the incorporation of a siderophore group that exploits the iron-uptake systems to diffuse through the Gram-negative outer membrane and avoid resistance induced by efflux systems and low permeability mutations. The monosulfactam BAL30072 is a monobactam with a siderophore group connected to the methoxyimino moiety of the ATMO side-chain (<xref ref-type="fig" rid="antibiotics-05-00012-f003">Figure 3</xref>) [<xref rid="B97-antibiotics-05-00012" ref-type="bibr">97</xref>]. It is active against <italic>P. aeruginosa, A. baumannii</italic> and KPC-possessing <italic>Klebsiella pneumoniae</italic>, with an enhanced activity when combined with meropenem or colistin [<xref rid="B98-antibiotics-05-00012" ref-type="bibr">98</xref>,<xref rid="B99-antibiotics-05-00012" ref-type="bibr">99</xref>,<xref rid="B100-antibiotics-05-00012" ref-type="bibr">100</xref>]. BAL30072 has a high affinity for PBP3 but also for PBP1a and PBP1b [<xref rid="B97-antibiotics-05-00012" ref-type="bibr">97</xref>]. Its aminothiazole group is expected to fit into the PBP3 active site, resulting in a high affinity for PBP3.</p><p>Along the same line, new monocarbams&#x02013;monocarbams are monocyclic &#x003b2;-lactams with a carbonylaminosulfonyl activating group at the N-1 position (<xref ref-type="fig" rid="antibiotics-05-00012-f003">Figure 3</xref>) have been developed by Pfizer ([<xref rid="B101-antibiotics-05-00012" ref-type="bibr">101</xref>], and references therein). MC-1 is a siderophore-conjugated monocarbam highly active against <italic>P. aeruginosa</italic> clinical isolates and the crystal structure of the adduct with PBP3 provided the structural basis for lead optimization [<xref rid="B77-antibiotics-05-00012" ref-type="bibr">77</xref>]. Structure activity relationships have been explored for the triazolone-based siderophore-conjugated monocarbam, providing potent inhibitors of <italic>P. aeruginosa</italic> PBP3 with good pharmacokinetic properties [<xref rid="B102-antibiotics-05-00012" ref-type="bibr">102</xref>]. Notwithstanding the valuable properties of siderophore-conjugated monocarbams, resistance could rapidly appear through mutations in the genes linked to various components of the siderophore-mediated iron uptake systems [<xref rid="B103-antibiotics-05-00012" ref-type="bibr">103</xref>].</p></sec></sec><sec id="sec3dot2-antibiotics-05-00012"><title>3.2. Non-&#x003b2;-Lactams</title><p>Non-&#x003b2;-lactam inhibitors of PBPs (reviewed in [<xref rid="B104-antibiotics-05-00012" ref-type="bibr">104</xref>]) escape the action of &#x003b2;-lactamases but none have yet undergone developments sufficient for initiating clinical trials. The most promising non-&#x003b2;-lactam inhibitors of PBPs are certainly lactivicin analogs (<xref ref-type="fig" rid="antibiotics-05-00012-f003">Figure 3</xref>). Known for more than 30 years, lactivicin derivatives have exhibited antimicrobial activity against a wide spectrum of infectious bacteria [<xref rid="B105-antibiotics-05-00012" ref-type="bibr">105</xref>]. Several derivatives resist the action of &#x003b2;-lactamases and may even behave as inhibitors of the latter [<xref rid="B106-antibiotics-05-00012" ref-type="bibr">106</xref>]. Lactivicin analogs form a stable covalent adduct with the active site serine and crystal structures of adducts with <italic>S. pneumoniae</italic> PBP1b [<xref rid="B107-antibiotics-05-00012" ref-type="bibr">107</xref>], and <italic>P. aeruginosa</italic> PBP3 and PBP1a [<xref rid="B108-antibiotics-05-00012" ref-type="bibr">108</xref>] revealed the opening of both monocyclic cycloserine and &#x003b3;-lactone rings upon acylation of the active serine. Recent developments have involved the incorporation of a siderophore moiety to benefit from the siderophore receptor uptake strategy (see chapter on monobactams) [<xref rid="B108-antibiotics-05-00012" ref-type="bibr">108</xref>]. Incorporation of a hydroxypyridone moiety linked to the side-chain oxyimino group improved MICs in <italic>P. aeruginosa</italic> and <italic>A. baumannii</italic> strains. In addition to the opening of both rings as observed in PBP-lactivicin structures, the crystal structure with <italic>P. aeruginosa</italic> PBP3 showed a positioning of the aminothiazole identical to that observed with ceftazidime and aztreonam, whereas the ethylene carboxylate moiety resulting from the opening of the lactone ring and the dihydroxypyridone sideromimic moiety did not form strong interactions with the enzyme, allowing for further improvement of the compound. Interestingly, linking a presumably more efficient sideromimic (dihydroxyphthalimide instead of dihydroxypyridone) to the &#x003b1;-lactone position resulted in lower MICs, with inhibition potency extended to class A PBPs.</p><p>Other reactive centers have been shown to react with the active serine of PBPs. A boronic acid and a trifluoroketone bearing an appropriate peptidoglycan mimetic side-chain could form covalent adducts with the <italic>Actinomadura</italic> R39 <sc>dd</sc>-peptidase [<xref rid="B109-antibiotics-05-00012" ref-type="bibr">109</xref>,<xref rid="B110-antibiotics-05-00012" ref-type="bibr">110</xref>]. Other boronic acids were also designed and shown to bind to <italic>S. pneumoniae</italic> PBP1b [<xref rid="B111-antibiotics-05-00012" ref-type="bibr">111</xref>]. Strikingly, the peptidoglycan mimetic boronic acid could not bind to HMW-PBPs [<xref rid="B112-antibiotics-05-00012" ref-type="bibr">112</xref>], demonstrating the poor affinity of HMW-PBPs for their natural substrate; however, a ceftazidime or cefotaxime such as boronic acid might possibly do so. A ceftazidime such as boronic acid was shown to tightly bind to CTX-M-9 and CTX-M-16 class A &#x003b2;-lactamases [<xref rid="B113-antibiotics-05-00012" ref-type="bibr">113</xref>], but, to our knowledge, it was not tested as an inhibitor of B3-PBPs.</p><p>Non-covalent inhibitors remain at a prospective level. Recent research, generally based on <italic>in silico</italic> screening, disclosed interesting compounds primarily targeting MRSA PBP2a. For example, the oxadiazoles were discovered by an <italic>in silico</italic> screening of compounds from the ZINC database [<xref rid="B114-antibiotics-05-00012" ref-type="bibr">114</xref>], showing attractive properties against Gram-positive bacterial strains [<xref rid="B115-antibiotics-05-00012" ref-type="bibr">115</xref>,<xref rid="B116-antibiotics-05-00012" ref-type="bibr">116</xref>]. Macrocycle-embedded &#x003b2;-lactams also show moderate PBP inhibition properties with <italic>S. aureus</italic> PBP2a and <italic>E. faecium</italic> PBP5 [<xref rid="B117-antibiotics-05-00012" ref-type="bibr">117</xref>].</p><p>PBP2a appears to use an allosteric site to trigger the active site opening [<xref rid="B67-antibiotics-05-00012" ref-type="bibr">67</xref>,<xref rid="B68-antibiotics-05-00012" ref-type="bibr">68</xref>]. This observation has stimulated the search for new compounds binding at the allosteric site with the help of molecular docking techniques [<xref rid="B118-antibiotics-05-00012" ref-type="bibr">118</xref>,<xref rid="B119-antibiotics-05-00012" ref-type="bibr">119</xref>]. The mechanism of action of these compounds and their potential to lead to clinically useful bactericidal drugs need further analysis.</p><p>In addition to <italic>in silico</italic> methods, a high-throughput screening assay was recently developed, allowing the screening of 50,000 compounds against <italic>N. gonorrhoeae</italic> PBP2 and the identification of seven non-&#x003b2;-lactam compounds active on penicillin-resistant gonococcal strains [<xref rid="B120-antibiotics-05-00012" ref-type="bibr">120</xref>]. The assay is based on the interaction of a fluorescent &#x003b2;-lactam, Bocillin-FL, with solubilized PBPs, which results in an increase of fluorescence anisotropy in a time-dependent manner [<xref rid="B121-antibiotics-05-00012" ref-type="bibr">121</xref>]. The assay can be monitored continuously in microtiter plates allowing the development of relatively high-throughput screening of TP inhibitors.</p></sec><sec id="sec3dot3-antibiotics-05-00012"><title>3.3. Synergistic Combinations</title><p>To circumvent the resistance to last resort antibiotics, synergistic use of &#x003b2;-lactams in combination with other &#x003b2;-lactams, &#x003b2;-lactamase inhibitors or other metabolic pathway&#x02013;targeting drugs has been revived. These combinations can be beneficial not only in fighting resistant pathogens but also bacteria that are apparently susceptible <italic>in vitro</italic>, in particular clinical situations [<xref rid="B122-antibiotics-05-00012" ref-type="bibr">122</xref>].</p><p>New inhibitors of &#x003b2;-lactamases and new inhibitors of PBPs have been combined, leading to original combinations that are targeted primarily against carbapenemase-producing Gram-negative pathogens. Several combinations are currently in clinical phase and two of them (ceftolozane/tazobactam and ceftazidime/avibactam) were recently approved by the FDA. We refer the reader to Bush&#x02019;s recent review [<xref rid="B12-antibiotics-05-00012" ref-type="bibr">12</xref>] for further information. Also covered by an extensive review, dual &#x003b2;-lactam therapy for Gram-negative bacteria is at least as effective as combinations of a &#x003b2;-lactam and an aminoglycoside, which is recommended for treatment of many serious Gram-negative infections [<xref rid="B123-antibiotics-05-00012" ref-type="bibr">123</xref>]. Dual &#x003b2;-lactam therapy is not limited to Gram-negative bacteria but can also contribute to combating resistance in MRSA [<xref rid="B124-antibiotics-05-00012" ref-type="bibr">124</xref>,<xref rid="B125-antibiotics-05-00012" ref-type="bibr">125</xref>].</p><p>Novel small molecules were recently shown to potentiate &#x003b2;-lactam activity against various pathogens: &#x003b2;-cyclodextrin (&#x003b2;-CD) derivatives [<xref rid="B126-antibiotics-05-00012" ref-type="bibr">126</xref>], fosfomycin [<xref rid="B127-antibiotics-05-00012" ref-type="bibr">127</xref>], a molecule with a hypothetical cell wall synthesis&#x02013;targeting function [<xref rid="B128-antibiotics-05-00012" ref-type="bibr">128</xref>] and a positive interaction between inhibitors of protein synthesis and cefepime against MRSA [<xref rid="B129-antibiotics-05-00012" ref-type="bibr">129</xref>].</p></sec></sec><sec id="sec4-antibiotics-05-00012"><title>4. Glycosyltrasferases Structure and Function</title><p>The GT module is found in bacteria as a single domain called monofunctional glycosyltransferase or as the N-terminal domain of the multimodular class A PBPs. It contains about 200 amino acid residues folded into a structure much like that of the bacteriophage lambda lysozyme but, in contrast to the hydrolytic enzyme, it is endowed with a fascinating, highly processive polymerase activity converting the lipid II substrate to long glycan chains. Based on sequence similarities, these enzymes form family 51 in the GT classification database (Cazy database). Several crystal structures of bifunctional (GT-TP) PBPs and monofunctional GTs are now available, both in complex with the inhibitor moenomycin, lipid II analog or without a ligand [<xref rid="B34-antibiotics-05-00012" ref-type="bibr">34</xref>,<xref rid="B130-antibiotics-05-00012" ref-type="bibr">130</xref>,<xref rid="B131-antibiotics-05-00012" ref-type="bibr">131</xref>,<xref rid="B132-antibiotics-05-00012" ref-type="bibr">132</xref>,<xref rid="B133-antibiotics-05-00012" ref-type="bibr">133</xref>]. The general structure is conserved among proteins from various species of microorganisms. The overall structure is composed mostly of alpha helices forming a globular domain with a large enzymatic cavity that divides this domain into two sub-domains (<xref ref-type="fig" rid="antibiotics-05-00012-f004">Figure 4</xref>). The features of the large one (&#x0201c;head&#x0201d; region) are reminiscent of those of the bacteriophage lambda lysozyme and the smaller one (&#x0201c;jaw&#x0201d; region) is characteristic of the family 51 GTs and contains a hydrophobic surface, suggesting that it is partially buried in the cytoplasmic membrane. Sequence alignment of GTs highlights five highly conserved consensus motifs [<xref rid="B5-antibiotics-05-00012" ref-type="bibr">5</xref>]. Most of them are directed toward the enzymatic cavity and were confirmed to be important for interactions with substrate and moenomycin and enzymatic catalysis [<xref rid="B3-antibiotics-05-00012" ref-type="bibr">3</xref>,<xref rid="B132-antibiotics-05-00012" ref-type="bibr">132</xref>,<xref rid="B133-antibiotics-05-00012" ref-type="bibr">133</xref>,<xref rid="B134-antibiotics-05-00012" ref-type="bibr">134</xref>,<xref rid="B135-antibiotics-05-00012" ref-type="bibr">135</xref>]. Six sugar units could be fitted into the GT enzymatic cavity based on the structure of the complex with moenomycin [<xref rid="B136-antibiotics-05-00012" ref-type="bibr">136</xref>], which binds to the donor site. Of these, four sugar units belong to the donor substrate (the elongating glycan chain whose remaining chain extends beyond the GT domain and could reach the TP active site in bifunctional PBPs about 70 &#x000c5; away) and two sugar units to the acceptor substrate, lipid II. The corresponding sub-sites are called donor and acceptor sites, respectively (<xref ref-type="fig" rid="antibiotics-05-00012-f004">Figure 4</xref>).</p><p>The catalytic mechanism of the polymerization reaction consists of a nucleophilic attack by the activated 4-OH group of the lipid II onto the C-1 carbon of the undecaprenyl pyrophosphate-linked glycan chain moiety (GlcNAc-MurNAc-peptide)<sub>n</sub> (<xref ref-type="fig" rid="antibiotics-05-00012-f001">Figure 1</xref>), leading to the formation of a new &#x003b2;-1,4 glycosidic bond. This process is repeated after translation of the chain containing n + 1 disaccharide units which allow the binding of a new lipid II into the acceptor site (see below). Analysis of moenomycin binding in the presence of substrate analogs, mimicking the donor and acceptor substrates respectively, shows a cooperative mechanism between the two corresponding sites [<xref rid="B137-antibiotics-05-00012" ref-type="bibr">137</xref>]. It has been also observed that preincubation of PBP1b with lipid IV (a donor which results from the condensation of two lipid II molecules) stimulates the initiation step of the GT reaction [<xref rid="B138-antibiotics-05-00012" ref-type="bibr">138</xref>]. This suggests that binding of the donor substrate induces structural rearrangements, including probably in the acceptor site that facilitates the binding of lipid II during the elongation phase of processive polymerization. If the coupling reaction leading to the formation of the &#x003b2;-1,4 glyosidic bond is well established, the mechanisms of the translocation of the elongating glycan chain from the acceptor site to the donor site and of chain termination are less well understood. Recently, a newly identified <italic>E. coli</italic> lytic transglycosylase, MltG, was shown to interact with PBP1b and was proposed to function in glycan chain termination [<xref rid="B139-antibiotics-05-00012" ref-type="bibr">139</xref>]. Also, it is not known how, <italic>in vitro</italic>, different GTs produce different glycan chain lengths characteristic of each enzyme [<xref rid="B140-antibiotics-05-00012" ref-type="bibr">140</xref>,<xref rid="B141-antibiotics-05-00012" ref-type="bibr">141</xref>]. This may be the result of different affinities of the enzyme for the elongating chain, with longer chains resulting from higher binding affinity.</p><p>GT crystal structures show a protruding and dynamic region between the donor and acceptor sites. The processive elongation of the glycan chain by the GT imposes several rounds of disaccharide-peptide additions before its release. This suggests that the intermediate products must shuttle from the acceptor site to the donor site after each reaction to allow the former to accommodate a new disaccharide. The dynamic protruding region could facilitate the translation of the product. On the other hand, the mobility of this region might be decreased by the binding of substrates in the active site [<xref rid="B137-antibiotics-05-00012" ref-type="bibr">137</xref>].</p></sec><sec id="sec5-antibiotics-05-00012"><title>5. Synthesis of Lipid II and Analogous Substrates, and Their Use to Study the GT</title><p>Lipid II is the immediate substrate of the GT, and its polymerization supplies the TP substrate. It must be available for the <italic>in vitro</italic> study of the GT and TP. Complete synthesis has been achieved [<xref rid="B142-antibiotics-05-00012" ref-type="bibr">142</xref>,<xref rid="B143-antibiotics-05-00012" ref-type="bibr">143</xref>,<xref rid="B144-antibiotics-05-00012" ref-type="bibr">144</xref>,<xref rid="B145-antibiotics-05-00012" ref-type="bibr">145</xref>,<xref rid="B146-antibiotics-05-00012" ref-type="bibr">146</xref>,<xref rid="B147-antibiotics-05-00012" ref-type="bibr">147</xref>,<xref rid="B148-antibiotics-05-00012" ref-type="bibr">148</xref>]. Although the preparation of the lipid II substrate remains a tedious task, it has become more easily accessible for enzymatic and semi-enzymatic synthesis [<xref rid="B145-antibiotics-05-00012" ref-type="bibr">145</xref>,<xref rid="B149-antibiotics-05-00012" ref-type="bibr">149</xref>,<xref rid="B150-antibiotics-05-00012" ref-type="bibr">150</xref>,<xref rid="B151-antibiotics-05-00012" ref-type="bibr">151</xref>] because the limiting lipid moiety can be obtained in sufficient quantity from plant leaves [<xref rid="B152-antibiotics-05-00012" ref-type="bibr">152</xref>]. In addition, MraY can use lipids of various sizes and structures, allowing variation and better solubility of the substrate [<xref rid="B2-antibiotics-05-00012" ref-type="bibr">2</xref>,<xref rid="B145-antibiotics-05-00012" ref-type="bibr">145</xref>,<xref rid="B150-antibiotics-05-00012" ref-type="bibr">150</xref>,<xref rid="B151-antibiotics-05-00012" ref-type="bibr">151</xref>,<xref rid="B153-antibiotics-05-00012" ref-type="bibr">153</xref>,<xref rid="B154-antibiotics-05-00012" ref-type="bibr">154</xref>]. These substrates can be labeled with radioactive isotopes in the peptide or the GlcNAc moieties, with various fluorescent chromophores attached to the peptide or with a dansyl group attached to the C20 polyprenyl [<xref rid="B154-antibiotics-05-00012" ref-type="bibr">154</xref>]. These labeled substrates facilitated the development of activity assays [<xref rid="B3-antibiotics-05-00012" ref-type="bibr">3</xref>,<xref rid="B143-antibiotics-05-00012" ref-type="bibr">143</xref>,<xref rid="B155-antibiotics-05-00012" ref-type="bibr">155</xref>,<xref rid="B156-antibiotics-05-00012" ref-type="bibr">156</xref>,<xref rid="B157-antibiotics-05-00012" ref-type="bibr">157</xref>]. The availability of substrate variants that serve as donor only, acceptor only, or that are not processed by the GT enzyme and thus function as inhibitors (see below) contributed greatly to the understanding of the specificity of the GT and TP catalyzed reactions [<xref rid="B138-antibiotics-05-00012" ref-type="bibr">138</xref>,<xref rid="B147-antibiotics-05-00012" ref-type="bibr">147</xref>,<xref rid="B158-antibiotics-05-00012" ref-type="bibr">158</xref>,<xref rid="B159-antibiotics-05-00012" ref-type="bibr">159</xref>,<xref rid="B160-antibiotics-05-00012" ref-type="bibr">160</xref>,<xref rid="B161-antibiotics-05-00012" ref-type="bibr">161</xref>,<xref rid="B162-antibiotics-05-00012" ref-type="bibr">162</xref>,<xref rid="B163-antibiotics-05-00012" ref-type="bibr">163</xref>]. Thanks to these substrates, lasting problems have been solved. For example, the elongation of the glycan chain by the GT at the reducing end of the growing chain was demonstrated experimentally [<xref rid="B163-antibiotics-05-00012" ref-type="bibr">163</xref>,<xref rid="B164-antibiotics-05-00012" ref-type="bibr">164</xref>]. It has also been shown that the donor and acceptor sites of the GT exhibit different requirements for the length of the lipid, with a minimum of 20 carbon atoms for the donor and a shorter size for the acceptor [<xref rid="B153-antibiotics-05-00012" ref-type="bibr">153</xref>]. A lipid length of more than 20 carbon atoms was particularly critical for the GT processivity [<xref rid="B153-antibiotics-05-00012" ref-type="bibr">153</xref>], and a C35 lipid was an even better substrate than a C55 one [<xref rid="B145-antibiotics-05-00012" ref-type="bibr">145</xref>]. Pentaprenyl (C25, 2-cis and 2-trans) was not a substrate for GT but, when a benzene extension or a tetraprenyl one with a dansyl group extension at the end of the lipid chain, both considered C27 mimics, was added, , these analogs were GT substrates [<xref rid="B154-antibiotics-05-00012" ref-type="bibr">154</xref>]. A penta-isoprene substrate with one isoprene in <italic>trans</italic> configuration was a better substrate than a penta-isoprene in all-<italic>cis</italic> configuration; this compound had a higher affinity towards several tested GT enzymes [<xref rid="B156-antibiotics-05-00012" ref-type="bibr">156</xref>]. Analogs with two to four isoprene in <italic>cis</italic> configuration were poor substrates for most tested GTs [<xref rid="B154-antibiotics-05-00012" ref-type="bibr">154</xref>]. Synthesis and evaluation of analogs of lipid II exhibiting different peptide sequences revealed that the <sc>d</sc>-lactate-<sc>l</sc>-Ala moiety of the peptide is required for the lipid II substrate to bind and be processed by the GT [<xref rid="B165-antibiotics-05-00012" ref-type="bibr">165</xref>]. The synthesis of lipid IV labeled with <sup>14</sup>C or a fluorophore [<xref rid="B146-antibiotics-05-00012" ref-type="bibr">146</xref>,<xref rid="B147-antibiotics-05-00012" ref-type="bibr">147</xref>,<xref rid="B148-antibiotics-05-00012" ref-type="bibr">148</xref>] revealed important differences between <italic>E. coli</italic> PBP1a and PBP1b: while PBP1b uses lipid IV only in the presence of lipid II, PBP1a is able to couple two lipid IV molecules in the absence of lipid II [<xref rid="B146-antibiotics-05-00012" ref-type="bibr">146</xref>].</p></sec><sec id="sec6-antibiotics-05-00012"><title>6. Inhibitors of the Glycosyltrasferase</title><p>The GT51 is considered a validated target based on the essentiality of the class A PBPs in peptidoglycan synthesis in most bacteria (<italic>E. coli, S. aureus, S. pneumoniae, etc.</italic>&#x02026;) and the antibacterial activity of moenomycin which binds specifically to the active site of the GT. Although in laboratory conditions the class A PBPs were not absolutely essential for the viability of <italic>Bacillus subtilis</italic> and <italic>Enterococcus faecalis</italic>&#x02014;the presence of a novel GT was proposed [<xref rid="B166-antibiotics-05-00012" ref-type="bibr">166</xref>,<xref rid="B167-antibiotics-05-00012" ref-type="bibr">167</xref>]&#x02014;they may be essential in the environment. Moenomycin did not pass the development trials for use in humans, and neither did any other GT inhibitor. Given the importance of the GT as a validated target, moenomycin was investigated in great detail, allowing a better understanding of the structure-activity relationships and inspiring the synthesis of new derivatives. The moenomycin A structure consists of a pentasaccharide (rings BCDEF) and a chromophore (ring A) linked to the moenocinyl lipid (H) via a phosphoglycerate (G) group (<xref ref-type="fig" rid="antibiotics-05-00012-f005">Figure 5</xref>). Its structure mimics the undecaprenyl-linked growing chain of the PG [<xref rid="B168-antibiotics-05-00012" ref-type="bibr">168</xref>] and binds to the donor site of the GT enzyme [<xref rid="B130-antibiotics-05-00012" ref-type="bibr">130</xref>] (<xref ref-type="fig" rid="antibiotics-05-00012-f004">Figure 4</xref>). The minimal structure that retains antibacterial and GT inhibition activities is the trisaccharide CEF-phosphoglycerate-lipid. Removal of ring C leads to a loss of antibacterial activity but retains significant activity <italic>in vitro</italic> [<xref rid="B168-antibiotics-05-00012" ref-type="bibr">168</xref>]. The crystal structures of GT-moenomycin complexes show that most interactions are mediated by this trisaccharide fragment [<xref rid="B130-antibiotics-05-00012" ref-type="bibr">130</xref>,<xref rid="B136-antibiotics-05-00012" ref-type="bibr">136</xref>,<xref rid="B169-antibiotics-05-00012" ref-type="bibr">169</xref>]. The two negatively charged groups of the phosphoglycerate moiety make critical contacts with conserved residues in the GT active site. These interactions were suggested to help orient the lipid chain for binding along the hydrophobic groove facing the cytoplasmic membrane. The lipid chain plays an important role in binding and its removal abolishes both antibacterial and <italic>in vitro</italic> GT activity [<xref rid="B168-antibiotics-05-00012" ref-type="bibr">168</xref>].</p><p>Moenomycin is a highly potent inhibitor of the growth of several Gram-positive bacteria (MIC values generally below 1 &#x000b5;g/mL) [<xref rid="B170-antibiotics-05-00012" ref-type="bibr">170</xref>,<xref rid="B171-antibiotics-05-00012" ref-type="bibr">171</xref>]. However, some <italic>Enterococcus faecium</italic> strains are naturally resistant to moenomiycin [<xref rid="B172-antibiotics-05-00012" ref-type="bibr">172</xref>]. Gram-negative bacteria are much less sensitive to moenomycin due to the presence of the outer membrane. Several GT from different microorganisms have been purified and tested <italic>in vitro</italic>, and most of them are inhibited by moenomycin at a nanomolar concentration ([<xref rid="B3-antibiotics-05-00012" ref-type="bibr">3</xref>,<xref rid="B156-antibiotics-05-00012" ref-type="bibr">156</xref>,<xref rid="B173-antibiotics-05-00012" ref-type="bibr">173</xref>]. One exception is the non-essential MtgA of <italic>E. coli</italic> which does not appear to be inhibited by moenomycin [<xref rid="B174-antibiotics-05-00012" ref-type="bibr">174</xref>].</p><p>Moenomycin was used as additive in feed stocks without major incidence on resistance development [<xref rid="B175-antibiotics-05-00012" ref-type="bibr">175</xref>], suggesting that its mechanism of action is less prone to resistance. In laboratory experiments, moenomycin-selected resistant <italic>S. aureus</italic> mutants have point mutations in the GT domain of the essential PBP2 (Y196D being the most frequent mutation) [<xref rid="B176-antibiotics-05-00012" ref-type="bibr">176</xref>]. This mutation causes a cell division defect phenotype when PBP2<sup>Y196D</sup> is the only GT present and SgtB (one of the monofunctional GT in <italic>S. aureus</italic> also called MtgA or MGT) [<xref rid="B177-antibiotics-05-00012" ref-type="bibr">177</xref>] is deleted or inhibited by sub-lethal concentrations of moenomycin. Moreover, the polymerase activity of PBP2<sup>Y196D</sup> produces shorter glycan chains. The mutated Y196 residue is not critical for catalysis or interaction with the essential pharmacophore of moenomycin. It interacts with ring A and could also interact with the elongating glycan chain; the mutation probably decreases the binding affinity of the polymer for the active site and its premature release, thus yielding glycan chains of reduced length.</p><sec id="sec6dot1-antibiotics-05-00012"><title>6.1. GT Inhibitors Based on Moenomycin and Lipid II Substrate</title><p>Moenomycin and lipid II substrate have been used as templates for the synthesis of GT inhibitory analogs and have been reviewed recently [<xref rid="B178-antibiotics-05-00012" ref-type="bibr">178</xref>]. In this review, we focus on the most recent studies (<xref ref-type="fig" rid="antibiotics-05-00012-f005">Figure 5</xref>). Zuegg and colleagues [<xref rid="B160-antibiotics-05-00012" ref-type="bibr">160</xref>] synthesized a disaccharide-based library mimicking the moenomycin EF pharmacophore. The compounds showed good antibacterial activity <italic>in vitro</italic> but had unfavorable physicochemical properties (less active in the presence of 50% serum). Subsequently, on the basis of their json and published results, they designed a library aimed at reducing the molecular mass and the lipophilicity, and used solid-phase combinatorial chemistry to synthesize a library of 500 monosaccharide compounds based on a pyranose scaffold substituted in order to mimic the features of the EF-phosphoglycerate disaccharide moiety of moenomycin. The active compounds (amino-benzimidazole chemotype series) contained lipophilic substituents such as alkyl moieties with a minimum length of 10 carbon atoms or a biaryl one. The two best compounds (<bold>ACL20215</bold> and <bold>ACL20964</bold>, <xref ref-type="fig" rid="antibiotics-05-00012-f005">Figure 5</xref>) inhibited the activity of the MtgA of <italic>S. aureus</italic> with IC50 values of 17 and 11 &#x000b5;g/mL, respectively, and showed antibacterial activity against resistant and sensitive Gram-positive strains (MIC values against MRSA 4&#x02013;8 &#x000b5;g/mL) but were inactive on <italic>E. coli</italic>. Interestingly, these compounds are devoid of membrane disruption activity and exhibit low toxicity, good pharmacokinetic properties and <italic>in vivo</italic> efficacy in certain infection model experiments. The <bold>ACL20215</bold> and <bold>ACL20964</bold> compounds were tested at 50 mg&#x000b7;kg<sup>&#x02212;1</sup> in a mouse model of septicemia inoculated with <italic>S. aureus</italic> resulting in 100% survival after seven days. Lower dose (4 mg&#x000b7;kg<sup>&#x02212;1</sup>) administration resulted in only 10% survival. Both compounds cleared 99% of inoculated <italic>S. aureus</italic> from the mouse mammary gland at a moderate dose [<xref rid="B160-antibiotics-05-00012" ref-type="bibr">160</xref>]. In addition, <bold>ACL20215</bold> induced mutation frequencies lower than 2.5 &#x000d7; 10<sup>&#x02212;10</sup> on <italic>S. aureus</italic> at 4&#x000d7; MIC. Docking experiments show that the ligand adopts a Y shape with the benzimidazole group located in the phosphoglycerate pocket and the remaining two arms oriented respectively towards the donor (ring E of moenomycin) and the acceptor sites.</p><p>Mesleh <italic>et al.</italic> [<xref rid="B159-antibiotics-05-00012" ref-type="bibr">159</xref>] performed computational solvent mapping of a GT to identify druggable pockets in the active site and to help in the design of new compounds. The major hotspot regions were identified in the donor site, overlapping with binding sites of rings EFG of moenomycin A near the essential glutamate and other conserved residues of the active site, confirming that the EFG pharmacophore is the best lead for GT inhibitor design. In addition, a minor hotspot was also found in the acceptor site which would allow an extension of a potential inhibitory compound and bridge the two sites to increase its affinity. In this study the authors also reported the synthesis of 250 disaccharide compounds, some of which demonstrated antibacterial activity against Gram-positive strains (MIC 4&#x02013;8 &#x000b5;g/mL). However, after further analysis, only two compounds (<bold>ACL19109</bold>, <bold>ACL19110</bold>, <xref ref-type="fig" rid="antibiotics-05-00012-f005">Figure 5</xref>) were confirmed as specific inhibitors of GT activity. Direct active site binding of the compounds was shown by competition with moenomycin using STD-NMR. Modeling has also emphasized the binding of compounds <bold>ACL19109</bold>, <bold>ACL19110</bold> to the donor site. The biphenyl group overlaps with portions of the lipid tail of moenomycin. The sugars overlap with rings DF of moenomycin A and the two trifluoromethyl benzene groups occupy two hydrophobic pockets near the major hotspot.</p><p>The GT is an inverting enzyme that uses an S<sub>N</sub>2 mechanism. Iminosugar C-glycosides based on analogy with the transition state structure of the lipid II substrate during the glycosidic reaction have been explored as GT inhibitors [<xref rid="B162-antibiotics-05-00012" ref-type="bibr">162</xref>]. The synthetic compounds, which contain shorter lipid chains (C15 or C20) than the natural substrate, lack the peptide moiety and have a C-glycosidic linkage to ensure their stability, were able to inhibit the PG synthesis activity of GT <italic>in vitro</italic>. The best compound <bold>1</bold> (<xref ref-type="fig" rid="antibiotics-05-00012-f005">Figure 5</xref>) has a Ki value of 6.3 &#x000b5;M for the <italic>Clostridium difficile</italic> GT (for moenomycin, Ki = 0.0015 &#x000b5;M). Comparison of different lipid variants (<bold>1</bold>, tetraprenyl <italic>vs.</italic>
<bold>21</bold>, triprenyl) (<xref ref-type="fig" rid="antibiotics-05-00012-f005">Figure 5</xref>) at 100 &#x000b5;M shows that tetrapenyl is a better inhibitor (100% for <bold>1</bold>
<italic>vs.</italic> 30% for <bold>21</bold>). Derivatives lacking the lipophilic moiety were inactive. Comparison of two phosphate linkages between the lipid and the iminosugar, phosphonate (<bold>21</bold>, im-C-PP-C15) and elongated phosphate analog (<bold>20</bold>, <xref ref-type="fig" rid="antibiotics-05-00012-f005">Figure 5</xref>), im-C-O-PP-C15), shows that the increase in the bond length between the lipid and the iminosugar decreases the inhibitory activity (from 30% to 0% at 100 &#x000b5;M) showing that the phosphonate yields a better activity. Uncleavable 1-C-glycoside lipid II analogs, with the minimal required structure consisting of the tetraprenyl (C20) lipid tail and the <sc>d</sc>-lac-<sc>l</sc>-Ala peptide, have been investigated as potential GT inhibitors in a study by Lin <italic>et al.</italic> [<xref rid="B161-antibiotics-05-00012" ref-type="bibr">161</xref>]. The comparison of the sugar-phosphate disaccharide-1-C-O-PP-C20 (<bold>1</bold>) (<xref ref-type="fig" rid="antibiotics-05-00012-f005">Figure 5</xref>) and the sugar-phosphonate disaccharide-1-C-PP-C20 (<bold>2</bold>) (<xref ref-type="fig" rid="antibiotics-05-00012-f005">Figure 5</xref>) shows that compound <bold>1</bold> has GT inhibitory activity with an IC50 value of 25 &#x000b5;M whereas compound <bold>2</bold> was completely inactive. The monophosphate fragment of <bold>1</bold> lacking the alkyl monophosphate moiety was also inactive. This result contrasts with that obtained with iminosugar compounds where the phosphonate variant was more active [<xref rid="B162-antibiotics-05-00012" ref-type="bibr">162</xref>].</p></sec><sec id="sec6dot2-antibiotics-05-00012"><title>6.2. Glycosyltransferases Assays and Screening of Small Molecule Inhibitors</title><p>High-throughput screening (HTS) of enzyme inhibitors requires a robust assay and easily available substrates or specific ligands. The available GT assays are rather low- to medium-throughput which prevents large screening campaigns. Because the lipid II substrate is expensive and its synthesis difficult, it is mostly used in low-throughput assays as a radioactive or fluorescent derivative. These assays are useful to confirm the activity of compounds identified by other techniques that are expected to include false positives. Lipid II&#x02013;based assays have the advantage of detecting lipid II polymerization, and therefore can identify inhibitors that interact with the enzyme or the substrate, and their effects on the donor and acceptor sites, while moenomycin-based assays (see below) only identify ligands binding to the donor site.</p><p>A coupled assay consisting of <italic>in situ</italic> synthesis of lipid II and its polymerization by PBPs (GT-TP) was proposed [<xref rid="B179-antibiotics-05-00012" ref-type="bibr">179</xref>]. The assay utilizes <italic>E. coli</italic> cytoplasmic membranes lacking PBP1b which accumulate labeled lipid II from precursors (including radioactive GlcNAc) which are more easily accessible. Subsequently, the membrane fraction containing PBP1b is added. The dual GT-TP activities of PBP1b convert lipid II to cross-linked PG which can be captured with wheat germ agglutinin-coated scintillation proximity beads in the presence of a detergent (Sarkosyl) for quantification. The assay can be performed in microtiter plates for the screening of inhibitors of the GT and TP activities of PBPs.</p><p>The most frequently used assay for characterization of the GT is based on purified radioactive lipid II. It is very sensitive and requires a low amount of substrate to quickly analyze the GT activity of an enzyme using TLC [<xref rid="B134-antibiotics-05-00012" ref-type="bibr">134</xref>,<xref rid="B180-antibiotics-05-00012" ref-type="bibr">180</xref>]. For the analysis of both the GT and TP activities the substrate is incubated with a bifunctional PBP, the product is digested by muramidase, and the radioactive muropetides are analyzed by HPLC [<xref rid="B155-antibiotics-05-00012" ref-type="bibr">155</xref>] or, when the unlabeled substrate is used, by LC/MS [<xref rid="B45-antibiotics-05-00012" ref-type="bibr">45</xref>,<xref rid="B48-antibiotics-05-00012" ref-type="bibr">48</xref>]. With the fluorescent substrate (fluorophore bound to the Lys), only the GT activity can be monitored using HPLC [<xref rid="B142-antibiotics-05-00012" ref-type="bibr">142</xref>,<xref rid="B148-antibiotics-05-00012" ref-type="bibr">148</xref>] or LC/MS. Non-digested reaction products formed in the presence of penicillin can be analyzed by SDS-PAGE, which allows the determination of glycan chain length [<xref rid="B157-antibiotics-05-00012" ref-type="bibr">157</xref>]. Omitting penicillin in the reaction mixture enables the identification of cross-linked PG by the TP [<xref rid="B44-antibiotics-05-00012" ref-type="bibr">44</xref>].</p><p>A continuous fluorescence assay was developed by Schwartz and colleagues [<xref rid="B143-antibiotics-05-00012" ref-type="bibr">143</xref>] based on dansyl lipid II. The fluorescent probe is attached to the Lys residue of the peptide, thus preventing the cross-linking reaction. During this assay, the polymerase activity of GT is accompanied by a fluorescence decrease when dansyl lipid II is converted to a polymer followed by muramidase hydrolysis. This assay has been further optimized and adapted to microtiter plate format [<xref rid="B141-antibiotics-05-00012" ref-type="bibr">141</xref>,<xref rid="B159-antibiotics-05-00012" ref-type="bibr">159</xref>]. It can be used for the screening of compounds but the presence of fluorescent molecules often interferes with the assay.</p><p>A F&#x000f6;rster resonance energy transfer (FRET-based assay was developed by Huang <italic>et al.</italic> [<xref rid="B156-antibiotics-05-00012" ref-type="bibr">156</xref>] using a C25 lipid II analog labeled with a dimethylamino-azobenzenesulfonyl (dabsyl) quencher at the end of the lipid chain and a coumarin fluorophore attached to the peptide Lys. The substrate alone is not fluorescent, but during the GT reaction, the departure of the pyrophosphate-polyprenol-dabsyl quencher followed by degradation of the polymer by a muramidase allows detection of high-coumarin fluorescence. The FRET assay has been employed to screen a 120,000 compound library. Four known inhibitors have been detected validating the assay; in addition, one new inhibitor (<bold>25</bold>) was identified. Compound <bold>25</bold> (<xref ref-type="fig" rid="antibiotics-05-00012-f006">Figure 6</xref>) inhibits the GT in a low-micromolar-concentration range (2.3&#x02013;4.6 &#x000b5;M) and exhibits a MIC value of 16 &#x000b5;g/mL against <italic>S. aureus</italic> but is not active against Gram-negative bacteria.</p><p>GT assays based on mass spectrometry analysis have been proposed recently. The first one uses LC/MS to monitor the decrease of the lipid II substrate after the GT reaction [<xref rid="B181-antibiotics-05-00012" ref-type="bibr">181</xref>]. The LC step can be time-consuming and thus may not be suitable for HTS. The second report [<xref rid="B159-antibiotics-05-00012" ref-type="bibr">159</xref>] describes a new GT activity assay developed using the RapidFire High-Throughput MS solid phase extraction system (Agilent Technologies). It is based on the detection of the C55PP product released during the reaction. This assay presents several advantages for HTS. It is based on the lipid II substrate, whose quantity was optimized to reduce the cost, and makes use of rapid solid phase extraction instead of LC separation, which shortens the process and allows fast analysis of a complete 96-well plate in 25 min. Moreover, this assay was found to be more sensitive than LC/MS/MS.</p><p>Alternative binding assays that do not rely on lipid II and are based on the displacement of fluorescently labeled moenomycin A (F-Moe) [<xref rid="B182-antibiotics-05-00012" ref-type="bibr">182</xref>,<xref rid="B183-antibiotics-05-00012" ref-type="bibr">183</xref>] or its analog [<xref rid="B184-antibiotics-05-00012" ref-type="bibr">184</xref>] have been used to screen large collections of compounds. A fluorescence anisotropy (FA)-based assay was developed using F-Moe to screen a 57,000 small molecule library (at a concentration of 50 &#x000b5;M) for interaction with full-length <italic>Helicobacter pylori</italic> PBP1a [<xref rid="B182-antibiotics-05-00012" ref-type="bibr">182</xref>]. Eleven hits were initially identified, among which three (<bold>6</bold>, <bold>7</bold>, <bold>8</bold>, <xref ref-type="fig" rid="antibiotics-05-00012-f006">Figure 6</xref>) were confirmed to bind to the GT (IC50 = 3&#x02013;34 &#x000b5;M) and exhibit antibacterial activity against <italic>S. aureus</italic> (MIC &#x0003e; 4 &#x000b5;g/mL). Confirmation with lipid II was not reported in this study. In another study [<xref rid="B183-antibiotics-05-00012" ref-type="bibr">183</xref>], cell-based HTS was first performed on a library with two million compound to search for MRSA inhibitors. The positive hits (252 with MIC values against MRSA of 0.03&#x02013;8 &#x000b5;g/mL) were then tested using the FA assay for competition with F-Moe binding to GT. Sixteen small molecules were identified, but after lipid II polymerization assays, only salicylanilide-based molecules (<bold>42</bold>&#x02013;<bold>10</bold> and <bold>42</bold>&#x02013;<bold>17</bold>, <xref ref-type="fig" rid="antibiotics-05-00012-f006">Figure 6</xref>) were confirmed to inhibit the GT activity <italic>in vitro</italic> (IC50 37 &#x000b5;M). Analogs of these compounds have been synthesized to evaluate their structure-activity relationship. The hydroxyls of ring A and the amide group (<xref ref-type="fig" rid="antibiotics-05-00012-f006">Figure 6</xref>) were found to be essential for GT inhibition. Salicylanilides with only rings A and B were inactive and the presence of an additional aromatic group on the aniline (ring B) was shown to be important for the inhibition of GT. Compounds (<bold>42</bold>&#x02013;<bold>31</bold> and <bold>42</bold>&#x02013;<bold>35</bold>, <xref ref-type="fig" rid="antibiotics-05-00012-f006">Figure 6</xref>) have good antibacterial activity (1&#x02013;8 &#x000b5;g/mL) and inhibit the GT competitively with Ki values ranging between 5 and 28 &#x000b5;M depending on the enzymes used.</p><p>As moenomycin A binds to the GT with nanomolar affinity, an analog with lower affinity for the GT has been synthesized to allow identification of inhibitors with micromolar affinities [<xref rid="B184-antibiotics-05-00012" ref-type="bibr">184</xref>]. It consisted of a C16-trisaccharide (CEF)-phosphoglycerate substituted with a fluorescein fluorophore on ring C. This probe was used to perform a FA screening assay with a library of 110,000 small molecules against <italic>S. aureus</italic> SgtB. An active compound (<bold>10</bold>, <xref ref-type="fig" rid="antibiotics-05-00012-f006">Figure 6</xref>) that inhibits PG synthesis <italic>in vitro</italic> was discovered. The IC50 values determined using a lipid II&#x02013;based GT activity assay were 12&#x02013;79 &#x000b5;M. The compound also exhibited antibacterial activity with MIC values of 4&#x02013;16 &#x000b5;g/mL against <italic>S. aureus</italic> and <italic>B. anthracis.</italic></p></sec><sec id="sec6dot3-antibiotics-05-00012"><title>6.3. GT Inhibitor Identified by Structure-Based Virtual Screening</title><p>Structure-based virtual screening was employed to search for GT inhibitors. The DrugBank and Life Chemical compounds databases (175,000 compounds) have been filtered based on Lipinski&#x02019;s rule of five before screening [<xref rid="B185-antibiotics-05-00012" ref-type="bibr">185</xref>]. Nine hits were identified and their potential binding modes verified by visual inspection. However, the enzymatic and antibacterial activities of these compounds were not confirmed experimentally.</p><p>High-throughput virtual screening of three million compounds against <italic>S. aureus</italic> PBP2 identified an isatin derivative [<xref rid="B186-antibiotics-05-00012" ref-type="bibr">186</xref>]. Based on this compound, four series of analogs were synthesized to establish structure-activity relationships. The best compound (<bold>4L</bold>, <xref ref-type="fig" rid="antibiotics-05-00012-f006">Figure 6</xref>) had a MIC value on <italic>S. aureus</italic> of 48 &#x000b5;g/mL and was shown by STD-NMR experiments to compete with moenomycin for binding to the GT.</p><p>Using structure-based computational screening, we identified tryptamine derivatives (<bold>5b</bold>, <xref ref-type="fig" rid="antibiotics-05-00012-f006">Figure 6</xref>) which inhibit the polymerase activity of several GTases with lipid II (IC<sub>50</sub> 30&#x02013;60 &#x000b5;M) [<xref rid="B187-antibiotics-05-00012" ref-type="bibr">187</xref>]. The compounds also exhibit antibacterial activity against several Gram-positive bacteria (MIC 4&#x02013;8 &#x000b5;g/mL) and were confirmed to specifically target cell wall synthesis. While direct binding to the GT could not be established with certainty, we found that compound <bold>5b</bold> interacts with the pyrophosphate motif of lipid II. Analogs of <bold>5b</bold> were recently synthesized and a compound (<bold>70</bold>, <xref ref-type="fig" rid="antibiotics-05-00012-f006">Figure 6</xref>) with reduced non-specific cytotoxicity but which retains antibacterial and GT inhibition activities was identified [<xref rid="B188-antibiotics-05-00012" ref-type="bibr">188</xref>].</p></sec></sec><sec id="sec7-antibiotics-05-00012"><title>7. Conclusions</title><p>In the fight against antibiotic resistance, the battlefield is increasingly crowded and each pathogen requires specific attention. To date, ceftaroline and ceftobiprole allow combating Gram-positive bacteria, especially MRSA. However, combating multidrug resistant Gram-negative pathogens constitute the most urgent problem because carbapenems, the present last resort antibiotics, are destroyed by an increasing number of carbapenemases that are now appearing in all classes of &#x003b2;-lactamases. New monocyclic &#x003b2;-lactams bearing a siderophore group are promising. In the same vein, good surprises could come from non &#x003b2;-lactams, especially lactivicins that have already demonstrated high antibacterial potency. Moreover, beyond the development of new antibacterial drugs, synergistic combinations of &#x003b2;-lactam with aminoglycosides, &#x003b2;-lactamase inhibitors, other &#x003b2;-lactams or new products may offer good prospects to extend the lifetime of existing molecules.</p><p>New antibiotics are now used with caution but resistances appear rapidly after these drugs are routinely used to treat bacterial infections. The fight against pathogenic bacteria needs recurrent renewal of the antibacterial pipeline. The &#x003b2;-lactam antibiotics remain excellent weapons against bacteria. In this respect, remarkable structural work on TPs and our detailed understanding of the &#x003b2;-lactam-PBP interaction at the atomic level will certainly help in the design of new antibiotics.</p><p>The PBP-associated GT domain is a promising target. Although no useful antibiotic has so far been developed against this target, research in this field is intensifying. Two strategies are being pursued to find GT inhibitors, substrate and moenomycin analogs, and small molecules identified by HTS. Structural studies of GT in complex with synthetic analogs or newly discovered small molecules could open original perspectives for the design of effective GT-targeting antibiotics.</p><p>Finally, the PBPs are central to the multiprotein complexes elongasome and divisome. These protein-protein interaction networks are essential for peptidoglycan sacculus enlargement and division. In <italic>E. coli</italic>, it has been established that the activation of PBPs by lipoproteins partners is essential for viability. These regulation mechanisms open new perspectives in the search of novel antibacterial. Development of screening assays that take advantage of these processes and report on the perturbation of peptidoglycan synthesis machineries could lead to new antibiotics with novel mechanisms of action.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank Jean&#x02013;Marie Fr&#x000e8;re for careful reading of the manuscript. This work was supported in part by the Belgian Program on Interuniversity Poles of Attraction initiated by the Belgian State, Prime Minister&#x02019;s Office, Science Policy program IAP 7/44 iPros, the Fonds de la Recherche Scientifique, (IISN 4.4509.11, FRFC 2.4511.06F, FRFC n 2.4543.12), and the University of Li&#x000e8;ge (Fonds sp&#x000e9;ciaux, Cr&#x000e9;dit classique, C-06/19 and C-09/75). MT is a research associate of the FNRS.</p></ack><notes><title>Author Contributions</title><p>Eric Sauvage wrote the transpeptidase section. Mohammed Terrak coordinated and co-wrote the manuscript.</p></notes><notes><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-antibiotics-05-00012"><label>1.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vollmer</surname><given-names>W.</given-names></name><name><surname>Blanot</surname><given-names>D.</given-names></name><name><surname>de Pedro</surname><given-names>M.A.</given-names></name></person-group>
<article-title>Peptidoglycan structure and architecture</article-title>
<source>FEMS Microbiol. Rev.</source>
<year>2008</year>
<volume>32</volume>
<fpage>149</fpage>
<lpage>167</lpage>
<pub-id pub-id-type="doi">10.1111/j.1574-6976.2007.00094.x</pub-id>
<pub-id pub-id-type="pmid">18194336</pub-id></element-citation></ref><ref id="B2-antibiotics-05-00012"><label>2.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bouhss</surname><given-names>A.</given-names></name><name><surname>Trunkfield</surname><given-names>A.E.</given-names></name><name><surname>Bugg</surname><given-names>T.D.</given-names></name><name><surname>Mengin-Lecreulx</surname><given-names>D.</given-names></name></person-group>
<article-title>The biosynthesis of peptidoglycan lipid-linked intermediates</article-title>
<source>FEMS Microbiol. Rev.</source>
<year>2008</year>
<volume>32</volume>
<fpage>208</fpage>
<lpage>233</lpage>
<pub-id pub-id-type="doi">10.1111/j.1574-6976.2007.00089.x</pub-id>
<pub-id pub-id-type="pmid">18081839</pub-id></element-citation></ref><ref id="B3-antibiotics-05-00012"><label>3.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Terrak</surname><given-names>M.</given-names></name><name><surname>Ghosh</surname><given-names>T.K.</given-names></name><name><surname>van Heijenoort</surname><given-names>J.</given-names></name><name><surname>Van Beeumen</surname><given-names>J.</given-names></name><name><surname>Lampilas</surname><given-names>M.</given-names></name><name><surname>Aszodi</surname><given-names>J.</given-names></name><name><surname>Ayala</surname><given-names>J.A.</given-names></name><name><surname>Ghuysen</surname><given-names>J.M.</given-names></name><name><surname>Nguyen-Dist&#x000e8;che</surname><given-names>M.</given-names></name></person-group>
<article-title>The catalytic, glycosyl transferase and acyl transferase modules of the cell wall peptidoglycan-polymerizing penicillin-binding protein 1b of <italic>Escherichia coli</italic></article-title>
<source>Mol. Microbiol.</source>
<year>1999</year>
<volume>34</volume>
<fpage>350</fpage>
<lpage>364</lpage>
<pub-id pub-id-type="doi">10.1046/j.1365-2958.1999.01612.x</pub-id>
<pub-id pub-id-type="pmid">10564478</pub-id></element-citation></ref><ref id="B4-antibiotics-05-00012"><label>4.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sauvage</surname><given-names>E.</given-names></name><name><surname>Kerff</surname><given-names>F.F.</given-names></name><name><surname>Terrak</surname><given-names>M.</given-names></name><name><surname>Ayala</surname><given-names>J.A.</given-names></name><name><surname>Charlier</surname><given-names>P.</given-names></name></person-group>
<article-title>The penicillin-binding proteins: Structure and role in peptidoglycan biosynthesis</article-title>
<source>FEMS Microbiol. Rev.</source>
<year>2008</year>
<volume>32</volume>
<fpage>234</fpage>
<lpage>258</lpage>
<pub-id pub-id-type="doi">10.1111/j.1574-6976.2008.00105.x</pub-id>
<pub-id pub-id-type="pmid">18266856</pub-id></element-citation></ref><ref id="B5-antibiotics-05-00012"><label>5.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goffin</surname><given-names>C.</given-names></name><name><surname>Ghuysen</surname><given-names>J.M.</given-names></name></person-group>
<article-title>Multimodular penicillin-binding proteins: An enigmatic family of orthologs and paralogs</article-title>
<source>Microbiol. Mol. Biol. Rev.</source>
<year>1998</year>
<volume>62</volume>
<fpage>1079</fpage>
<lpage>1093</lpage>
<pub-id pub-id-type="pmid">9841666</pub-id></element-citation></ref><ref id="B6-antibiotics-05-00012"><label>6.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Banzhaf</surname><given-names>M.</given-names></name><name><surname>van den Berg van Saparoea</surname><given-names>B.</given-names></name><name><surname>Terrak</surname><given-names>M.</given-names></name><name><surname>Fraipont</surname><given-names>C.</given-names></name><name><surname>Egan</surname><given-names>A.</given-names></name><name><surname>Philippe</surname><given-names>J.</given-names></name><name><surname>Zapun</surname><given-names>A.</given-names></name><name><surname>Breukink</surname><given-names>E.</given-names></name><name><surname>Nguyen-Dist&#x000e8;che</surname><given-names>M.</given-names></name><name><surname>den Blaauwen</surname><given-names>T.</given-names></name><etal/></person-group>
<article-title>Cooperativity of peptidoglycan synthases active in bacterial cell elongation</article-title>
<source>Mol. Microbiol.</source>
<year>2012</year>
<volume>85</volume>
<fpage>179</fpage>
<lpage>194</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2958.2012.08103.x</pub-id>
<pub-id pub-id-type="pmid">22606933</pub-id></element-citation></ref><ref id="B7-antibiotics-05-00012"><label>7.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lupoli</surname><given-names>T.J.</given-names></name><name><surname>Lebar</surname><given-names>M.D.</given-names></name><name><surname>Markovski</surname><given-names>M.</given-names></name><name><surname>Bernhardt</surname><given-names>T.</given-names></name><name><surname>Kahne</surname><given-names>D.</given-names></name><name><surname>Walker</surname><given-names>S.</given-names></name></person-group>
<article-title>Lipoprotein activators stimulate <italic>Escherichia coli</italic> penicillin-binding proteins by different mechanisms</article-title>
<source>J. Am. Chem. Soc.</source>
<year>2014</year>
<volume>136</volume>
<fpage>52</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="doi">10.1021/ja410813j</pub-id>
<pub-id pub-id-type="pmid">24341982</pub-id></element-citation></ref><ref id="B8-antibiotics-05-00012"><label>8.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Born</surname><given-names>P.</given-names></name><name><surname>Breukink</surname><given-names>E.</given-names></name><name><surname>Vollmer</surname><given-names>W.</given-names></name></person-group>
<article-title><italic>In vitro</italic> synthesis of cross-linked murein and its attachment to sacculi by PBP1A from <italic>Escherichia coli</italic></article-title>
<source>J. Biol. Chem.</source>
<year>2006</year>
<volume>281</volume>
<fpage>26985</fpage>
<lpage>26993</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M604083200</pub-id>
<pub-id pub-id-type="pmid">16840781</pub-id></element-citation></ref><ref id="B9-antibiotics-05-00012"><label>9.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bertsche</surname><given-names>U.</given-names></name><name><surname>Breukink</surname><given-names>E.</given-names></name><name><surname>Kast</surname><given-names>T.</given-names></name><name><surname>Vollmer</surname><given-names>W.</given-names></name></person-group>
<article-title><italic>In vitro</italic> murein peptidoglycan synthesis by dimers of the bifunctional transglycosylase-transpeptidase PBP1B from <italic>Escherichia coli</italic></article-title>
<source>J. Biol. Chem.</source>
<year>2005</year>
<volume>280</volume>
<fpage>38096</fpage>
<lpage>38101</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M508646200</pub-id>
<pub-id pub-id-type="pmid">16154998</pub-id></element-citation></ref><ref id="B10-antibiotics-05-00012"><label>10.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Egan</surname><given-names>A.J.F.</given-names></name><name><surname>Biboy</surname><given-names>J.</given-names></name><name><surname>van&#x02019;t Veer</surname><given-names>I.</given-names></name><name><surname>Breukink</surname><given-names>E.</given-names></name><name><surname>Vollmer</surname><given-names>W.</given-names></name></person-group>
<article-title>Activities and regulation of peptidoglycan synthases</article-title>
<source>Philos. Trans. R. Soc. B Biol. Sci.</source>
<year>2015</year>
<volume>370</volume>
<pub-id pub-id-type="doi">10.1098/rstb.2015.0031</pub-id>
<pub-id pub-id-type="pmid">26370943</pub-id></element-citation></ref><ref id="B11-antibiotics-05-00012"><label>11.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Silver</surname><given-names>L.L.</given-names></name></person-group>
<article-title>Viable screening targets related to the bacterial cell wall</article-title>
<source>Ann. N. Y. Acad. Sci.</source>
<year>2013</year>
<volume>1277</volume>
<fpage>29</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="doi">10.1111/nyas.12006</pub-id>
<pub-id pub-id-type="pmid">23278681</pub-id></element-citation></ref><ref id="B12-antibiotics-05-00012"><label>12.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bush</surname><given-names>K.</given-names></name></person-group>
<article-title>A resurgence of &#x003b2;-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens</article-title>
<source>Int. J. Antimicrob. Agents</source>
<year>2015</year>
<volume>46</volume>
<fpage>483</fpage>
<lpage>493</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijantimicag.2015.08.011</pub-id>
<pub-id pub-id-type="pmid">26498989</pub-id></element-citation></ref><ref id="B13-antibiotics-05-00012"><label>13.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fr&#x000e8;re</surname><given-names>J.-M.</given-names></name><name><surname>Sauvage</surname><given-names>E.</given-names></name><name><surname>Kerff</surname><given-names>F.</given-names></name></person-group>
<article-title>From &#x000ab;&#x0202f;An enzyme able to destroy penicillin&#x0202f;&#x000bb; to carbapenemases: 70 years of beta-lactamase misbehavior</article-title>
<source>Curr. Drug Targets</source>
<year>2015</year>
<pub-id pub-id-type="doi">10.2174/1389450116666151001112859</pub-id>
</element-citation></ref><ref id="B14-antibiotics-05-00012"><label>14.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chang</surname><given-names>H.-H.</given-names></name><name><surname>Cohen</surname><given-names>T.</given-names></name><name><surname>Grad</surname><given-names>Y.H.</given-names></name><name><surname>Hanage</surname><given-names>W.P.</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>T.F.</given-names></name><name><surname>Lipsitch</surname><given-names>M.</given-names></name></person-group>
<article-title>Origin and proliferation of multiple-drug resistance in bacterial pathogens</article-title>
<source>Microbiol. Mol. Biol. Rev.</source>
<year>2015</year>
<volume>79</volume>
<fpage>101</fpage>
<lpage>116</lpage>
<pub-id pub-id-type="doi">10.1128/MMBR.00039-14</pub-id>
<pub-id pub-id-type="pmid">25652543</pub-id></element-citation></ref><ref id="B15-antibiotics-05-00012"><label>15.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oppedijk</surname><given-names>S.F.</given-names></name><name><surname>Martin</surname><given-names>N.I.</given-names></name><name><surname>Breukink</surname><given-names>E.</given-names></name></person-group>
<article-title>Hit &#x02019;em where it hurts: The growing and structurally diverse family of peptides that target lipid-II</article-title>
<source>Biochim. Biophys. Acta</source>
<year>2015</year>
<pub-id pub-id-type="doi">10.1016/j.bbamem.2015.10.024</pub-id>
<pub-id pub-id-type="pmid">26523408</pub-id></element-citation></ref><ref id="B16-antibiotics-05-00012"><label>16.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>M&#x000fc;nch</surname><given-names>D.</given-names></name><name><surname>Sahl</surname><given-names>H.-G.</given-names></name></person-group>
<article-title>Structural variations of the cell wall precursor lipid II in Gram-positive bacteria&#x02014;Impact on binding and efficacy of antimicrobial peptides</article-title>
<source>Biochim. Biophys. Acta</source>
<year>2015</year>
<volume>1848</volume>
<fpage>3062</fpage>
<lpage>3071</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbamem.2015.04.014</pub-id>
<pub-id pub-id-type="pmid">25934055</pub-id></element-citation></ref><ref id="B17-antibiotics-05-00012"><label>17.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schneider</surname><given-names>T.</given-names></name><name><surname>Sahl</surname><given-names>H.-G.</given-names></name></person-group>
<article-title>Lipid II and other bactoprenol-bound cell wall precursors as drug targets</article-title>
<source>Curr. Opin. Investig. Drugs</source>
<year>2010</year>
<volume>11</volume>
<fpage>157</fpage>
<lpage>164</lpage>
<pub-id pub-id-type="pmid">20112165</pub-id></element-citation></ref><ref id="B18-antibiotics-05-00012"><label>18.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ling</surname><given-names>L.L.</given-names></name><name><surname>Schneider</surname><given-names>T.</given-names></name><name><surname>Peoples</surname><given-names>A.J.</given-names></name><name><surname>Spoering</surname><given-names>A.L.</given-names></name><name><surname>Engels</surname><given-names>I.</given-names></name><name><surname>Conlon</surname><given-names>B.P.</given-names></name><name><surname>Mueller</surname><given-names>A.</given-names></name><name><surname>Sch&#x000e4;berle</surname><given-names>T.F.</given-names></name><name><surname>Hughes</surname><given-names>D.E.</given-names></name><name><surname>Epstein</surname><given-names>S.</given-names></name><etal/></person-group>
<article-title>A new antibiotic kills pathogens without detectable resistance</article-title>
<source>Nature</source>
<year>2015</year>
<volume>517</volume>
<fpage>455</fpage>
<lpage>459</lpage>
<pub-id pub-id-type="doi">10.1038/nature14098</pub-id>
<pub-id pub-id-type="pmid">25561178</pub-id></element-citation></ref><ref id="B19-antibiotics-05-00012"><label>19.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clardy</surname><given-names>J.</given-names></name><name><surname>Fischbach</surname><given-names>M.A.</given-names></name><name><surname>Walsh</surname><given-names>C.T.</given-names></name></person-group>
<article-title>New antibiotics from bacterial natural products</article-title>
<source>Nat. Biotechnol.</source>
<year>2006</year>
<volume>24</volume>
<fpage>1541</fpage>
<lpage>1550</lpage>
<pub-id pub-id-type="doi">10.1038/nbt1266</pub-id>
<pub-id pub-id-type="pmid">17160060</pub-id></element-citation></ref><ref id="B20-antibiotics-05-00012"><label>20.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nichols</surname><given-names>D.</given-names></name><name><surname>Cahoon</surname><given-names>N.</given-names></name><name><surname>Trakhtenberg</surname><given-names>E.M.</given-names></name><name><surname>Pham</surname><given-names>L.</given-names></name><name><surname>Mehta</surname><given-names>A.</given-names></name><name><surname>Belanger</surname><given-names>A.</given-names></name><name><surname>Kanigan</surname><given-names>T.</given-names></name><name><surname>Lewis</surname><given-names>K.</given-names></name><name><surname>Epstein</surname><given-names>S.S.</given-names></name></person-group>
<article-title>Use of ichip for high-throughput <italic>in situ</italic> cultivation of &#x0201c;uncultivable&#x0201d; microbial species</article-title>
<source>Appl. Environ. Microbiol.</source>
<year>2010</year>
<volume>76</volume>
<fpage>2445</fpage>
<lpage>2450</lpage>
<pub-id pub-id-type="doi">10.1128/AEM.01754-09</pub-id>
<pub-id pub-id-type="pmid">20173072</pub-id></element-citation></ref><ref id="B21-antibiotics-05-00012"><label>21.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Packiam</surname><given-names>M.</given-names></name><name><surname>Weinrick</surname><given-names>B.</given-names></name><name><surname>Jacobs</surname><given-names>W.R.</given-names></name><name><surname>Maurelli</surname><given-names>A.T.</given-names></name></person-group>
<article-title>Structural characterization of muropeptides from Chlamydia trachomatis peptidoglycan by mass spectrometry resolves &#x0201c;chlamydial anomaly&#x0201d;</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>2015</year>
<volume>112</volume>
<fpage>11660</fpage>
<lpage>11665</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1514026112</pub-id>
<pub-id pub-id-type="pmid">26290580</pub-id></element-citation></ref><ref id="B22-antibiotics-05-00012"><label>22.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liechti</surname><given-names>G.W.</given-names></name><name><surname>Kuru</surname><given-names>E.</given-names></name><name><surname>Hall</surname><given-names>E.</given-names></name><name><surname>Kalinda</surname><given-names>A.</given-names></name><name><surname>Brun</surname><given-names>Y.V.</given-names></name><name><surname>VanNieuwenhze</surname><given-names>M.</given-names></name><name><surname>Maurelli</surname><given-names>A.T.</given-names></name></person-group>
<article-title>A new metabolic cell-wall labelling method reveals peptidoglycan in Chlamydia trachomatis</article-title>
<source>Nature</source>
<year>2014</year>
<volume>506</volume>
<fpage>507</fpage>
<lpage>510</lpage>
<pub-id pub-id-type="doi">10.1038/nature12892</pub-id>
<pub-id pub-id-type="pmid">24336210</pub-id></element-citation></ref><ref id="B23-antibiotics-05-00012"><label>23.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zapun</surname><given-names>A.</given-names></name><name><surname>Vernet</surname><given-names>T.</given-names></name><name><surname>Pinho</surname><given-names>M.G.</given-names></name></person-group>
<article-title>The different shapes of cocci</article-title>
<source>FEMS Microbiol. Rev.</source>
<year>2008</year>
<volume>32</volume>
<fpage>345</fpage>
<lpage>360</lpage>
<pub-id pub-id-type="doi">10.1111/j.1574-6976.2007.00098.x</pub-id>
<pub-id pub-id-type="pmid">18266741</pub-id></element-citation></ref><ref id="B24-antibiotics-05-00012"><label>24.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zapun</surname><given-names>A.</given-names></name><name><surname>Contreras-Martel</surname><given-names>C.</given-names></name><name><surname>Vernet</surname><given-names>T.</given-names></name></person-group>
<article-title>Penicillin-binding proteins and beta-lactam resistance</article-title>
<source>FEMS Microbiol. Rev.</source>
<year>2008</year>
<volume>32</volume>
<fpage>361</fpage>
<lpage>385</lpage>
<pub-id pub-id-type="doi">10.1111/j.1574-6976.2007.00095.x</pub-id>
<pub-id pub-id-type="pmid">18248419</pub-id></element-citation></ref><ref id="B25-antibiotics-05-00012"><label>25.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Slimings</surname><given-names>C.</given-names></name><name><surname>Riley</surname><given-names>T.V.</given-names></name></person-group>
<article-title>Antibiotics and hospital-acquired Clostridium difficile infection: Update of systematic review and meta-analysis</article-title>
<source>J. Antimicrob. Chemother.</source>
<year>2014</year>
<volume>69</volume>
<fpage>881</fpage>
<lpage>891</lpage>
<pub-id pub-id-type="doi">10.1093/jac/dkt477</pub-id>
<pub-id pub-id-type="pmid">24324224</pub-id></element-citation></ref><ref id="B26-antibiotics-05-00012"><label>26.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van Heijenoort</surname><given-names>J.</given-names></name></person-group>
<article-title>Peptidoglycan hydrolases of <italic>Escherichia coli</italic></article-title>
<source>Microbiol. Mol. Biol. Rev.</source>
<year>2011</year>
<volume>75</volume>
<fpage>636</fpage>
<lpage>663</lpage>
<pub-id pub-id-type="doi">10.1128/MMBR.00022-11</pub-id>
<pub-id pub-id-type="pmid">22126997</pub-id></element-citation></ref><ref id="B27-antibiotics-05-00012"><label>27.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Denome</surname><given-names>S.A.</given-names></name><name><surname>Elf</surname><given-names>P.K.</given-names></name><name><surname>Henderson</surname><given-names>T.A.</given-names></name><name><surname>Nelson</surname><given-names>D.E.</given-names></name><name><surname>Young</surname><given-names>K.D.</given-names></name></person-group>
<article-title><italic>Escherichia coli</italic> mutants lacking all possible combinations of eight penicillin binding proteins: Viability, characteristics, and implications for peptidoglycan synthesis</article-title>
<source>J. Bacteriol.</source>
<year>1999</year>
<volume>181</volume>
<fpage>3981</fpage>
<lpage>3993</lpage>
<pub-id pub-id-type="pmid">10383966</pub-id></element-citation></ref><ref id="B28-antibiotics-05-00012"><label>28.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vollmer</surname><given-names>W.</given-names></name><name><surname>Joris</surname><given-names>B.</given-names></name><name><surname>Charlier</surname><given-names>P.</given-names></name><name><surname>Foster</surname><given-names>S.</given-names></name></person-group>
<article-title>Bacterial peptidoglycan (murein) hydrolases</article-title>
<source>FEMS Microbiol. Rev.</source>
<year>2008</year>
<volume>32</volume>
<fpage>259</fpage>
<lpage>286</lpage>
<pub-id pub-id-type="doi">10.1111/j.1574-6976.2007.00099.x</pub-id>
<pub-id pub-id-type="pmid">18266855</pub-id></element-citation></ref><ref id="B29-antibiotics-05-00012"><label>29.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sarkar</surname><given-names>S.K.</given-names></name><name><surname>Chowdhury</surname><given-names>C.</given-names></name><name><surname>Ghosh</surname><given-names>A.S.</given-names></name></person-group>
<article-title>Deletion of penicillin-binding protein 5 (PBP5) sensitises <italic>Escherichia coli</italic> cells to beta-lactam agents</article-title>
<source>Int. J. Antimicrob. Agents</source>
<year>2010</year>
<volume>35</volume>
<fpage>244</fpage>
<lpage>249</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijantimicag.2009.11.004</pub-id>
<pub-id pub-id-type="pmid">20047819</pub-id></element-citation></ref><ref id="B30-antibiotics-05-00012"><label>30.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dutta</surname><given-names>M.</given-names></name><name><surname>Kar</surname><given-names>D.</given-names></name><name><surname>Bansal</surname><given-names>A.</given-names></name><name><surname>Chakraborty</surname><given-names>S.</given-names></name><name><surname>Ghosh</surname><given-names>A.S.</given-names></name></person-group>
<article-title>A single amino acid substitution in the &#x003a9;-like loop of E. coli PBP5 disrupts its ability to maintain cell shape and intrinsic beta-lactam resistance</article-title>
<source>Microbiology</source>
<year>2015</year>
<volume>161</volume>
<fpage>895</fpage>
<lpage>902</lpage>
<pub-id pub-id-type="doi">10.1099/mic.0.000052</pub-id>
<pub-id pub-id-type="pmid">25667006</pub-id></element-citation></ref><ref id="B31-antibiotics-05-00012"><label>31.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Macheboeuf</surname><given-names>P.</given-names></name><name><surname>Contreras-Martel</surname><given-names>C.</given-names></name><name><surname>Job</surname><given-names>V.</given-names></name><name><surname>Dideberg</surname><given-names>O.</given-names></name><name><surname>Dessen</surname><given-names>A.</given-names></name></person-group>
<article-title>Penicillin binding proteins: Key players in bacterial cell cycle and drug resistance processes</article-title>
<source>FEMS Microbiol. Rev.</source>
<year>2006</year>
<volume>30</volume>
<fpage>673</fpage>
<lpage>691</lpage>
<pub-id pub-id-type="doi">10.1111/j.1574-6976.2006.00024.x</pub-id>
<pub-id pub-id-type="pmid">16911039</pub-id></element-citation></ref><ref id="B32-antibiotics-05-00012"><label>32.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sauvage</surname><given-names>E.</given-names></name><name><surname>Derouaux</surname><given-names>A.</given-names></name><name><surname>Fraipont</surname><given-names>C.</given-names></name><name><surname>Joris</surname><given-names>M.</given-names></name><name><surname>Herman</surname><given-names>R.</given-names></name><name><surname>Rocaboy</surname><given-names>M.</given-names></name><name><surname>Schloesser</surname><given-names>M.</given-names></name><name><surname>Dumas</surname><given-names>J.</given-names></name><name><surname>Kerff</surname><given-names>F.</given-names></name><name><surname>Nguyen-Dist&#x000e8;che</surname><given-names>M.</given-names></name><etal/></person-group>
<article-title>Crystal structure of penicillin-binding protein 3 (PBP3) from <italic>Escherichia coli</italic></article-title>
<source>PLoS ONE</source>
<year>2014</year>
<volume>9</volume>
<elocation-id>12</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0098042</pub-id>
<pub-id pub-id-type="pmid">24875494</pub-id></element-citation></ref><ref id="B33-antibiotics-05-00012"><label>33.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bertsche</surname><given-names>U.</given-names></name><name><surname>Kast</surname><given-names>T.</given-names></name><name><surname>Wolf</surname><given-names>B.</given-names></name><name><surname>Fraipont</surname><given-names>C.</given-names></name><name><surname>Aarsman</surname><given-names>M.E.</given-names></name><name><surname>Kannenberg</surname><given-names>K.</given-names></name><name><surname>von Rechenberg</surname><given-names>M.</given-names></name><name><surname>Nguyen-Dist&#x000e8;che</surname><given-names>M.</given-names></name><name><surname>den Blaauwen</surname><given-names>T.</given-names></name><name><surname>H&#x000f6;ltje</surname><given-names>J.V.</given-names></name><etal/></person-group>
<article-title>Interaction between two murein (peptidoglycan) synthases, PBP3 and PBP1B, in <italic>Escherichia coli</italic></article-title>
<source>Mol. Microbiol.</source>
<year>2006</year>
<volume>61</volume>
<fpage>675</fpage>
<lpage>690</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2958.2006.05280.x</pub-id>
<pub-id pub-id-type="pmid">16803586</pub-id></element-citation></ref><ref id="B34-antibiotics-05-00012"><label>34.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sung</surname><given-names>M.T.</given-names></name><name><surname>Lai</surname><given-names>Y.T.</given-names></name><name><surname>Huang</surname><given-names>C.Y.</given-names></name><name><surname>Chou</surname><given-names>L.Y.</given-names></name><name><surname>Shih</surname><given-names>H.W.</given-names></name><name><surname>Cheng</surname><given-names>W.C.</given-names></name><name><surname>Wong</surname><given-names>C.H.</given-names></name><name><surname>Ma</surname><given-names>C.</given-names></name></person-group>
<article-title>Crystal structure of the membrane-bound bifunctional transglycosylase PBP1b from <italic>Escherichia coli</italic></article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>2009</year>
<volume>106</volume>
<fpage>8824</fpage>
<lpage>8829</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0904030106</pub-id>
<pub-id pub-id-type="pmid">19458048</pub-id></element-citation></ref><ref id="B35-antibiotics-05-00012"><label>35.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kishida</surname><given-names>H.</given-names></name><name><surname>Unzai</surname><given-names>S.</given-names></name><name><surname>Roper</surname><given-names>D.I.</given-names></name><name><surname>Lloyd</surname><given-names>A.</given-names></name><name><surname>Park</surname><given-names>S.Y.</given-names></name><name><surname>Tame</surname><given-names>J.R.</given-names></name></person-group>
<article-title>Crystal structure of penicillin binding protein 4 (dacB) from <italic>Escherichia coli</italic>, both in the native form and covalently linked to various antibiotics</article-title>
<source>Biochemistry</source>
<year>2006</year>
<volume>45</volume>
<fpage>783</fpage>
<lpage>792</lpage>
<pub-id pub-id-type="doi">10.1021/bi051533t</pub-id>
<pub-id pub-id-type="pmid">16411754</pub-id></element-citation></ref><ref id="B36-antibiotics-05-00012"><label>36.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nicholas</surname><given-names>R.A.</given-names></name><name><surname>Krings</surname><given-names>S.</given-names></name><name><surname>Tomberg</surname><given-names>J.</given-names></name><name><surname>Nicola</surname><given-names>G.</given-names></name><name><surname>Davies</surname><given-names>C.</given-names></name></person-group>
<article-title>Crystal structure of wild-type penicillin-binding protein 5 from <italic>Escherichia coli</italic>: Implications for deacylation of the acyl-enzyme complex</article-title>
<source>J. Biol. Chem.</source>
<year>2003</year>
<volume>278</volume>
<fpage>52826</fpage>
<lpage>52833</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M310177200</pub-id>
<pub-id pub-id-type="pmid">14555648</pub-id></element-citation></ref><ref id="B37-antibiotics-05-00012"><label>37.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Typas</surname><given-names>A.</given-names></name><name><surname>Banzhaf</surname><given-names>M.</given-names></name><name><surname>van den Berg van Saparoea</surname><given-names>B.</given-names></name><name><surname>Verheul</surname><given-names>J.</given-names></name><name><surname>Biboy</surname><given-names>J.</given-names></name><name><surname>Nichols</surname><given-names>R.J.</given-names></name><name><surname>Zietek</surname><given-names>M.</given-names></name><name><surname>Beilharz</surname><given-names>K.</given-names></name><name><surname>Kannenberg</surname><given-names>K.</given-names></name><name><surname>von Rechenberg</surname><given-names>M.</given-names></name><etal/></person-group>
<article-title>Regulation of peptidoglycan synthesis by outer-membrane proteins</article-title>
<source>Cell</source>
<year>2010</year>
<volume>143</volume>
<fpage>1097</fpage>
<lpage>1109</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2010.11.038</pub-id>
<pub-id pub-id-type="pmid">21183073</pub-id></element-citation></ref><ref id="B38-antibiotics-05-00012"><label>38.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Paradis-Bleau</surname><given-names>C.</given-names></name><name><surname>Markovski</surname><given-names>M.</given-names></name><name><surname>Uehara</surname><given-names>T.</given-names></name><name><surname>Lupoli</surname><given-names>T.J.</given-names></name><name><surname>Walker</surname><given-names>S.</given-names></name><name><surname>Kahne</surname><given-names>D.E.</given-names></name><name><surname>Bernhardt</surname><given-names>T.G.</given-names></name></person-group>
<article-title>Lipoprotein cofactors located in the outer membrane activate bacterial cell wall polymerases</article-title>
<source>Cell</source>
<year>2010</year>
<volume>143</volume>
<fpage>1110</fpage>
<lpage>1120</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2010.11.037</pub-id>
<pub-id pub-id-type="pmid">21183074</pub-id></element-citation></ref><ref id="B39-antibiotics-05-00012"><label>39.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pares</surname><given-names>S.</given-names></name><name><surname>Mouz</surname><given-names>N.</given-names></name><name><surname>P&#x000e9;tillot</surname><given-names>Y.</given-names></name><name><surname>Hakenbeck</surname><given-names>R.</given-names></name><name><surname>Dideberg</surname><given-names>O.</given-names></name></person-group>
<article-title>X-ray structure of Streptococcus pneumoniae PBP2x, a primary penicillin target enzyme</article-title>
<source>Nat. Struct. Biol.</source>
<year>1996</year>
<volume>3</volume>
<fpage>284</fpage>
<lpage>289</lpage>
<pub-id pub-id-type="doi">10.1038/nsb0396-284</pub-id>
<pub-id pub-id-type="pmid">8605631</pub-id></element-citation></ref><ref id="B40-antibiotics-05-00012"><label>40.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maurer</surname><given-names>P.</given-names></name><name><surname>Todorova</surname><given-names>K.</given-names></name><name><surname>Sauerbier</surname><given-names>J.</given-names></name><name><surname>Hakenbeck</surname><given-names>R.</given-names></name></person-group>
<article-title>Mutations in Streptococcus pneumoniae penicillin-binding protein 2x: Importance of the C-terminal penicillin-binding protein and serine/threonine kinase-associated domains for beta-lactam binding</article-title>
<source>Microb. Drug Resist.</source>
<year>2012</year>
<volume>18</volume>
<fpage>314</fpage>
<lpage>321</lpage>
<pub-id pub-id-type="doi">10.1089/mdr.2012.0022</pub-id>
<pub-id pub-id-type="pmid">22455550</pub-id></element-citation></ref><ref id="B41-antibiotics-05-00012"><label>41.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schweizer</surname><given-names>I.</given-names></name><name><surname>Peters</surname><given-names>K.</given-names></name><name><surname>Stahlmann</surname><given-names>C.</given-names></name><name><surname>Hakenbeck</surname><given-names>R.</given-names></name><name><surname>Denapaite</surname><given-names>D.</given-names></name></person-group>
<article-title>Penicillin-binding protein 2x of Streptococcus pneumoniae: The mutation Ala707Asp within the C-terminal PASTA2 domain leads to destabilization</article-title>
<source>Microb. Drug Resist.</source>
<year>2014</year>
<volume>20</volume>
<fpage>250</fpage>
<lpage>257</lpage>
<pub-id pub-id-type="doi">10.1089/mdr.2014.0082</pub-id>
<pub-id pub-id-type="pmid">24841912</pub-id></element-citation></ref><ref id="B42-antibiotics-05-00012"><label>42.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peters</surname><given-names>K.</given-names></name><name><surname>Schweizer</surname><given-names>I.</given-names></name><name><surname>Beilharz</surname><given-names>K.</given-names></name><name><surname>Stahlmann</surname><given-names>C.</given-names></name><name><surname>Veening</surname><given-names>J.-W.</given-names></name><name><surname>Hakenbeck</surname><given-names>R.</given-names></name><name><surname>Denapaite</surname><given-names>D.</given-names></name></person-group>
<article-title>Streptococcus pneumoniae PBP2x mid-cell localization requires the C-terminal PASTA domains and is essential for cell shape maintenance</article-title>
<source>Mol. Microbiol.</source>
<year>2014</year>
<volume>92</volume>
<fpage>733</fpage>
<lpage>755</lpage>
<pub-id pub-id-type="doi">10.1111/mmi.12588</pub-id>
<pub-id pub-id-type="pmid">24655324</pub-id></element-citation></ref><ref id="B43-antibiotics-05-00012"><label>43.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sieradzki</surname><given-names>K.</given-names></name><name><surname>Pinho</surname><given-names>M.G.</given-names></name><name><surname>Tomasz</surname><given-names>A.</given-names></name></person-group>
<article-title>Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus</article-title>
<source>J. Biol. Chem.</source>
<year>1999</year>
<volume>274</volume>
<fpage>18942</fpage>
<lpage>18946</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.274.27.18942</pub-id>
<pub-id pub-id-type="pmid">10383392</pub-id></element-citation></ref><ref id="B44-antibiotics-05-00012"><label>44.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zapun</surname><given-names>A.</given-names></name><name><surname>Philippe</surname><given-names>J.</given-names></name><name><surname>Abrahams</surname><given-names>K.A.</given-names></name><name><surname>Signor</surname><given-names>L.</given-names></name><name><surname>Roper</surname><given-names>D.I.</given-names></name><name><surname>Breukink</surname><given-names>E.</given-names></name><name><surname>Vernet</surname><given-names>T.</given-names></name></person-group>
<article-title><italic>In vitro</italic> reconstitution of peptidoglycan assembly from the Gram-positive pathogen Streptococcus pneumoniae</article-title>
<source>ACS Chem. Biol.</source>
<year>2013</year>
<volume>8</volume>
<fpage>2688</fpage>
<lpage>2696</lpage>
<pub-id pub-id-type="doi">10.1021/cb400575t</pub-id>
<pub-id pub-id-type="pmid">24044435</pub-id></element-citation></ref><ref id="B45-antibiotics-05-00012"><label>45.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lebar</surname><given-names>M.D.</given-names></name><name><surname>May</surname><given-names>J.M.</given-names></name><name><surname>Meeske</surname><given-names>A.J.</given-names></name><name><surname>Leiman</surname><given-names>S.A.</given-names></name><name><surname>Lupoli</surname><given-names>T.J.</given-names></name><name><surname>Tsukamoto</surname><given-names>H.</given-names></name><name><surname>Losick</surname><given-names>R.</given-names></name><name><surname>Rudner</surname><given-names>D.Z.</given-names></name><name><surname>Walker</surname><given-names>S.</given-names></name><name><surname>Kahne</surname><given-names>D.</given-names></name></person-group>
<article-title>Reconstitution of peptidoglycan cross-linking leads to improved fluorescent probes of cell wall synthesis</article-title>
<source>J. Am. Chem. Soc.</source>
<year>2014</year>
<volume>136</volume>
<fpage>10874</fpage>
<lpage>10877</lpage>
<pub-id pub-id-type="doi">10.1021/ja505668f</pub-id>
<pub-id pub-id-type="pmid">25036369</pub-id></element-citation></ref><ref id="B46-antibiotics-05-00012"><label>46.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Levefaudes</surname><given-names>M.</given-names></name><name><surname>Patin</surname><given-names>D.</given-names></name><name><surname>de Sousa-d&#x02019;Auria</surname><given-names>C.</given-names></name><name><surname>Chami</surname><given-names>M.</given-names></name><name><surname>Blanot</surname><given-names>D.</given-names></name><name><surname>Herv&#x000e9;</surname><given-names>M.</given-names></name><name><surname>Arthur</surname><given-names>M.</given-names></name><name><surname>Houssin</surname><given-names>C.</given-names></name><name><surname>Mengin-Lecreulx</surname><given-names>D.</given-names></name></person-group>
<article-title>Diaminopimelic Acid Amidation in Corynebacteriales: New insights into the role of ltsa in peptidoglycan modification</article-title>
<source>J. Biol. Chem.</source>
<year>2015</year>
<volume>290</volume>
<fpage>13079</fpage>
<lpage>13094</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M115.642843</pub-id>
<pub-id pub-id-type="pmid">25847251</pub-id></element-citation></ref><ref id="B47-antibiotics-05-00012"><label>47.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mainardi</surname><given-names>J.-L.</given-names></name><name><surname>Villet</surname><given-names>R.</given-names></name><name><surname>Bugg</surname><given-names>T.D.</given-names></name><name><surname>Mayer</surname><given-names>C.</given-names></name><name><surname>Arthur</surname><given-names>M.</given-names></name></person-group>
<article-title>Evolution of peptidoglycan biosynthesis under the selective pressure of antibiotics in Gram-positive bacteria</article-title>
<source>FEMS Microbiol. Rev.</source>
<year>2008</year>
<volume>32</volume>
<fpage>386</fpage>
<lpage>408</lpage>
<pub-id pub-id-type="doi">10.1111/j.1574-6976.2007.00097.x</pub-id>
<pub-id pub-id-type="pmid">18266857</pub-id></element-citation></ref><ref id="B48-antibiotics-05-00012"><label>48.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Qiao</surname><given-names>Y.</given-names></name><name><surname>Lebar</surname><given-names>M.D.</given-names></name><name><surname>Schirner</surname><given-names>K.</given-names></name><name><surname>Schaefer</surname><given-names>K.</given-names></name><name><surname>Tsukamoto</surname><given-names>H.</given-names></name><name><surname>Kahne</surname><given-names>D.</given-names></name><name><surname>Walker</surname><given-names>S.</given-names></name></person-group>
<article-title>Detection of lipid-linked peptidoglycan precursors by exploiting an unexpected transpeptidase reaction</article-title>
<source>J. Am. Chem. Soc.</source>
<year>2014</year>
<volume>136</volume>
<fpage>14678</fpage>
<lpage>81461</lpage>
<pub-id pub-id-type="doi">10.1021/ja508147s</pub-id>
<pub-id pub-id-type="pmid">25291014</pub-id></element-citation></ref><ref id="B49-antibiotics-05-00012"><label>49.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pollock</surname><given-names>J.J.</given-names></name><name><surname>Ghuysen</surname><given-names>J.M.</given-names></name><name><surname>Linder</surname><given-names>R.</given-names></name><name><surname>Salton</surname><given-names>M.R.</given-names></name><name><surname>Perkins</surname><given-names>H.R.</given-names></name><name><surname>Nieto</surname><given-names>M.</given-names></name><name><surname>Leyh-Bouille</surname><given-names>M.</given-names></name><name><surname>Frere</surname><given-names>J.M.</given-names></name><name><surname>Johnson</surname><given-names>K.</given-names></name></person-group>
<article-title>Transpeptidase activity of Streptomyces <sc>d</sc>-alanyl-<sc>d</sc> carboxypeptidases</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>1972</year>
<volume>69</volume>
<fpage>662</fpage>
<lpage>666</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.69.3.662</pub-id>
<pub-id pub-id-type="pmid">4501580</pub-id></element-citation></ref><ref id="B50-antibiotics-05-00012"><label>50.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nguyen-Dist&#x000e8;che</surname><given-names>M.</given-names></name><name><surname>Leyh-Bouille</surname><given-names>M.</given-names></name><name><surname>Ghuysen</surname><given-names>J.M.</given-names></name></person-group>
<article-title>Isolation of the membrane-bound 26 000-Mr penicillin-binding protein of Streptomyces strain K15 in the form of a penicillin-sensitive <sc>d</sc>-alanyl-<sc>d</sc>-alanine-cleaving transpeptidase</article-title>
<source>Biochem. J.</source>
<year>1982</year>
<volume>207</volume>
<fpage>109</fpage>
<lpage>115</lpage>
<pub-id pub-id-type="doi">10.1042/bj2070109</pub-id>
<pub-id pub-id-type="pmid">7181854</pub-id></element-citation></ref><ref id="B51-antibiotics-05-00012"><label>51.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Adam</surname><given-names>M.</given-names></name><name><surname>Damblon</surname><given-names>C.</given-names></name><name><surname>Jamin</surname><given-names>M.</given-names></name><name><surname>Zorzi</surname><given-names>W.</given-names></name><name><surname>Dusart</surname><given-names>V.</given-names></name><name><surname>Galleni</surname><given-names>M.</given-names></name><name><surname>el Kharroubi</surname><given-names>A.</given-names></name><name><surname>Piras</surname><given-names>G.</given-names></name><name><surname>Spratt</surname><given-names>B.G.</given-names></name><name><surname>Keck</surname><given-names>W.</given-names></name><etal/></person-group>
<article-title>Acyltransferase activities of the high-molecular-mass essential penicillin-binding proteins</article-title>
<source>Biochem. J.</source>
<year>1991</year>
<volume>279</volume>
<fpage>601</fpage>
<lpage>604</lpage>
<pub-id pub-id-type="doi">10.1042/bj2790601</pub-id>
<pub-id pub-id-type="pmid">1953655</pub-id></element-citation></ref><ref id="B52-antibiotics-05-00012"><label>52.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Pedro</surname><given-names>M.A.</given-names></name><name><surname>Quintela</surname><given-names>J.C.</given-names></name><name><surname>H&#x000f6;ltje</surname><given-names>J.V.</given-names></name><name><surname>Schwarz</surname><given-names>H.</given-names></name></person-group>
<article-title>Murein segregation in <italic>Escherichia coli</italic></article-title>
<source>J. Bacteriol.</source>
<year>1997</year>
<volume>179</volume>
<fpage>2823</fpage>
<lpage>2834</lpage>
<pub-id pub-id-type="pmid">9139895</pub-id></element-citation></ref><ref id="B53-antibiotics-05-00012"><label>53.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lupoli</surname><given-names>T.J.</given-names></name><name><surname>Tsukamoto</surname><given-names>H.</given-names></name><name><surname>Doud</surname><given-names>E.H.</given-names></name><name><surname>Wang</surname><given-names>T.-S.A.</given-names></name><name><surname>Walker</surname><given-names>S.</given-names></name><name><surname>Kahne</surname><given-names>D.</given-names></name></person-group>
<article-title>Transpeptidase-mediated incorporation of <sc>d</sc>-amino acids into bacterial peptidoglycan</article-title>
<source>J. Am. Chem. Soc.</source>
<year>2011</year>
<volume>133</volume>
<fpage>10748</fpage>
<lpage>10751</lpage>
<pub-id pub-id-type="doi">10.1021/ja2040656</pub-id>
<pub-id pub-id-type="pmid">21682301</pub-id></element-citation></ref><ref id="B54-antibiotics-05-00012"><label>54.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van Dam</surname><given-names>V.</given-names></name><name><surname>Olrichs</surname><given-names>N.</given-names></name><name><surname>Breukink</surname><given-names>E.</given-names></name></person-group>
<article-title>Specific labeling of peptidoglycan precursors as a tool for bacterial cell wall studies</article-title>
<source>Chembiochem</source>
<year>2009</year>
<volume>10</volume>
<fpage>617</fpage>
<lpage>624</lpage>
<pub-id pub-id-type="doi">10.1002/cbic.200800678</pub-id>
<pub-id pub-id-type="pmid">19173317</pub-id></element-citation></ref><ref id="B55-antibiotics-05-00012"><label>55.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kuru</surname><given-names>E.</given-names></name><name><surname>Hughes</surname><given-names>H.V.</given-names></name><name><surname>Brown</surname><given-names>P.J.</given-names></name><name><surname>Hall</surname><given-names>E.</given-names></name><name><surname>Tekkam</surname><given-names>S.</given-names></name><name><surname>Cava</surname><given-names>F.</given-names></name><name><surname>de Pedro</surname><given-names>M.A.</given-names></name><name><surname>Brun</surname><given-names>Y.V.</given-names></name><name><surname>VanNieuwenhze</surname><given-names>M.S.</given-names></name></person-group>
<article-title><italic>In Situ</italic> probing of newly synthesized peptidoglycan in live bacteria with fluorescent <sc>d</sc>-amino acids</article-title>
<source>Angew. Chem. Int. Ed. Engl.</source>
<year>2012</year>
<volume>51</volume>
<fpage>12519</fpage>
<lpage>12523</lpage>
<pub-id pub-id-type="pmid">23055266</pub-id></element-citation></ref><ref id="B56-antibiotics-05-00012"><label>56.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tipper</surname><given-names>D.J.</given-names></name><name><surname>Strominger</surname><given-names>J.L.</given-names></name></person-group>
<article-title>Mechanism of action of penicillins: A proposal based on their structural similarity to acyl-<sc>d</sc>-alanyl-<sc>d</sc>-alanine</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>1965</year>
<volume>54</volume>
<fpage>1133</fpage>
<lpage>1141</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.54.4.1133</pub-id>
<pub-id pub-id-type="pmid">5219821</pub-id></element-citation></ref><ref id="B57-antibiotics-05-00012"><label>57.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mpenge</surname><given-names>M.A.</given-names></name><name><surname>MacGowan</surname><given-names>A.P.</given-names></name></person-group>
<article-title>Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia</article-title>
<source>Ther. Clin. Risk Manag.</source>
<year>2015</year>
<volume>11</volume>
<fpage>565</fpage>
<lpage>579</lpage>
<pub-id pub-id-type="doi">10.2147/TCRM.S75412</pub-id>
<pub-id pub-id-type="pmid">25897241</pub-id></element-citation></ref><ref id="B58-antibiotics-05-00012"><label>58.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ghamrawi</surname><given-names>R.J.</given-names></name><name><surname>Neuner</surname><given-names>E.</given-names></name><name><surname>Rehm</surname><given-names>S.J.</given-names></name></person-group>
<article-title>Ceftaroline fosamil: A super-cephalosporin?</article-title>
<source>Cleve. Clin. J. Med.</source>
<year>2015</year>
<volume>82</volume>
<fpage>437</fpage>
<lpage>444</lpage>
<pub-id pub-id-type="pmid">26185943</pub-id></element-citation></ref><ref id="B59-antibiotics-05-00012"><label>59.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davies</surname><given-names>T.A.</given-names></name><name><surname>Flamm</surname><given-names>R.K.</given-names></name><name><surname>Lynch</surname><given-names>A.S.</given-names></name></person-group>
<article-title>Activity of ceftobiprole against Streptococcus pneumoniae isolates exhibiting high-level resistance to ceftriaxone</article-title>
<source>Int. J. Antimicrob. Agents</source>
<year>2012</year>
<volume>39</volume>
<fpage>534</fpage>
<lpage>538</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijantimicag.2012.02.016</pub-id>
<pub-id pub-id-type="pmid">22526015</pub-id></element-citation></ref><ref id="B60-antibiotics-05-00012"><label>60.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Villegas-Estrada</surname><given-names>A.</given-names></name><name><surname>Lee</surname><given-names>M.</given-names></name><name><surname>Hesek</surname><given-names>D.</given-names></name><name><surname>Vakulenko</surname><given-names>S.B.</given-names></name><name><surname>Mobashery</surname><given-names>S.</given-names></name></person-group>
<article-title>Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: Potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics</article-title>
<source>J. Am. Chem. Soc.</source>
<year>2008</year>
<volume>130</volume>
<fpage>9212</fpage>
<lpage>9213</lpage>
<pub-id pub-id-type="doi">10.1021/ja8029448</pub-id>
<pub-id pub-id-type="pmid">18582062</pub-id></element-citation></ref><ref id="B61-antibiotics-05-00012"><label>61.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hebeisen</surname><given-names>P.</given-names></name><name><surname>Heinze-Krauss</surname><given-names>I.</given-names></name><name><surname>Angehrn</surname><given-names>P.</given-names></name><name><surname>Hohl</surname><given-names>P.</given-names></name><name><surname>Page</surname><given-names>M.G.</given-names></name><name><surname>Then</surname><given-names>R.L.</given-names></name></person-group>
<article-title><italic>In vitro</italic> and <italic>in vivo</italic> properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>2001</year>
<volume>45</volume>
<fpage>825</fpage>
<lpage>836</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.45.3.825-836.2001</pub-id>
<pub-id pub-id-type="pmid">11181368</pub-id></element-citation></ref><ref id="B62-antibiotics-05-00012"><label>62.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Henry</surname><given-names>X.</given-names></name><name><surname>Amoroso</surname><given-names>A.</given-names></name><name><surname>Coyette</surname><given-names>J.</given-names></name><name><surname>Joris</surname><given-names>B.</given-names></name></person-group>
<article-title>Interaction of ceftobiprole with the low-affinity PBP 5 of Enterococcus faecium</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>2010</year>
<volume>54</volume>
<fpage>953</fpage>
<lpage>955</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.00983-09</pub-id>
<pub-id pub-id-type="pmid">19917749</pub-id></element-citation></ref><ref id="B63-antibiotics-05-00012"><label>63.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Henry</surname><given-names>X.</given-names></name><name><surname>Verlaine</surname><given-names>O.</given-names></name><name><surname>Amoroso</surname><given-names>A.</given-names></name><name><surname>Coyette</surname><given-names>J.</given-names></name><name><surname>Frere</surname><given-names>J.M.</given-names></name><name><surname>Joris</surname><given-names>B.</given-names></name></person-group>
<article-title>Activity of ceftaroline against Enterococcus faecium PBP5</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>2013</year>
<volume>57</volume>
<fpage>6358</fpage>
<lpage>6360</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.00923-13</pub-id>
<pub-id pub-id-type="pmid">24060866</pub-id></element-citation></ref><ref id="B64-antibiotics-05-00012"><label>64.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zervosen</surname><given-names>A.</given-names></name><name><surname>Zapun</surname><given-names>A.</given-names></name><name><surname>Fr&#x000e8;re</surname><given-names>J.-M.</given-names></name></person-group>
<article-title>Inhibition of Streptococcus pneumoniae penicillin-binding protein 2x and Actinomadura R39 <sc>dd</sc>-peptidase activities by ceftaroline</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>2013</year>
<volume>57</volume>
<fpage>661</fpage>
<lpage>663</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.01593-12</pub-id>
<pub-id pub-id-type="pmid">23147739</pub-id></element-citation></ref><ref id="B65-antibiotics-05-00012"><label>65.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kosowska-Shick</surname><given-names>K.</given-names></name><name><surname>McGhee</surname><given-names>P.L.</given-names></name><name><surname>Appelbaum</surname><given-names>P.C.</given-names></name></person-group>
<article-title>Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>2010</year>
<volume>54</volume>
<fpage>1670</fpage>
<lpage>1677</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.00019-10</pub-id>
<pub-id pub-id-type="pmid">20194704</pub-id></element-citation></ref><ref id="B66-antibiotics-05-00012"><label>66.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lovering</surname><given-names>A.L.</given-names></name><name><surname>Gretes</surname><given-names>M.C.</given-names></name><name><surname>Safadi</surname><given-names>S.S.</given-names></name><name><surname>Danel</surname><given-names>F.</given-names></name><name><surname>De Castro</surname><given-names>L.</given-names></name><name><surname>Page</surname><given-names>M.G.</given-names></name><name><surname>Strynadka</surname><given-names>N.C.</given-names></name></person-group>
<article-title>Structural Insights into the Anti- Methicillin-Resistant Staphylococcus aureus (MRSA) Activity of Ceftobiprole</article-title>
<source>J. Biol. Chem.</source>
<year>2012</year>
<volume>287</volume>
<fpage>32096</fpage>
<lpage>32102</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M112.355644</pub-id>
<pub-id pub-id-type="pmid">22815485</pub-id></element-citation></ref><ref id="B67-antibiotics-05-00012"><label>67.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Otero</surname><given-names>L.H.</given-names></name><name><surname>Rojas-Altuve</surname><given-names>A.</given-names></name><name><surname>Llarrull</surname><given-names>L.I.</given-names></name><name><surname>Carrasco-L&#x000f3;pez</surname><given-names>C.</given-names></name><name><surname>Kumarasiri</surname><given-names>M.</given-names></name><name><surname>Lastochkin</surname><given-names>E.</given-names></name><name><surname>Fishovitz</surname><given-names>J.</given-names></name><name><surname>Dawley</surname><given-names>M.</given-names></name><name><surname>Hesek</surname><given-names>D.</given-names></name><name><surname>Lee</surname><given-names>M.</given-names></name><etal/></person-group>
<article-title>How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>2013</year>
<volume>110</volume>
<fpage>16808</fpage>
<lpage>16813</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1300118110</pub-id>
<pub-id pub-id-type="pmid">24085846</pub-id></element-citation></ref><ref id="B68-antibiotics-05-00012"><label>68.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fishovitz</surname><given-names>J.</given-names></name><name><surname>Rojas-Altuve</surname><given-names>A.</given-names></name><name><surname>Otero</surname><given-names>L.H.</given-names></name><name><surname>Dawley</surname><given-names>M.</given-names></name><name><surname>Carrasco-L&#x000f3;pez</surname><given-names>C.</given-names></name><name><surname>Chang</surname><given-names>M.</given-names></name><name><surname>Hermoso</surname><given-names>J.A.</given-names></name><name><surname>Mobashery</surname><given-names>S.</given-names></name></person-group>
<article-title>Disruption of allosteric response as an unprecedented mechanism of resistance to antibiotics</article-title>
<source>J. Am. Chem. Soc.</source>
<year>2014</year>
<volume>136</volume>
<fpage>9814</fpage>
<lpage>9817</lpage>
<pub-id pub-id-type="doi">10.1021/ja5030657</pub-id>
<pub-id pub-id-type="pmid">24955778</pub-id></element-citation></ref><ref id="B69-antibiotics-05-00012"><label>69.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lim</surname><given-names>D.</given-names></name><name><surname>Strynadka</surname><given-names>N.C.</given-names></name></person-group>
<article-title>Structural basis for the beta lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus</article-title>
<source>Nat. Struct. Biol.</source>
<year>2002</year>
<volume>9</volume>
<fpage>870</fpage>
<lpage>876</lpage>
<pub-id pub-id-type="pmid">12389036</pub-id></element-citation></ref><ref id="B70-antibiotics-05-00012"><label>70.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sauvage</surname><given-names>E.</given-names></name><name><surname>Kerff</surname><given-names>F.</given-names></name><name><surname>Fonze</surname><given-names>E.</given-names></name><name><surname>Herman</surname><given-names>R.</given-names></name><name><surname>Schoot</surname><given-names>B.</given-names></name><name><surname>Marquette</surname><given-names>J.P.</given-names></name><name><surname>Taburet</surname><given-names>Y.</given-names></name><name><surname>Prevost</surname><given-names>D.</given-names></name><name><surname>Dumas</surname><given-names>J.</given-names></name><name><surname>Leonard</surname><given-names>G.</given-names></name><etal/></person-group>
<article-title>The 2.4-A crystal structure of the penicillin-resistant penicillin-binding protein PBP5fm from Enterococcus faecium in complex with benzylpenicillin</article-title>
<source>Cell. Mol. Life Sci.</source>
<year>2002</year>
<volume>59</volume>
<fpage>1223</fpage>
<lpage>1232</lpage>
<pub-id pub-id-type="doi">10.1007/s00018-002-8500-0</pub-id>
<pub-id pub-id-type="pmid">12222968</pub-id></element-citation></ref><ref id="B71-antibiotics-05-00012"><label>71.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kelley</surname><given-names>W.L.</given-names></name><name><surname>Jousselin</surname><given-names>A.</given-names></name><name><surname>Barras</surname><given-names>C.</given-names></name><name><surname>Lelong</surname><given-names>E.</given-names></name><name><surname>Renzoni</surname><given-names>A.</given-names></name></person-group>
<article-title>Missense mutations in PBP2A Affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant Staphylococcus aureus clonotypes ST228 and ST247 in Western Switzerland archived since <italic>Antimicrob</italic></article-title>
<source>Agents Chemother.</source>
<year>2015</year>
<volume>59</volume>
<fpage>1922</fpage>
<lpage>1930</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.04068-14</pub-id>
<pub-id pub-id-type="pmid">25583724</pub-id></element-citation></ref><ref id="B72-antibiotics-05-00012"><label>72.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alm</surname><given-names>R.A.</given-names></name><name><surname>McLaughlin</surname><given-names>R.E.</given-names></name><name><surname>Kos</surname><given-names>V.N.</given-names></name><name><surname>Sader</surname><given-names>H.S.</given-names></name><name><surname>Iaconis</surname><given-names>J.P.</given-names></name><name><surname>Lahiri</surname><given-names>S.D.</given-names></name></person-group>
<article-title>Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: An epidemiological and structural perspective</article-title>
<source>J. Antimicrob. Chemother.</source>
<year>2014</year>
<volume>69</volume>
<fpage>2065</fpage>
<lpage>2075</lpage>
<pub-id pub-id-type="doi">10.1093/jac/dku114</pub-id>
<pub-id pub-id-type="pmid">24777906</pub-id></element-citation></ref><ref id="B73-antibiotics-05-00012"><label>73.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Long</surname><given-names>S.W.</given-names></name><name><surname>Olsen</surname><given-names>R.J.</given-names></name><name><surname>Mehta</surname><given-names>S.C.</given-names></name><name><surname>Palzkill</surname><given-names>T.</given-names></name><name><surname>Cernoch</surname><given-names>P.L.</given-names></name><name><surname>Perez</surname><given-names>K.K.</given-names></name><name><surname>Musick</surname><given-names>W.L.</given-names></name><name><surname>Rosato</surname><given-names>A.E.</given-names></name><name><surname>Musser</surname><given-names>J.M.</given-names></name></person-group>
<article-title>PBP2a mutations causing high-level Ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>2014</year>
<volume>58</volume>
<fpage>6668</fpage>
<lpage>6674</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.03622-14</pub-id>
<pub-id pub-id-type="pmid">25155594</pub-id></element-citation></ref><ref id="B74-antibiotics-05-00012"><label>74.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lahiri</surname><given-names>S.D.</given-names></name><name><surname>McLaughlin</surname><given-names>R.E.</given-names></name><name><surname>Whiteaker</surname><given-names>J.D.</given-names></name><name><surname>Ambler</surname><given-names>J.E.</given-names></name><name><surname>Alm</surname><given-names>R.A.</given-names></name></person-group>
<article-title>Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: The role of PBP2a in the activity of ceftaroline</article-title>
<source>J. Antimicrob. Chemother.</source>
<year>2015</year>
<volume>70</volume>
<fpage>2488</fpage>
<lpage>2498</lpage>
<pub-id pub-id-type="doi">10.1093/jac/dkv131</pub-id>
<pub-id pub-id-type="pmid">26045529</pub-id></element-citation></ref><ref id="B75-antibiotics-05-00012"><label>75.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rybkine</surname><given-names>T.</given-names></name><name><surname>Mainardi</surname><given-names>J.L.</given-names></name><name><surname>Sougakoff</surname><given-names>W.</given-names></name><name><surname>Collatz</surname><given-names>E.</given-names></name><name><surname>Gutmann</surname><given-names>L.</given-names></name></person-group>
<article-title>Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of beta-lactam resistance</article-title>
<source>J. Infect. Dis.</source>
<year>1998</year>
<volume>178</volume>
<fpage>159</fpage>
<lpage>163</lpage>
<pub-id pub-id-type="doi">10.1086/515605</pub-id>
<pub-id pub-id-type="pmid">9652435</pub-id></element-citation></ref><ref id="B76-antibiotics-05-00012"><label>76.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fedarovich</surname><given-names>A.</given-names></name><name><surname>Cook</surname><given-names>E.</given-names></name><name><surname>Tomberg</surname><given-names>J.</given-names></name><name><surname>Nicholas</surname><given-names>R.A.</given-names></name><name><surname>Davies</surname><given-names>C.</given-names></name></person-group>
<article-title>Structural effect of the Asp345a insertion in penicillin-binding protein 2 from penicillin-resistant strains of Neisseria gonorrhoeae</article-title>
<source>Biochemistry</source>
<year>2014</year>
<volume>53</volume>
<fpage>7596</fpage>
<lpage>7603</lpage>
<pub-id pub-id-type="doi">10.1021/bi5011317</pub-id>
<pub-id pub-id-type="pmid">25403720</pub-id></element-citation></ref><ref id="B77-antibiotics-05-00012"><label>77.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Han</surname><given-names>S.</given-names></name><name><surname>Zaniewski</surname><given-names>R.P.</given-names></name><name><surname>Marr</surname><given-names>E.S.</given-names></name><name><surname>Lacey</surname><given-names>B.M.</given-names></name><name><surname>Tomaras</surname><given-names>A.P.</given-names></name><name><surname>Evdokimov</surname><given-names>A.</given-names></name><name><surname>Miller</surname><given-names>J.R.</given-names></name><name><surname>Shanmugasundaram</surname><given-names>V.</given-names></name></person-group>
<article-title>Structural basis for effectiveness of siderophore-conjugated monocarbams against clinically relevant strains of Pseudomonas aeruginosa</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>2010</year>
<volume>107</volume>
<fpage>22002</fpage>
<lpage>22007</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1013092107</pub-id>
<pub-id pub-id-type="pmid">21135211</pub-id></element-citation></ref><ref id="B78-antibiotics-05-00012"><label>78.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Han</surname><given-names>S.</given-names></name><name><surname>Caspers</surname><given-names>N.</given-names></name><name><surname>Zaniewski</surname><given-names>R.P.</given-names></name><name><surname>Lacey</surname><given-names>B.M.</given-names></name><name><surname>Tomaras</surname><given-names>A.P.</given-names></name><name><surname>Feng</surname><given-names>X.</given-names></name><name><surname>Geoghegan</surname><given-names>K.F.</given-names></name><name><surname>Shanmugasundaram</surname><given-names>V.</given-names></name></person-group>
<article-title>Distinctive attributes of beta-lactam target proteins in Acinetobacter baumannii relevant to development of new antibiotics</article-title>
<source>J. Am. Chem. Soc.</source>
<year>2011</year>
<volume>133</volume>
<fpage>20536</fpage>
<lpage>20545</lpage>
<pub-id pub-id-type="doi">10.1021/ja208835z</pub-id>
<pub-id pub-id-type="pmid">22050378</pub-id></element-citation></ref><ref id="B79-antibiotics-05-00012"><label>79.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sainsbury</surname><given-names>S.</given-names></name><name><surname>Bird</surname><given-names>L.</given-names></name><name><surname>Rao</surname><given-names>V.</given-names></name><name><surname>Shepherd</surname><given-names>S.M.</given-names></name><name><surname>Stuart</surname><given-names>D.I.</given-names></name><name><surname>Hunter</surname><given-names>W.N.</given-names></name><name><surname>Owens</surname><given-names>R.J.</given-names></name><name><surname>Ren</surname><given-names>J.</given-names></name></person-group>
<article-title>Crystal structures of penicillin-binding protein 3 from Pseudomonas aeruginosa: Comparison of native and antibiotic-bound forms</article-title>
<source>J. Mol. Biol.</source>
<year>2011</year>
<volume>405</volume>
<fpage>173</fpage>
<lpage>184</lpage>
<pub-id pub-id-type="doi">10.1016/j.jmb.2010.10.024</pub-id>
<pub-id pub-id-type="pmid">20974151</pub-id></element-citation></ref><ref id="B80-antibiotics-05-00012"><label>80.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Van Berkel</surname><given-names>S.S.</given-names></name><name><surname>Nettleship</surname><given-names>J.E.</given-names></name><name><surname>Leung</surname><given-names>I.K.H.</given-names></name><name><surname>Brem</surname><given-names>J.</given-names></name><name><surname>Choi</surname><given-names>H.</given-names></name><name><surname>Stuart</surname><given-names>D.I.</given-names></name><name><surname>Claridge</surname><given-names>T.D.W.</given-names></name><name><surname>McDonough</surname><given-names>M.A.</given-names></name><name><surname>Owens</surname><given-names>R.J.</given-names></name><name><surname>Ren</surname><given-names>J.</given-names></name><etal/></person-group>
<article-title>Binding of (5S)-penicilloic acid to penicillin binding protein 3</article-title>
<source>ACS Chem. Biol.</source>
<year>2013</year>
<volume>8</volume>
<fpage>2112</fpage>
<lpage>2116</lpage>
<pub-id pub-id-type="doi">10.1021/cb400200h</pub-id>
<pub-id pub-id-type="pmid">23899657</pub-id></element-citation></ref><ref id="B81-antibiotics-05-00012"><label>81.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Trehan</surname><given-names>I.</given-names></name><name><surname>Morandi</surname><given-names>F.</given-names></name><name><surname>Blaszczak</surname><given-names>L.C.</given-names></name><name><surname>Shoichet</surname><given-names>B.K.</given-names></name></person-group>
<article-title>Using Steric Hindrance to Design New Inhibitors of Class C &#x003b2;-Lactamases</article-title>
<source>Chem. Biol.</source>
<year>2002</year>
<volume>9</volume>
<fpage>971</fpage>
<lpage>980</lpage>
<pub-id pub-id-type="doi">10.1016/S1074-5521(02)00211-9</pub-id>
<pub-id pub-id-type="pmid">12323371</pub-id></element-citation></ref><ref id="B82-antibiotics-05-00012"><label>82.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schweizer</surname><given-names>H.P.</given-names></name></person-group>
<article-title>Mechanisms of antibiotic resistance in Burkholderia pseudomallei: Implications for treatment of melioidosis</article-title>
<source>Future Microbiol.</source>
<year>2012</year>
<volume>7</volume>
<fpage>1389</fpage>
<lpage>1399</lpage>
<pub-id pub-id-type="doi">10.2217/fmb.12.116</pub-id>
<pub-id pub-id-type="pmid">23231488</pub-id></element-citation></ref><ref id="B83-antibiotics-05-00012"><label>83.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alm</surname><given-names>R.A.</given-names></name><name><surname>Johnstone</surname><given-names>M.R.</given-names></name><name><surname>Lahiri</surname><given-names>S.D.</given-names></name></person-group>
<article-title>Characterization of <italic>Escherichia coli</italic> NDM isolates with decreased susceptibility to aztreonam/avibactam: Role of a novel insertion in PBP3</article-title>
<source>J. Antimicrob. Chemother.</source>
<year>2015</year>
<volume>70</volume>
<fpage>1420</fpage>
<lpage>1428</lpage>
<pub-id pub-id-type="doi">10.1093/jac/dku568</pub-id>
<pub-id pub-id-type="pmid">25634992</pub-id></element-citation></ref><ref id="B84-antibiotics-05-00012"><label>84.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tomberg</surname><given-names>J.</given-names></name><name><surname>Temple</surname><given-names>B.</given-names></name><name><surname>Fedarovich</surname><given-names>A.</given-names></name><name><surname>Davies</surname><given-names>C.</given-names></name><name><surname>Nicholas</surname><given-names>R.A.</given-names></name></person-group>
<article-title>A highly conserved interaction involving the middle residue of the SXN active-site motif is crucial for function of class B penicillin-binding proteins: Mutational and computational analysis of PBP 2 from N. gonorrhoeae</article-title>
<source>Biochemistry</source>
<year>2012</year>
<volume>51</volume>
<fpage>2775</fpage>
<lpage>2784</lpage>
<pub-id pub-id-type="doi">10.1021/bi2017987</pub-id>
<pub-id pub-id-type="pmid">22397678</pub-id></element-citation></ref><ref id="B85-antibiotics-05-00012"><label>85.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maiden</surname><given-names>M.C.</given-names></name></person-group>
<article-title>Horizontal genetic exchange, evolution, and spread of antibiotic resistance in bacteria</article-title>
<source>Clin. Infect. Dis.</source>
<year>1998</year>
<volume>27</volume>
<issue>Suppl. 1</issue>
<fpage>S12</fpage>
<lpage>S20</lpage>
<pub-id pub-id-type="doi">10.1086/514917</pub-id>
<pub-id pub-id-type="pmid">9710667</pub-id></element-citation></ref><ref id="B86-antibiotics-05-00012"><label>86.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sumita</surname><given-names>Y.</given-names></name><name><surname>Fukasawa</surname><given-names>M.</given-names></name></person-group>
<article-title>Potent activity of meropenem against <italic>Escherichia coli</italic> arising from its simultaneous binding to penicillin-binding proteins 2 and 3</article-title>
<source>J. Antimicrob. Chemother.</source>
<year>1995</year>
<volume>36</volume>
<fpage>53</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="doi">10.1093/jac/36.1.53</pub-id>
<pub-id pub-id-type="pmid">8537284</pub-id></element-citation></ref><ref id="B87-antibiotics-05-00012"><label>87.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davies</surname><given-names>T.A.</given-names></name><name><surname>Shang</surname><given-names>W.</given-names></name><name><surname>Bush</surname><given-names>K.</given-names></name><name><surname>Flamm</surname><given-names>R.K.</given-names></name></person-group>
<article-title>Affinity of doripenem and comparators to penicillin-binding proteins in <italic>Escherichia coli</italic> and Pseudomonas aeruginosa</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>2008</year>
<volume>52</volume>
<fpage>1510</fpage>
<lpage>1512</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.01529-07</pub-id>
<pub-id pub-id-type="pmid">18250190</pub-id></element-citation></ref><ref id="B88-antibiotics-05-00012"><label>88.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mainardi</surname><given-names>J.-L.</given-names></name><name><surname>Hugonnet</surname><given-names>J.-E.</given-names></name><name><surname>Rusconi</surname><given-names>F.</given-names></name><name><surname>Fourgeaud</surname><given-names>M.</given-names></name><name><surname>Dubost</surname><given-names>L.</given-names></name><name><surname>Moumi</surname><given-names>A.N.</given-names></name><name><surname>Delfosse</surname><given-names>V.</given-names></name><name><surname>Mayer</surname><given-names>C.</given-names></name><name><surname>Gutmann</surname><given-names>L.</given-names></name><name><surname>Rice</surname><given-names>L.B.</given-names></name><etal/></person-group>
<article-title>Unexpected inhibition of peptidoglycan <sc>ld</sc>-transpeptidase from Enterococcus faecium by the beta-lactam imipenem</article-title>
<source>J. Biol. Chem.</source>
<year>2007</year>
<volume>282</volume>
<fpage>30414</fpage>
<lpage>30422</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M704286200</pub-id>
<pub-id pub-id-type="pmid">17646161</pub-id></element-citation></ref><ref id="B89-antibiotics-05-00012"><label>89.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Triboulet</surname><given-names>S.</given-names></name><name><surname>Dub&#x000e9;e</surname><given-names>V.</given-names></name><name><surname>Lecoq</surname><given-names>L.</given-names></name><name><surname>Bougault</surname><given-names>C.</given-names></name><name><surname>Mainardi</surname><given-names>J.-L.</given-names></name><name><surname>Rice</surname><given-names>L.B.</given-names></name><name><surname>Eth&#x000e8;ve-Quelquejeu</surname><given-names>M.</given-names></name><name><surname>Gutmann</surname><given-names>L.</given-names></name><name><surname>Marie</surname><given-names>A.</given-names></name><name><surname>Dubost</surname><given-names>L.</given-names></name><etal/></person-group>
<article-title>Kinetic features of <sc>l</sc>,<sc>d</sc>-transpeptidase inactivation critical for &#x003b2;-lactam antibacterial activity</article-title>
<source>PLoS ONE</source>
<year>2013</year>
<volume>8</volume>
<elocation-id>12</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0067831</pub-id>
<pub-id pub-id-type="pmid">23861815</pub-id></element-citation></ref><ref id="B90-antibiotics-05-00012"><label>90.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lecoq</surname><given-names>L.</given-names></name><name><surname>Dub&#x000e9;e</surname><given-names>V.</given-names></name><name><surname>Triboulet</surname><given-names>S.</given-names></name><name><surname>Bougault</surname><given-names>C.</given-names></name><name><surname>Hugonnet</surname><given-names>J.-E.</given-names></name><name><surname>Arthur</surname><given-names>M.</given-names></name><name><surname>Simorre</surname><given-names>J.-P.</given-names></name></person-group>
<article-title>Structure of Enterococcus faeciuml,<sc>d</sc>-transpeptidase acylated by ertapenem provides insight into the inactivation mechanism</article-title>
<source>ACS Chem. Biol.</source>
<year>2013</year>
<volume>8</volume>
<fpage>1140</fpage>
<lpage>1146</lpage>
<pub-id pub-id-type="doi">10.1021/cb4001603</pub-id>
<pub-id pub-id-type="pmid">23574509</pub-id></element-citation></ref><ref id="B91-antibiotics-05-00012"><label>91.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Correale</surname><given-names>S.</given-names></name><name><surname>Ruggiero</surname><given-names>A.</given-names></name><name><surname>Capparelli</surname><given-names>R.</given-names></name><name><surname>Pedone</surname><given-names>E.</given-names></name><name><surname>Berisio</surname><given-names>R.</given-names></name></person-group>
<article-title>Structures of free and inhibited forms of the <sc>l</sc>,<sc>d</sc>-transpeptidase LdtMt1 from Mycobacterium tuberculosis</article-title>
<source>Acta Crystallogr. D Biol. Crystallogr.</source>
<year>2013</year>
<volume>69</volume>
<fpage>1697</fpage>
<lpage>706</lpage>
<pub-id pub-id-type="doi">10.1107/S0907444913013085</pub-id>
<pub-id pub-id-type="pmid">23999293</pub-id></element-citation></ref><ref id="B92-antibiotics-05-00012"><label>92.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schanda</surname><given-names>P.</given-names></name><name><surname>Triboulet</surname><given-names>S.</given-names></name><name><surname>Laguri</surname><given-names>C.</given-names></name><name><surname>Bougault</surname><given-names>C.M.</given-names></name><name><surname>Ayala</surname><given-names>I.</given-names></name><name><surname>Callon</surname><given-names>M.</given-names></name><name><surname>Arthur</surname><given-names>M.</given-names></name><name><surname>Simorre</surname><given-names>J.-P.</given-names></name></person-group>
<article-title>Atomic model of a cell-wall cross-linking enzyme in complex with an intact bacterial peptidoglycan</article-title>
<source>J. Am. Chem. Soc.</source>
<year>2014</year>
<volume>136</volume>
<fpage>17852</fpage>
<lpage>17860</lpage>
<pub-id pub-id-type="doi">10.1021/ja5105987</pub-id>
<pub-id pub-id-type="pmid">25429710</pub-id></element-citation></ref><ref id="B93-antibiotics-05-00012"><label>93.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lavollay</surname><given-names>M.</given-names></name><name><surname>Arthur</surname><given-names>M.</given-names></name><name><surname>Fourgeaud</surname><given-names>M.</given-names></name><name><surname>Dubost</surname><given-names>L.</given-names></name><name><surname>Marie</surname><given-names>A.</given-names></name><name><surname>Veziris</surname><given-names>N.</given-names></name><name><surname>Blanot</surname><given-names>D.</given-names></name><name><surname>Gutmann</surname><given-names>L.</given-names></name><name><surname>Mainardi</surname><given-names>J.-L.</given-names></name></person-group>
<article-title>The peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by <sc>l</sc>,<sc>d</sc>-transpeptidation</article-title>
<source>J. Bacteriol.</source>
<year>2008</year>
<volume>190</volume>
<fpage>4360</fpage>
<lpage>4366</lpage>
<pub-id pub-id-type="doi">10.1128/JB.00239-08</pub-id>
<pub-id pub-id-type="pmid">18408028</pub-id></element-citation></ref><ref id="B94-antibiotics-05-00012"><label>94.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chowdhury</surname><given-names>A.</given-names></name><name><surname>Paul</surname><given-names>P.</given-names></name><name><surname>Bhattacharjee</surname><given-names>A.</given-names></name><name><surname>Talukdar</surname><given-names>A.</given-names></name></person-group>
<article-title>Das; Choudhury, M.D. Virtual high throughput screening of carbapenem derivatives as new generation carbapenemase and penicillin binding protein inhibitors: A hunt to save drug of last resort</article-title>
<source>Comb. Chem. High Throughput Screen.</source>
<year>2015</year>
<volume>18</volume>
<fpage>18</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="doi">10.2174/1386207317666141226131709</pub-id>
<pub-id pub-id-type="pmid">25542226</pub-id></element-citation></ref><ref id="B95-antibiotics-05-00012"><label>95.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yamachika</surname><given-names>S.</given-names></name><name><surname>Sugihara</surname><given-names>C.</given-names></name><name><surname>Kamai</surname><given-names>Y.</given-names></name><name><surname>Yamashita</surname><given-names>M.</given-names></name></person-group>
<article-title>Correlation between penicillin-binding protein 2 mutations and carbapenem resistance in <italic>Escherichia coli</italic></article-title>
<source>J. Med. Microbiol.</source>
<year>2013</year>
<volume>62</volume>
<fpage>429</fpage>
<lpage>436</lpage>
<pub-id pub-id-type="doi">10.1099/jmm.0.051631-0</pub-id>
<pub-id pub-id-type="pmid">23222859</pub-id></element-citation></ref><ref id="B96-antibiotics-05-00012"><label>96.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aissa</surname><given-names>N.</given-names></name><name><surname>Mayer</surname><given-names>N.</given-names></name><name><surname>Bert</surname><given-names>F.</given-names></name><name><surname>Labia</surname><given-names>R.</given-names></name><name><surname>Lozniewski</surname><given-names>A.</given-names></name><name><surname>Nicolas-Chanoine</surname><given-names>M.-H.</given-names></name></person-group>
<article-title>A new mechanism to render clinical isolates of <italic>Escherichia coli</italic> non-susceptible to imipenem: Substitutions in the PBP2 penicillin-binding domain</article-title>
<source>J. Antimicrob. Chemother.</source>
<year>2015</year>
<volume>71</volume>
<fpage>76</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="doi">10.1093/jac/dkv318</pub-id>
<pub-id pub-id-type="pmid">26462991</pub-id></element-citation></ref><ref id="B97-antibiotics-05-00012"><label>97.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Page</surname><given-names>M.G.P.</given-names></name><name><surname>Dantier</surname><given-names>C.</given-names></name><name><surname>Desarbre</surname><given-names>E.</given-names></name></person-group>
<article-title><italic>In vitro</italic> properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>2010</year>
<volume>54</volume>
<fpage>2291</fpage>
<lpage>2302</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.01525-09</pub-id>
<pub-id pub-id-type="pmid">20308379</pub-id></element-citation></ref><ref id="B98-antibiotics-05-00012"><label>98.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Landman</surname><given-names>D.</given-names></name><name><surname>Singh</surname><given-names>M.</given-names></name><name><surname>El-Imad</surname><given-names>B.</given-names></name><name><surname>Miller</surname><given-names>E.</given-names></name><name><surname>Win</surname><given-names>T.</given-names></name><name><surname>Quale</surname><given-names>J.</given-names></name></person-group>
<article-title><italic>In vitro</italic> activity of the siderophore monosulfactam BAL30072 against contemporary Gram-negative pathogens from New York City, including multidrug-resistant isolates</article-title>
<source>Int. J. Antimicrob. Agents</source>
<year>2014</year>
<volume>43</volume>
<fpage>527</fpage>
<lpage>532</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijantimicag.2014.02.017</pub-id>
<pub-id pub-id-type="pmid">24796217</pub-id></element-citation></ref><ref id="B99-antibiotics-05-00012"><label>99.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Higgins</surname><given-names>P.G.</given-names></name><name><surname>Stefanik</surname><given-names>D.</given-names></name><name><surname>Page</surname><given-names>M.G.P.</given-names></name><name><surname>Hackel</surname><given-names>M.</given-names></name><name><surname>Seifert</surname><given-names>H.</given-names></name></person-group>
<article-title><italic>In vitro</italic> activity of the siderophore monosulfactam BAL30072 against meropenem-non-susceptible Acinetobacter baumannii</article-title>
<source>J. Antimicrob. Chemother.</source>
<year>2012</year>
<volume>67</volume>
<fpage>1167</fpage>
<lpage>1169</lpage>
<pub-id pub-id-type="doi">10.1093/jac/dks009</pub-id>
<pub-id pub-id-type="pmid">22294643</pub-id></element-citation></ref><ref id="B100-antibiotics-05-00012"><label>100.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Russo</surname><given-names>T.A.</given-names></name><name><surname>Page</surname><given-names>M.G.P.</given-names></name><name><surname>Beanan</surname><given-names>J.M.</given-names></name><name><surname>Olson</surname><given-names>R.</given-names></name><name><surname>Hujer</surname><given-names>A.M.</given-names></name><name><surname>Hujer</surname><given-names>K.M.</given-names></name><name><surname>Jacobs</surname><given-names>M.</given-names></name><name><surname>Bajaksouzian</surname><given-names>S.</given-names></name><name><surname>Endimiani</surname><given-names>A.</given-names></name><name><surname>Bonomo</surname><given-names>R.A.</given-names></name></person-group>
<article-title><italic>In vivo</italic> and <italic>in vitro</italic> activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii</article-title>
<source>J. Antimicrob. Chemother.</source>
<year>2011</year>
<volume>66</volume>
<fpage>867</fpage>
<lpage>873</lpage>
<pub-id pub-id-type="doi">10.1093/jac/dkr013</pub-id>
<pub-id pub-id-type="pmid">21393224</pub-id></element-citation></ref><ref id="B101-antibiotics-05-00012"><label>101.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Flanagan</surname><given-names>M.E.</given-names></name><name><surname>Brickner</surname><given-names>S.J.</given-names></name><name><surname>Lall</surname><given-names>M.</given-names></name><name><surname>Casavant</surname><given-names>J.</given-names></name><name><surname>Deschenes</surname><given-names>L.</given-names></name><name><surname>Finegan</surname><given-names>S.M.</given-names></name><name><surname>George</surname><given-names>D.M.</given-names></name><name><surname>Granskog</surname><given-names>K.</given-names></name><name><surname>Hardink</surname><given-names>J.R.</given-names></name><name><surname>Huband</surname><given-names>M.D.</given-names></name><etal/></person-group>
<article-title>Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols</article-title>
<source>ACS Med. Chem. Lett.</source>
<year>2011</year>
<volume>2</volume>
<fpage>385</fpage>
<lpage>390</lpage>
<pub-id pub-id-type="doi">10.1021/ml200012f</pub-id>
<pub-id pub-id-type="pmid">24900319</pub-id></element-citation></ref><ref id="B102-antibiotics-05-00012"><label>102.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Murphy-Benenato</surname><given-names>K.E.</given-names></name><name><surname>Dangel</surname><given-names>B.</given-names></name><name><surname>Davis</surname><given-names>H.E.</given-names></name><name><surname>Durand-R&#x000e9;ville</surname><given-names>T.F.</given-names></name><name><surname>Ferguson</surname><given-names>A.D.</given-names></name><name><surname>Gao</surname><given-names>N.</given-names></name><name><surname>Jahi&#x00107;</surname><given-names>H.</given-names></name><name><surname>Mueller</surname><given-names>J.P.</given-names></name><name><surname>Manyak</surname><given-names>E.L.</given-names></name><name><surname>Quiroga</surname><given-names>O.</given-names></name><etal/></person-group>
<article-title>SAR and Structural Analysis of Siderophore-Conjugated Monocarbam Inhibitors of Pseudomonas aeruginosa PBP3</article-title>
<source>ACS Med. Chem. Lett.</source>
<year>2015</year>
<volume>6</volume>
<fpage>537</fpage>
<lpage>542</lpage>
<pub-id pub-id-type="doi">10.1021/acsmedchemlett.5b00026</pub-id>
<pub-id pub-id-type="pmid">26005529</pub-id></element-citation></ref><ref id="B103-antibiotics-05-00012"><label>103.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>A.</given-names></name><name><surname>Kutschke</surname><given-names>A.</given-names></name><name><surname>Ehmann</surname><given-names>D.E.</given-names></name><name><surname>Patey</surname><given-names>S.A.</given-names></name><name><surname>Crandon</surname><given-names>J.L.</given-names></name><name><surname>Gorseth</surname><given-names>E.</given-names></name><name><surname>Miller</surname><given-names>A.A.</given-names></name><name><surname>McLaughlin</surname><given-names>R.E.</given-names></name><name><surname>Blinn</surname><given-names>C.M.</given-names></name><name><surname>Chen</surname><given-names>A.</given-names></name><etal/></person-group>
<article-title>Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>2015</year>
<volume>59</volume>
<fpage>7743</fpage>
<lpage>7752</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.00831-15</pub-id>
<pub-id pub-id-type="pmid">26438502</pub-id></element-citation></ref><ref id="B104-antibiotics-05-00012"><label>104.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zervosen</surname><given-names>A.</given-names></name><name><surname>Sauvage</surname><given-names>E.</given-names></name><name><surname>Fr&#x000e8;re</surname><given-names>J.M.</given-names></name><name><surname>Charlier</surname><given-names>P.</given-names></name><name><surname>Luxen</surname><given-names>A.</given-names></name></person-group>
<article-title>Development of new drugs for an old target&#x02014;The penicillin binding proteins</article-title>
<source>Molecules</source>
<year>2012</year>
<volume>17</volume>
<fpage>12478</fpage>
<lpage>12505</lpage>
<pub-id pub-id-type="doi">10.3390/molecules171112478</pub-id>
<pub-id pub-id-type="pmid">23095893</pub-id></element-citation></ref><ref id="B105-antibiotics-05-00012"><label>105.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tamura</surname><given-names>N.</given-names></name><name><surname>Matsushita</surname><given-names>Y.</given-names></name><name><surname>Kawano</surname><given-names>Y.</given-names></name><name><surname>Yoshioka</surname><given-names>K.</given-names></name></person-group>
<article-title>Synthesis and antibacterial activity of lactivicin derivatives</article-title>
<source>Chem. Pharm. Bull. (Tokyo)</source>
<year>1990</year>
<volume>38</volume>
<fpage>116</fpage>
<lpage>122</lpage>
<pub-id pub-id-type="doi">10.1248/cpb.38.116</pub-id>
<pub-id pub-id-type="pmid">2337934</pub-id></element-citation></ref><ref id="B106-antibiotics-05-00012"><label>106.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brown</surname><given-names>T.</given-names></name><name><surname>Charlier</surname><given-names>P.</given-names></name><name><surname>Herman</surname><given-names>R.</given-names></name><name><surname>Schofield</surname><given-names>C.J.</given-names></name><name><surname>Sauvage</surname><given-names>E.</given-names></name></person-group>
<article-title>Structural basis for the interaction of lactivicins with serine &#x003b2;-lactamases</article-title>
<source>J. Med. Chem.</source>
<year>2010</year>
<volume>53</volume>
<fpage>5890</fpage>
<lpage>5894</lpage>
<pub-id pub-id-type="doi">10.1021/jm100437u</pub-id>
<pub-id pub-id-type="pmid">20593835</pub-id></element-citation></ref><ref id="B107-antibiotics-05-00012"><label>107.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Macheboeuf</surname><given-names>P.</given-names></name><name><surname>Fischer</surname><given-names>D.S.</given-names></name><name><surname>Brown</surname><given-names>T.</given-names><suffix>Jr.</suffix></name><name><surname>Zervosen</surname><given-names>A.</given-names></name><name><surname>Luxen</surname><given-names>A.</given-names></name><name><surname>Joris</surname><given-names>B.</given-names></name><name><surname>Dessen</surname><given-names>A.</given-names></name><name><surname>Schofield</surname><given-names>C.J.</given-names></name></person-group>
<article-title>Structural and mechanistic basis of penicillin-binding protein inhibition by lactivicins</article-title>
<source>Nat. Chem. Biol.</source>
<year>2007</year>
<volume>3</volume>
<fpage>565</fpage>
<lpage>569</lpage>
<pub-id pub-id-type="doi">10.1038/nchembio.2007.21</pub-id>
<pub-id pub-id-type="pmid">17676039</pub-id></element-citation></ref><ref id="B108-antibiotics-05-00012"><label>108.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Starr</surname><given-names>J.</given-names></name><name><surname>Brown</surname><given-names>M.F.</given-names></name><name><surname>Aschenbrenner</surname><given-names>L.</given-names></name><name><surname>Caspers</surname><given-names>N.</given-names></name><name><surname>Che</surname><given-names>Y.</given-names></name><name><surname>Gerstenberger</surname><given-names>B.S.</given-names></name><name><surname>Huband</surname><given-names>M.</given-names></name><name><surname>Knafels</surname><given-names>J.D.</given-names></name><name><surname>Lemmon</surname><given-names>M.M.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><etal/></person-group>
<article-title>Siderophore receptor-mediated uptake of lactivicin analogues in gram-negative bacteria</article-title>
<source>J. Med. Chem.</source>
<year>2014</year>
<volume>57</volume>
<fpage>3845</fpage>
<lpage>3855</lpage>
<pub-id pub-id-type="doi">10.1021/jm500219c</pub-id>
<pub-id pub-id-type="pmid">24694215</pub-id></element-citation></ref><ref id="B109-antibiotics-05-00012"><label>109.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dzhekieva</surname><given-names>L.</given-names></name><name><surname>Rocaboy</surname><given-names>M.</given-names></name><name><surname>Kerff</surname><given-names>F.</given-names></name><name><surname>Charlier</surname><given-names>P.</given-names></name><name><surname>Sauvage</surname><given-names>E.</given-names></name><name><surname>Pratt</surname><given-names>R.F.</given-names></name></person-group>
<article-title>Crystal structure of a complex between the actinomadura R39 dd -peptidase and a peptidoglycan-mimetic boronate inhibitor: Interpretation of a transition state analogue in terms of catalytic mechanism</article-title>
<source>Biochemistry</source>
<year>2010</year>
<volume>49</volume>
<fpage>6411</fpage>
<lpage>6419</lpage>
<pub-id pub-id-type="doi">10.1021/bi100757c</pub-id>
<pub-id pub-id-type="pmid">20608745</pub-id></element-citation></ref><ref id="B110-antibiotics-05-00012"><label>110.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dzhekieva</surname><given-names>L.</given-names></name><name><surname>Adediran</surname><given-names>S.A.</given-names></name><name><surname>Herman</surname><given-names>R.</given-names></name><name><surname>Kerff</surname><given-names>F.</given-names></name><name><surname>Duez</surname><given-names>C.</given-names></name><name><surname>Charlier</surname><given-names>P.</given-names></name><name><surname>Sauvage</surname><given-names>E.</given-names></name><name><surname>Pratt</surname><given-names>R.F.</given-names></name></person-group>
<article-title>Inhibition of <sc>dd</sc>-peptidases by a specific trifluoroketone: Crystal structure of a complex with the Actinomadura R39 <sc>dd</sc>-peptidase</article-title>
<source>Biochemistry</source>
<year>2013</year>
<volume>52</volume>
<fpage>2128</fpage>
<lpage>2138</lpage>
<pub-id pub-id-type="doi">10.1021/bi400048s</pub-id>
<pub-id pub-id-type="pmid">23484909</pub-id></element-citation></ref><ref id="B111-antibiotics-05-00012"><label>111.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Contreras-Martel</surname><given-names>C.</given-names></name><name><surname>Amoroso</surname><given-names>A.</given-names></name><name><surname>Woon</surname><given-names>E.C.</given-names></name><name><surname>Zervosen</surname><given-names>A.</given-names></name><name><surname>Inglis</surname><given-names>S.</given-names></name><name><surname>Martins</surname><given-names>A.</given-names></name><name><surname>Verlaine</surname><given-names>O.</given-names></name><name><surname>Rydzik</surname><given-names>A.M.</given-names></name><name><surname>Job</surname><given-names>V.</given-names></name><name><surname>Luxen</surname><given-names>A.</given-names></name><etal/></person-group>
<article-title>Structure-guided design of cell wall biosynthesis inhibitors that overcome beta-lactam resistance in Staphylococcus aureus (MRSA)</article-title>
<source>ACS Chem. Biol.</source>
<year>2011</year>
<volume>6</volume>
<fpage>943</fpage>
<lpage>951</lpage>
<pub-id pub-id-type="doi">10.1021/cb2001846</pub-id>
<pub-id pub-id-type="pmid">21732689</pub-id></element-citation></ref><ref id="B112-antibiotics-05-00012"><label>112.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dzhekieva</surname><given-names>L.</given-names></name><name><surname>Kumar</surname><given-names>I.</given-names></name><name><surname>Pratt</surname><given-names>R.F.</given-names></name></person-group>
<article-title>Inhibition of bacterial <sc>dd</sc>-peptidases (penicillin-binding proteins) in membranes and <italic>in vivo</italic> by peptidoglycan-mimetic boronic acids</article-title>
<source>Biochemistry</source>
<year>2012</year>
<volume>51</volume>
<fpage>2804</fpage>
<lpage>2811</lpage>
<pub-id pub-id-type="doi">10.1021/bi300148v</pub-id>
<pub-id pub-id-type="pmid">22443299</pub-id></element-citation></ref><ref id="B113-antibiotics-05-00012"><label>113.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Delmas</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Prati</surname><given-names>F.</given-names></name><name><surname>Robin</surname><given-names>F.</given-names></name><name><surname>Shoichet</surname><given-names>B.K.</given-names></name><name><surname>Bonnet</surname><given-names>R.</given-names></name></person-group>
<article-title>Structure and dynamics of CTX-M enzymes reveal insights into substrate accommodation by extended-spectrum beta-lactamases</article-title>
<source>J. Mol. Biol.</source>
<year>2008</year>
<volume>375</volume>
<fpage>192</fpage>
<lpage>201</lpage>
<pub-id pub-id-type="doi">10.1016/j.jmb.2007.10.026</pub-id>
<pub-id pub-id-type="pmid">17999931</pub-id></element-citation></ref><ref id="B114-antibiotics-05-00012"><label>114.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Irwin</surname><given-names>J.J.</given-names></name><name><surname>Sterling</surname><given-names>T.</given-names></name><name><surname>Mysinger</surname><given-names>M.M.</given-names></name><name><surname>Bolstad</surname><given-names>E.S.</given-names></name><name><surname>Coleman</surname><given-names>R.G.</given-names></name></person-group>
<article-title>ZINC: A free tool to discover chemistry for biology</article-title>
<source>J. Chem. Inf. Model</source>
<year>2012</year>
<volume>52</volume>
<fpage>1757</fpage>
<lpage>1768</lpage>
<pub-id pub-id-type="doi">10.1021/ci3001277</pub-id>
<pub-id pub-id-type="pmid">22587354</pub-id></element-citation></ref><ref id="B115-antibiotics-05-00012"><label>115.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O&#x02019;Daniel</surname><given-names>P.I.</given-names></name><name><surname>Peng</surname><given-names>Z.</given-names></name><name><surname>Pi</surname><given-names>H.</given-names></name><name><surname>Testero</surname><given-names>S.A.</given-names></name><name><surname>Ding</surname><given-names>D.</given-names></name><name><surname>Spink</surname><given-names>E.</given-names></name><name><surname>Leemans</surname><given-names>E.</given-names></name><name><surname>Boudreau</surname><given-names>M.A.</given-names></name><name><surname>Yamaguchi</surname><given-names>T.</given-names></name><name><surname>Schroeder</surname><given-names>V.A.</given-names></name><etal/></person-group>
<article-title>Discovery of a new class of non-&#x003b2;-lactam inhibitors of penicillin-binding proteins with Gram-positive antibacterial activity</article-title>
<source>J. Am. Chem. Soc.</source>
<year>2014</year>
<volume>136</volume>
<fpage>3664</fpage>
<lpage>3672</lpage>
<pub-id pub-id-type="doi">10.1021/ja500053x</pub-id>
<pub-id pub-id-type="pmid">24517363</pub-id></element-citation></ref><ref id="B116-antibiotics-05-00012"><label>116.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spink</surname><given-names>E.</given-names></name><name><surname>Ding</surname><given-names>D.</given-names></name><name><surname>Peng</surname><given-names>Z.</given-names></name><name><surname>Boudreau</surname><given-names>M.A.</given-names></name><name><surname>Leemans</surname><given-names>E.</given-names></name><name><surname>Lastochkin</surname><given-names>E.</given-names></name><name><surname>Song</surname><given-names>W.</given-names></name><name><surname>Lichtenwalter</surname><given-names>K.</given-names></name><name><surname>O&#x02019;Daniel</surname><given-names>P.I.</given-names></name><name><surname>Testero</surname><given-names>S.A.</given-names></name><etal/></person-group>
<article-title>Structure-activity relationship for the oxadiazole class of antibiotics</article-title>
<source>J. Med. Chem.</source>
<year>2015</year>
<volume>58</volume>
<fpage>1380</fpage>
<lpage>1389</lpage>
<pub-id pub-id-type="doi">10.1021/jm501661f</pub-id>
<pub-id pub-id-type="pmid">25590813</pub-id></element-citation></ref><ref id="B117-antibiotics-05-00012"><label>117.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dive</surname><given-names>G.</given-names></name><name><surname>Bouillon</surname><given-names>C.</given-names></name><name><surname>Sliwa</surname><given-names>A.</given-names></name><name><surname>Valet</surname><given-names>B.</given-names></name><name><surname>Verlaine</surname><given-names>O.</given-names></name><name><surname>Sauvage</surname><given-names>E.</given-names></name><name><surname>Marchand-Brynaert</surname><given-names>J.</given-names></name></person-group>
<article-title>Macrocycle-embedded &#x003b2;-lactams as novel inhibitors of the Penicillin Binding Protein PBP2a from MRSA</article-title>
<source>Eur. J. Med. Chem.</source>
<year>2013</year>
<volume>64</volume>
<fpage>365</fpage>
<lpage>376</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejmech.2013.03.052</pub-id>
<pub-id pub-id-type="pmid">23648973</pub-id></element-citation></ref><ref id="B118-antibiotics-05-00012"><label>118.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rani</surname><given-names>N.</given-names></name><name><surname>Saravanan</surname><given-names>V.</given-names></name><name><surname>Lakshmi</surname><given-names>P.T.V.</given-names></name><name><surname>Arunachalam</surname><given-names>A.</given-names></name></person-group>
<article-title>Allosteric site mediated active site inhibition of PBP2a using Quercetin 3-<italic>O</italic>-Rutinoside and its combination</article-title>
<source>J. Biomol. Struct. Dyn.</source>
<year>2015</year>
<fpage>1</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="doi">10.1080/07391102.2015.1092096</pub-id>
<pub-id pub-id-type="pmid">26360629</pub-id></element-citation></ref><ref id="B119-antibiotics-05-00012"><label>119.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lavanya</surname><given-names>P.</given-names></name><name><surname>Ramaiah</surname><given-names>S.</given-names></name><name><surname>Anbarasu</surname><given-names>A.</given-names></name></person-group>
<article-title>A Molecular Docking and Dynamics Study to Screen Potent Anti-Staphylococcal Compounds Against Ceftaroline Resistant MRSA</article-title>
<source>J. Cell. Biochem.</source>
<year>2015</year>
<volume>117</volume>
<fpage>542</fpage>
<lpage>548</lpage>
<pub-id pub-id-type="doi">10.1002/jcb.25307</pub-id>
<pub-id pub-id-type="pmid">26252252</pub-id></element-citation></ref><ref id="B120-antibiotics-05-00012"><label>120.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fedarovich</surname><given-names>A.</given-names></name><name><surname>Djordjevic</surname><given-names>K.A.</given-names></name><name><surname>Swanson</surname><given-names>S.M.</given-names></name><name><surname>Peterson</surname><given-names>Y.K.</given-names></name><name><surname>Nicholas</surname><given-names>R.A.</given-names></name><name><surname>Davies</surname><given-names>C.</given-names></name></person-group>
<article-title>High-throughput screening for novel inhibitors of Neisseria gonorrhoeae penicillin-binding protein 2</article-title>
<source>PLoS ONE</source>
<year>2012</year>
<volume>7</volume>
<elocation-id>12</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0044918</pub-id>
<pub-id pub-id-type="pmid">23049763</pub-id></element-citation></ref><ref id="B121-antibiotics-05-00012"><label>121.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>G.</given-names></name><name><surname>Meier</surname><given-names>T.I.</given-names></name><name><surname>Kahl</surname><given-names>S.D.</given-names></name><name><surname>Gee</surname><given-names>K.R.</given-names></name><name><surname>Blaszczak</surname><given-names>L.C.</given-names></name></person-group>
<article-title>BOCILLIN FL, a sensitive and commercially available reagent for detection of penicillin-binding proteins</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>1999</year>
<volume>43</volume>
<fpage>1124</fpage>
<lpage>1128</lpage>
<pub-id pub-id-type="pmid">10223924</pub-id></element-citation></ref><ref id="B122-antibiotics-05-00012"><label>122.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>English</surname><given-names>B.K.</given-names></name></person-group>
<article-title>Limitations of beta-lactam therapy for infections caused by susceptible Gram-positive bacteria</article-title>
<source>J. Infect.</source>
<year>2014</year>
<volume>69</volume>
<issue>Suppl. 1</issue>
<fpage>S5</fpage>
<lpage>S9</lpage>
<pub-id pub-id-type="doi">10.1016/j.jinf.2014.07.010</pub-id>
<pub-id pub-id-type="pmid">25124369</pub-id></element-citation></ref><ref id="B123-antibiotics-05-00012"><label>123.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rahme</surname><given-names>C.</given-names></name><name><surname>Butterfield</surname><given-names>J.M.</given-names></name><name><surname>Nicasio</surname><given-names>A.M.</given-names></name><name><surname>Lodise</surname><given-names>T.P.</given-names></name></person-group>
<article-title>Dual beta-lactam therapy for serious Gram-negative infections: Is it time to revisit?</article-title>
<source>Diagn. Microbiol. Infect. Dis.</source>
<year>2014</year>
<volume>80</volume>
<fpage>239</fpage>
<lpage>259</lpage>
<pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2014.07.007</pub-id>
<pub-id pub-id-type="pmid">25308565</pub-id></element-citation></ref><ref id="B124-antibiotics-05-00012"><label>124.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>R.</given-names></name><name><surname>Fernandez</surname><given-names>M.G.</given-names></name><name><surname>Enthaler</surname><given-names>N.</given-names></name><name><surname>Graml</surname><given-names>C.</given-names></name><name><surname>Greenwood-Quaintance</surname><given-names>K.E.</given-names></name><name><surname>Patel</surname><given-names>R.</given-names></name></person-group>
<article-title>Combinations of cefoxitin plus other &#x003b2;-lactams are synergistic <italic>in vitro</italic> against community associated methicillin-resistant Staphylococcus aureus</article-title>
<source>Eur. J. Clin. Microbiol. Infect. Dis.</source>
<year>2013</year>
<volume>32</volume>
<fpage>827</fpage>
<lpage>833</lpage>
<pub-id pub-id-type="doi">10.1007/s10096-013-1817-9</pub-id>
<pub-id pub-id-type="pmid">23340864</pub-id></element-citation></ref><ref id="B125-antibiotics-05-00012"><label>125.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gonzales</surname><given-names>P.R.</given-names></name><name><surname>Pesesky</surname><given-names>M.W.</given-names></name><name><surname>Bouley</surname><given-names>R.</given-names></name><name><surname>Ballard</surname><given-names>A.</given-names></name><name><surname>Biddy</surname><given-names>B.A.</given-names></name><name><surname>Suckow</surname><given-names>M.A.</given-names></name><name><surname>Wolter</surname><given-names>W.R.</given-names></name><name><surname>Schroeder</surname><given-names>V.A.</given-names></name><name><surname>Burnham</surname><given-names>C.-A.D.</given-names></name><name><surname>Mobashery</surname><given-names>S.</given-names></name><etal/></person-group>
<article-title>Synergistic, collaterally sensitive &#x003b2;-lactam combinations suppress resistance in MRSA</article-title>
<source>Nat. Chem. Biol.</source>
<year>2015</year>
<comment>in press</comment>
</element-citation></ref><ref id="B126-antibiotics-05-00012"><label>126.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deng</surname><given-names>J.-Z.</given-names></name></person-group>
<article-title>Methicillin/per-6-(4-methoxylbenzyl)-amino-6-deoxy-&#x003b2;-cyclodextrin 1:1 complex and its potentiation <italic>in vitro</italic> against methicillin-resistant Staphylococcus aureus</article-title>
<source>J. Antibiot. (Tokyo)</source>
<year>2013</year>
<volume>66</volume>
<fpage>517</fpage>
<lpage>521</lpage>
<pub-id pub-id-type="doi">10.1038/ja.2013.51</pub-id>
<pub-id pub-id-type="pmid">23715036</pub-id></element-citation></ref><ref id="B127-antibiotics-05-00012"><label>127.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Del R&#x000ed;o</surname><given-names>A.</given-names></name><name><surname>Garc&#x000ed;a-de-la-M&#x000e0;ria</surname><given-names>C.</given-names></name><name><surname>Entenza</surname><given-names>J.M.</given-names></name><name><surname>Gasch</surname><given-names>O.</given-names></name><name><surname>Armero</surname><given-names>Y.</given-names></name><name><surname>Soy</surname><given-names>D.</given-names></name><name><surname>Mestres</surname><given-names>C.A.</given-names></name><name><surname>Peric&#x000e1;s</surname><given-names>J.M.</given-names></name><name><surname>Falces</surname><given-names>C.</given-names></name><name><surname>Ninot</surname><given-names>S.</given-names></name><etal/></person-group>
<article-title>Fosfomycin plus Beta-lactams: Synergistic Bactericidal Combinations in Methicillin-resistant (MRSA) and Glycopeptide-Intermediate Resistant (GISA) Staphylococcus aureus Experimental Endocarditis</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>2015</year>
<volume>60</volume>
<fpage>478</fpage>
<lpage>486</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.02139-15</pub-id>
<pub-id pub-id-type="pmid">26525803</pub-id></element-citation></ref><ref id="B128-antibiotics-05-00012"><label>128.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nair</surname><given-names>D.R.</given-names></name><name><surname>Monteiro</surname><given-names>J.M.</given-names></name><name><surname>Memmi</surname><given-names>G.</given-names></name><name><surname>Thanassi</surname><given-names>J.</given-names></name><name><surname>Pucci</surname><given-names>M.</given-names></name><name><surname>Schwartzman</surname><given-names>J.</given-names></name><name><surname>Pinho</surname><given-names>M.G.</given-names></name><name><surname>Cheung</surname><given-names>A.L.</given-names></name></person-group>
<article-title>Characterization of a Novel Small Molecule That Potentiates &#x003b2;-Lactam Activity against Gram-Positive and Gram-Negative Pathogens</article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>2015</year>
<volume>59</volume>
<fpage>1876</fpage>
<lpage>1885</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.04164-14</pub-id>
<pub-id pub-id-type="pmid">25583731</pub-id></element-citation></ref><ref id="B129-antibiotics-05-00012"><label>129.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guignard</surname><given-names>B.</given-names></name><name><surname>Vouillamoz</surname><given-names>J.</given-names></name><name><surname>Giddey</surname><given-names>M.</given-names></name><name><surname>Moreillon</surname><given-names>P.</given-names></name></person-group>
<article-title>A positive interaction between inhibitors of protein synthesis and cefepime in the fight against methicillin-resistant Staphylococcus aureus</article-title>
<source>Eur. J. Clin. Microbiol. Infect. Dis.</source>
<year>2013</year>
<volume>32</volume>
<fpage>899</fpage>
<lpage>907</lpage>
<pub-id pub-id-type="doi">10.1007/s10096-013-1824-x</pub-id>
<pub-id pub-id-type="pmid">23370969</pub-id></element-citation></ref><ref id="B130-antibiotics-05-00012"><label>130.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lovering</surname><given-names>A.L.</given-names></name><name><surname>de Castro</surname><given-names>L.H.</given-names></name><name><surname>Lim</surname><given-names>D.</given-names></name><name><surname>Strynadka</surname><given-names>N.C.</given-names></name></person-group>
<article-title>Structural insight into the transglycosylation step of bacterial cell-wall biosynthesis</article-title>
<source>Science</source>
<year>2007</year>
<volume>315</volume>
<fpage>1402</fpage>
<lpage>1405</lpage>
<pub-id pub-id-type="doi">10.1126/science.1136611</pub-id>
<pub-id pub-id-type="pmid">17347437</pub-id></element-citation></ref><ref id="B131-antibiotics-05-00012"><label>131.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yuan</surname><given-names>Y.</given-names></name><name><surname>Barrett</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Kahne</surname><given-names>D.</given-names></name><name><surname>Sliz</surname><given-names>P.</given-names></name><name><surname>Walker</surname><given-names>S.</given-names></name></person-group>
<article-title>Crystal structure of a peptidoglycan glycosyltransferase suggests a model for processive glycan chain synthesis</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>2007</year>
<volume>104</volume>
<fpage>5348</fpage>
<lpage>5353</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0701160104</pub-id>
<pub-id pub-id-type="pmid">17360321</pub-id></element-citation></ref><ref id="B132-antibiotics-05-00012"><label>132.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Heaslet</surname><given-names>H.</given-names></name><name><surname>Shaw</surname><given-names>B.</given-names></name><name><surname>Mistry</surname><given-names>A.</given-names></name><name><surname>Miller</surname><given-names>A.A.</given-names></name></person-group>
<article-title>Characterization of the active site of S. aureus monofunctional glycosyltransferase (Mtg) by site-directed mutation and structural analysis of the protein complexed with moenomycin</article-title>
<source>J. Struct. Biol.</source>
<year>2009</year>
<volume>167</volume>
<fpage>129</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="doi">10.1016/j.jsb.2009.04.010</pub-id>
<pub-id pub-id-type="pmid">19416756</pub-id></element-citation></ref><ref id="B133-antibiotics-05-00012"><label>133.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.Y.</given-names></name><name><surname>Shih</surname><given-names>H.W.</given-names></name><name><surname>Lin</surname><given-names>L.Y.</given-names></name><name><surname>Tien</surname><given-names>Y.W.</given-names></name><name><surname>Cheng</surname><given-names>T.J.</given-names></name><name><surname>Cheng</surname><given-names>W.C.</given-names></name><name><surname>Wong</surname><given-names>C.H.</given-names></name><name><surname>Ma</surname><given-names>C.</given-names></name></person-group>
<article-title>Crystal structure of Staphylococcus aureus transglycosylase in complex with a lipid II analog and elucidation of peptidoglycan synthesis mechanism</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>2012</year>
<volume>109</volume>
<fpage>6496</fpage>
<lpage>6501</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1203900109</pub-id>
<pub-id pub-id-type="pmid">22493270</pub-id></element-citation></ref><ref id="B134-antibiotics-05-00012"><label>134.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Terrak</surname><given-names>M.</given-names></name><name><surname>Sauvage</surname><given-names>E.</given-names></name><name><surname>Derouaux</surname><given-names>A.</given-names></name><name><surname>Dehareng</surname><given-names>D.</given-names></name><name><surname>Bouhss</surname><given-names>A.</given-names></name><name><surname>Breukink</surname><given-names>E.</given-names></name><name><surname>Jeanjean</surname><given-names>S.</given-names></name><name><surname>Nguyen-Dist&#x000e8;che</surname><given-names>M.</given-names></name></person-group>
<article-title>Importance of the conserved residues in the peptidoglycan glycosyltransferase module of the class A penicillin-binding protein 1b of <italic>Escherichia coli</italic></article-title>
<source>J. Biol. Chem.</source>
<year>2008</year>
<volume>283</volume>
<fpage>28464</fpage>
<lpage>28470</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M803223200</pub-id>
<pub-id pub-id-type="pmid">18701463</pub-id></element-citation></ref><ref id="B135-antibiotics-05-00012"><label>135.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yuan</surname><given-names>Y.</given-names></name><name><surname>Fuse</surname><given-names>S.</given-names></name><name><surname>Ostash</surname><given-names>B.</given-names></name><name><surname>Sliz</surname><given-names>P.</given-names></name><name><surname>Kahne</surname><given-names>D.</given-names></name><name><surname>Walker</surname><given-names>S.</given-names></name></person-group>
<article-title>Structural analysis of the contacts anchoring moenomycin to peptidoglycan glycosyltransferases and implications for antibiotic design</article-title>
<source>ACS Chem. Biol.</source>
<year>2008</year>
<volume>3</volume>
<fpage>429</fpage>
<lpage>436</lpage>
<pub-id pub-id-type="doi">10.1021/cb800078a</pub-id>
<pub-id pub-id-type="pmid">18642800</pub-id></element-citation></ref><ref id="B136-antibiotics-05-00012"><label>136.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lovering</surname><given-names>A.L.</given-names></name><name><surname>De Castro</surname><given-names>L.</given-names></name><name><surname>Strynadka</surname><given-names>N.C.</given-names></name></person-group>
<article-title>Identification of dynamic structural motifs involved in peptidoglycan glycosyltransfer</article-title>
<source>J. Mol. Biol.</source>
<year>2008</year>
<volume>383</volume>
<fpage>167</fpage>
<lpage>177</lpage>
<pub-id pub-id-type="doi">10.1016/j.jmb.2008.08.020</pub-id>
<pub-id pub-id-type="pmid">18760285</pub-id></element-citation></ref><ref id="B137-antibiotics-05-00012"><label>137.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bury</surname><given-names>D.</given-names></name><name><surname>Dahmane</surname><given-names>I.</given-names></name><name><surname>Derouaux</surname><given-names>A.</given-names></name><name><surname>Dumbre</surname><given-names>S.</given-names></name><name><surname>Herdewijn</surname><given-names>P.</given-names></name><name><surname>Matagne</surname><given-names>A.</given-names></name><name><surname>Breukink</surname><given-names>E.</given-names></name><name><surname>Mueller-Seitz</surname><given-names>E.</given-names></name><name><surname>Petz</surname><given-names>M.</given-names></name><name><surname>Terrak</surname><given-names>M.</given-names></name></person-group>
<article-title>Positive cooperativity between acceptor and donor sites of the peptidoglycan glycosyltransferase</article-title>
<source>Biochem. Pharmacol.</source>
<year>2015</year>
<volume>93</volume>
<fpage>141</fpage>
<lpage>150</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2014.11.003</pub-id>
<pub-id pub-id-type="pmid">25462814</pub-id></element-citation></ref><ref id="B138-antibiotics-05-00012"><label>138.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>T.-S.A.</given-names></name><name><surname>Lupoli</surname><given-names>T.J.</given-names></name><name><surname>Sumida</surname><given-names>Y.</given-names></name><name><surname>Tsukamoto</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Rebets</surname><given-names>Y.</given-names></name><name><surname>Kahne</surname><given-names>D.E.</given-names></name><name><surname>Walker</surname><given-names>S.</given-names></name></person-group>
<article-title>Primer preactivation of peptidoglycan polymerases</article-title>
<source>J. Am. Chem. Soc.</source>
<year>2011</year>
<volume>133</volume>
<fpage>8528</fpage>
<lpage>8530</lpage>
<pub-id pub-id-type="doi">10.1021/ja2028712</pub-id>
<pub-id pub-id-type="pmid">21568328</pub-id></element-citation></ref><ref id="B139-antibiotics-05-00012"><label>139.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yunck</surname><given-names>R.</given-names></name><name><surname>Cho</surname><given-names>H.</given-names></name><name><surname>Bernhardt</surname><given-names>T.G.</given-names></name></person-group>
<article-title>Identification of MltG as a potential terminase for peptidoglycan polymerization in bacteria</article-title>
<source>Mol. Microbiol.</source>
<year>2015</year>
<pub-id pub-id-type="doi">10.1111/mmi.13258</pub-id>
<pub-id pub-id-type="pmid">26507882</pub-id></element-citation></ref><ref id="B140-antibiotics-05-00012"><label>140.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>T.-S.A.</given-names></name><name><surname>Manning</surname><given-names>S.A.</given-names></name><name><surname>Walker</surname><given-names>S.</given-names></name><name><surname>Kahne</surname><given-names>D.</given-names></name></person-group>
<article-title>Isolated peptidoglycan glycosyltransferases from different organisms produce different glycan chain lengths</article-title>
<source>J. Am. Chem. Soc.</source>
<year>2008</year>
<volume>130</volume>
<fpage>14068</fpage>
<lpage>14069</lpage>
<pub-id pub-id-type="doi">10.1021/ja806016y</pub-id>
<pub-id pub-id-type="pmid">18834124</pub-id></element-citation></ref><ref id="B141-antibiotics-05-00012"><label>141.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Offant</surname><given-names>J.</given-names></name><name><surname>Terrak</surname><given-names>M.</given-names></name><name><surname>Derouaux</surname><given-names>A.</given-names></name><name><surname>Breukink</surname><given-names>E.</given-names></name><name><surname>Nguyen-Dist&#x000e8;che</surname><given-names>M.</given-names></name><name><surname>Zapun</surname><given-names>A.</given-names></name><name><surname>Vernet</surname><given-names>T.</given-names></name></person-group>
<article-title>Optimization of conditions for the glycosyltransferase activity of penicillin-binding protein 1a from Thermotoga maritima</article-title>
<source>FEBS J.</source>
<year>2010</year>
<volume>277</volume>
<fpage>4290</fpage>
<lpage>4298</lpage>
<pub-id pub-id-type="doi">10.1111/j.1742-4658.2010.07817.x</pub-id>
<pub-id pub-id-type="pmid">20849416</pub-id></element-citation></ref><ref id="B142-antibiotics-05-00012"><label>142.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>B.</given-names></name><name><surname>Markwalder</surname><given-names>J.A.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name></person-group>
<article-title>Lipid II: Total synthesis of the bacterial cell wall precursor and utilization as a substrate for glycosyltransfer and transpeptidation by penicillin binding protein (PBP) 1b of <italic>Escherichia coli</italic></article-title>
<source>J. Am. Chem. Soc.</source>
<year>2001</year>
<volume>123</volume>
<fpage>11638</fpage>
<lpage>11643</lpage>
<pub-id pub-id-type="doi">10.1021/ja0166848</pub-id>
<pub-id pub-id-type="pmid">11716719</pub-id></element-citation></ref><ref id="B143-antibiotics-05-00012"><label>143.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>B.</given-names></name><name><surname>Markwalder</surname><given-names>J.A.</given-names></name><name><surname>Seitz</surname><given-names>S.P.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Stein</surname><given-names>R.L.</given-names></name></person-group>
<article-title>A kinetic characterization of the glycosyltransferase activity of Eschericia coli PBP1b and development of a continuous fluorescence assay</article-title>
<source>Biochemistry</source>
<year>2002</year>
<volume>41</volume>
<fpage>12552</fpage>
<lpage>12561</lpage>
<pub-id pub-id-type="doi">10.1021/bi026205x</pub-id>
<pub-id pub-id-type="pmid">12369847</pub-id></element-citation></ref><ref id="B144-antibiotics-05-00012"><label>144.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>VanNieuwenhze</surname><given-names>M.S.</given-names></name><name><surname>Mauldin</surname><given-names>S.C.</given-names></name><name><surname>Zia-Ebrahimi</surname><given-names>M.</given-names></name><name><surname>Winger</surname><given-names>B.E.</given-names></name><name><surname>Hornback</surname><given-names>W.J.</given-names></name><name><surname>Saha</surname><given-names>S.L.</given-names></name><name><surname>Aikins</surname><given-names>J.A.</given-names></name><name><surname>Blaszczak</surname><given-names>L.C.</given-names></name></person-group>
<article-title>The first total synthesis of lipid II: The final monomeric intermediate in bacterial cell wall biosynthesis</article-title>
<source>J. Am. Chem. Soc.</source>
<year>2002</year>
<volume>124</volume>
<fpage>3656</fpage>
<lpage>3660</lpage>
<pub-id pub-id-type="doi">10.1021/ja017386d</pub-id>
<pub-id pub-id-type="pmid">11929255</pub-id></element-citation></ref><ref id="B145-antibiotics-05-00012"><label>145.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ye</surname><given-names>X.Y.</given-names></name><name><surname>Lo</surname><given-names>M.C.</given-names></name><name><surname>Brunner</surname><given-names>L.</given-names></name><name><surname>Walker</surname><given-names>D.</given-names></name><name><surname>Kahne</surname><given-names>D.</given-names></name><name><surname>Walker</surname><given-names>S.</given-names></name></person-group>
<article-title>Better substrates for bacterial transglycosylases</article-title>
<source>J. Am. Chem. Soc.</source>
<year>2001</year>
<volume>123</volume>
<fpage>3155</fpage>
<lpage>3156</lpage>
<pub-id pub-id-type="doi">10.1021/ja010028q</pub-id>
<pub-id pub-id-type="pmid">11457035</pub-id></element-citation></ref><ref id="B146-antibiotics-05-00012"><label>146.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Fechter</surname><given-names>E.J.</given-names></name><name><surname>Wang</surname><given-names>T.S.</given-names></name><name><surname>Barrett</surname><given-names>D.</given-names></name><name><surname>Walker</surname><given-names>S.</given-names></name><name><surname>Kahne</surname><given-names>D.E.</given-names></name></person-group>
<article-title>Synthesis of heptaprenyl-lipid IV to analyze peptidoglycan glycosyltransferases</article-title>
<source>J. Am. Chem. Soc.</source>
<year>2007</year>
<volume>129</volume>
<fpage>3080</fpage>
<lpage>3081</lpage>
<pub-id pub-id-type="doi">10.1021/ja069060g</pub-id>
<pub-id pub-id-type="pmid">17323951</pub-id></element-citation></ref><ref id="B147-antibiotics-05-00012"><label>147.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gampe</surname><given-names>C.M.</given-names></name><name><surname>Tsukamoto</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>T.S.</given-names></name><name><surname>Walker</surname><given-names>S.</given-names></name><name><surname>Kahne</surname><given-names>D.</given-names></name></person-group>
<article-title>Modular synthesis of diphospholipid oligosaccharide fragments of the bacterial cell wall and their use to study the mechanism of moenomycin and other antibiotics</article-title>
<source>Tetrahedron</source>
<year>2011</year>
<volume>67</volume>
<fpage>9771</fpage>
<lpage>9778</lpage>
<pub-id pub-id-type="doi">10.1016/j.tet.2011.09.114</pub-id>
<pub-id pub-id-type="pmid">22505780</pub-id></element-citation></ref><ref id="B148-antibiotics-05-00012"><label>148.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shih</surname><given-names>H.-W.</given-names></name><name><surname>Chen</surname><given-names>K.-T.</given-names></name><name><surname>Cheng</surname><given-names>T.-J.R.</given-names></name><name><surname>Wong</surname><given-names>C.-H.</given-names></name><name><surname>Cheng</surname><given-names>W.-C.</given-names></name></person-group>
<article-title>A new synthetic approach toward bacterial transglycosylase substrates, Lipid II and Lipid IV</article-title>
<source>Org. Lett.</source>
<year>2011</year>
<volume>13</volume>
<fpage>4600</fpage>
<lpage>4603</lpage>
<pub-id pub-id-type="doi">10.1021/ol201806d</pub-id>
<pub-id pub-id-type="pmid">21797279</pub-id></element-citation></ref><ref id="B149-antibiotics-05-00012"><label>149.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van Heijenoort</surname><given-names>Y.</given-names></name><name><surname>Gomez</surname><given-names>M.</given-names></name><name><surname>Derrien</surname><given-names>M.</given-names></name><name><surname>Ayala</surname><given-names>J.</given-names></name><name><surname>van Heijenoort</surname><given-names>J.</given-names></name></person-group>
<article-title>Membrane intermediates in the peptidoglycan metabolism of <italic>Escherichia coli</italic>: Possible roles of PBP 1b and PBP 3</article-title>
<source>J. Bacteriol.</source>
<year>1992</year>
<volume>174</volume>
<fpage>3549</fpage>
<lpage>3557</lpage>
<pub-id pub-id-type="pmid">1592809</pub-id></element-citation></ref><ref id="B150-antibiotics-05-00012"><label>150.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Breukink</surname><given-names>E.</given-names></name><name><surname>van Heusden</surname><given-names>H.E.</given-names></name><name><surname>Vollmerhaus</surname><given-names>P.J.</given-names></name><name><surname>Swiezewska</surname><given-names>E.</given-names></name><name><surname>Brunner</surname><given-names>L.</given-names></name><name><surname>Walker</surname><given-names>S.</given-names></name><name><surname>Heck</surname><given-names>A.J.</given-names></name><name><surname>de Kruijff</surname><given-names>B.</given-names></name></person-group>
<article-title>Lipid II is an intrinsic component of the pore induced by nisin in bacterial membranes</article-title>
<source>J. Biol. Chem.</source>
<year>2003</year>
<volume>278</volume>
<fpage>19898</fpage>
<lpage>19903</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M301463200</pub-id>
<pub-id pub-id-type="pmid">12663672</pub-id></element-citation></ref><ref id="B151-antibiotics-05-00012"><label>151.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>L.-Y.</given-names></name><name><surname>Huang</surname><given-names>S.-H.</given-names></name><name><surname>Chang</surname><given-names>Y.-C.</given-names></name><name><surname>Cheng</surname><given-names>W.-C.</given-names></name><name><surname>Cheng</surname><given-names>T.-J.R.</given-names></name><name><surname>Wong</surname><given-names>C.-H.</given-names></name></person-group>
<article-title>Enzymatic synthesis of lipid II and analogues</article-title>
<source>Angew. Chem. Int. Ed. Engl.</source>
<year>2014</year>
<volume>53</volume>
<fpage>8060</fpage>
<lpage>8065</lpage>
<pub-id pub-id-type="doi">10.1002/anie.201402313</pub-id>
<pub-id pub-id-type="pmid">24990652</pub-id></element-citation></ref><ref id="B152-antibiotics-05-00012"><label>152.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ranjan</surname><given-names>R.</given-names></name><name><surname>Marczewski</surname><given-names>A.</given-names></name><name><surname>Chojnacki</surname><given-names>T.</given-names></name><name><surname>Hertel</surname><given-names>J.</given-names></name><name><surname>Swiezewska</surname><given-names>E.</given-names></name></person-group>
<article-title>Search for polyprenols in leaves of evergreen and deciduous Ericaceae plants</article-title>
<source>Acta Biochim. Pol.</source>
<year>2001</year>
<volume>48</volume>
<fpage>579</fpage>
<lpage>584</lpage>
<pub-id pub-id-type="pmid">11732627</pub-id></element-citation></ref><ref id="B153-antibiotics-05-00012"><label>153.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perlstein</surname><given-names>D.L.</given-names></name><name><surname>Wang</surname><given-names>T.S.</given-names></name><name><surname>Doud</surname><given-names>E.H.</given-names></name><name><surname>Kahne</surname><given-names>D.</given-names></name><name><surname>Walker</surname><given-names>S.</given-names></name></person-group>
<article-title>The role of the substrate lipid in processive glycan polymerization by the peptidoglycan glycosyltransferases</article-title>
<source>J. Am. Chem. Soc.</source>
<year>2010</year>
<volume>132</volume>
<fpage>48</fpage>
<lpage>49</lpage>
<pub-id pub-id-type="doi">10.1021/ja909325m</pub-id>
<pub-id pub-id-type="pmid">20017480</pub-id></element-citation></ref><ref id="B154-antibiotics-05-00012"><label>154.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>C.-Y.</given-names></name><name><surname>Guo</surname><given-names>C.-W.</given-names></name><name><surname>Chang</surname><given-names>Y.-F.</given-names></name><name><surname>Wang</surname><given-names>J.-T.</given-names></name><name><surname>Shih</surname><given-names>H.-W.</given-names></name><name><surname>Hsu</surname><given-names>Y.-F.</given-names></name><name><surname>Chen</surname><given-names>C.-W.</given-names></name><name><surname>Chen</surname><given-names>S.-K.</given-names></name><name><surname>Wang</surname><given-names>Y.-C.</given-names></name><name><surname>Cheng</surname><given-names>T.-J.R.</given-names></name><etal/></person-group>
<article-title>Synthesis and evaluation of a new fluorescent transglycosylase substrate: Lipid II-based molecule possessing a dansyl-C20 polyprenyl moiety</article-title>
<source>Org. Lett.</source>
<year>2010</year>
<volume>12</volume>
<fpage>1608</fpage>
<lpage>1611</lpage>
<pub-id pub-id-type="doi">10.1021/ol100338v</pub-id>
<pub-id pub-id-type="pmid">20187630</pub-id></element-citation></ref><ref id="B155-antibiotics-05-00012"><label>155.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Biboy</surname><given-names>J.</given-names></name><name><surname>Bui</surname><given-names>N.K.</given-names></name><name><surname>Vollmer</surname><given-names>W.</given-names></name></person-group>
<article-title><italic>In vitro</italic> peptidoglycan synthesis assay with lipid II substrate</article-title>
<source>Methods Mol. Biol.</source>
<year>2013</year>
<volume>966</volume>
<fpage>273</fpage>
<lpage>288</lpage>
<pub-id pub-id-type="pmid">23299741</pub-id></element-citation></ref><ref id="B156-antibiotics-05-00012"><label>156.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>S.H.</given-names></name><name><surname>Wu</surname><given-names>W.S.</given-names></name><name><surname>Huang</surname><given-names>L.Y.</given-names></name><name><surname>Huang</surname><given-names>W.F.</given-names></name><name><surname>Fu</surname><given-names>W.C.</given-names></name><name><surname>Chen</surname><given-names>P.T.</given-names></name><name><surname>Fang</surname><given-names>J.M.</given-names></name><name><surname>Cheng</surname><given-names>W.C.</given-names></name><name><surname>Cheng</surname><given-names>T.J.</given-names></name><name><surname>Wong</surname><given-names>C.H.</given-names></name></person-group>
<article-title>New continuous fluorometric assay for bacterial transglycosylase using Forster resonance energy transfer</article-title>
<source>J. Am. Chem. Soc.</source>
<year>2013</year>
<volume>135</volume>
<fpage>17078</fpage>
<lpage>17089</lpage>
<pub-id pub-id-type="doi">10.1021/ja407985m</pub-id>
<pub-id pub-id-type="pmid">24131464</pub-id></element-citation></ref><ref id="B157-antibiotics-05-00012"><label>157.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barrett</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>T.S.</given-names></name><name><surname>Yuan</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Kahne</surname><given-names>D.</given-names></name><name><surname>Walker</surname><given-names>S.</given-names></name></person-group>
<article-title>Analysis of glycan polymers produced by peptidoglycan glycosyltransferases</article-title>
<source>J. Biol. Chem.</source>
<year>2007</year>
<volume>282</volume>
<fpage>31964</fpage>
<lpage>31971</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M705440200</pub-id>
<pub-id pub-id-type="pmid">17704540</pub-id></element-citation></ref><ref id="B158-antibiotics-05-00012"><label>158.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dumbre</surname><given-names>S.</given-names></name><name><surname>Derouaux</surname><given-names>A.</given-names></name><name><surname>Lescrinier</surname><given-names>E.</given-names></name><name><surname>Piette</surname><given-names>A.</given-names></name><name><surname>Joris</surname><given-names>B.</given-names></name><name><surname>Terrak</surname><given-names>M.</given-names></name><name><surname>Herdewijn</surname><given-names>P.</given-names></name></person-group>
<article-title>Synthesis of modified peptidoglycan precursor analogues for the inhibition of glycosyltransferase</article-title>
<source>J. Am. Chem. Soc.</source>
<year>2012</year>
<volume>134</volume>
<fpage>9343</fpage>
<lpage>9351</lpage>
<pub-id pub-id-type="doi">10.1021/ja302099u</pub-id>
<pub-id pub-id-type="pmid">22550974</pub-id></element-citation></ref><ref id="B159-antibiotics-05-00012"><label>159.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mesleh</surname><given-names>M.F.</given-names></name><name><surname>Rajaratnam</surname><given-names>P.</given-names></name><name><surname>Conrad</surname><given-names>M.</given-names></name><name><surname>Chandrasekaran</surname><given-names>V.</given-names></name><name><surname>Liu</surname><given-names>C.M.</given-names></name><name><surname>Pandya</surname><given-names>B.</given-names></name><name><surname>Hwang</surname><given-names>Y.S.</given-names></name><name><surname>Rye</surname><given-names>P.T.</given-names></name><name><surname>Muldoon</surname><given-names>C.</given-names></name><name><surname>Becker</surname><given-names>B.</given-names></name><etal/></person-group>
<article-title>Targeting bacterial cell wall peptidoglycan synthesis by inhibition of glycosyltransferase activity</article-title>
<source>Chem. Biol. Drug Des.</source>
<year>2015</year>
<volume>87</volume>
<fpage>190</fpage>
<lpage>199</lpage>
<pub-id pub-id-type="doi">10.1111/cbdd.12662</pub-id>
<pub-id pub-id-type="pmid">26358369</pub-id></element-citation></ref><ref id="B160-antibiotics-05-00012"><label>160.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zuegg</surname><given-names>J.</given-names></name><name><surname>Muldoon</surname><given-names>C.</given-names></name><name><surname>Adamson</surname><given-names>G.</given-names></name><name><surname>McKeveney</surname><given-names>D.</given-names></name><name><surname>Le Thanh</surname><given-names>G.</given-names></name><name><surname>Premraj</surname><given-names>R.</given-names></name><name><surname>Becker</surname><given-names>B.</given-names></name><name><surname>Cheng</surname><given-names>M.</given-names></name><name><surname>Elliott</surname><given-names>A.G.</given-names></name><name><surname>Huang</surname><given-names>J.X.</given-names></name><etal/></person-group>
<article-title>Carbohydrate scaffolds as glycosyltransferase inhibitors with <italic>in vivo</italic> antibacterial activity</article-title>
<source>Nat. Commun.</source>
<year>2015</year>
<volume>6</volume>
<fpage>7719</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms8719</pub-id>
<pub-id pub-id-type="pmid">26194781</pub-id></element-citation></ref><ref id="B161-antibiotics-05-00012"><label>161.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lin</surname><given-names>C.-K.</given-names></name><name><surname>Chen</surname><given-names>K.-T.</given-names></name><name><surname>Hu</surname><given-names>C.-M.</given-names></name><name><surname>Yun</surname><given-names>W.-Y.</given-names></name><name><surname>Cheng</surname><given-names>W.-C.</given-names></name></person-group>
<article-title>Synthesis of 1-<italic>C</italic>-Glycoside-Linked Lipid II Analogues Toward Bacterial Transglycosylase Inhibition</article-title>
<source>Chemistry</source>
<year>2015</year>
<volume>21</volume>
<fpage>7511</fpage>
<lpage>7519</lpage>
<pub-id pub-id-type="doi">10.1002/chem.201406629</pub-id>
<pub-id pub-id-type="pmid">25820317</pub-id></element-citation></ref><ref id="B162-antibiotics-05-00012"><label>162.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hsu</surname><given-names>C.-H.</given-names></name><name><surname>Schelwies</surname><given-names>M.</given-names></name><name><surname>Enck</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>L.-Y.</given-names></name><name><surname>Huang</surname><given-names>S.-H.</given-names></name><name><surname>Chang</surname><given-names>Y.-F.</given-names></name><name><surname>Cheng</surname><given-names>T.-J.R.</given-names></name><name><surname>Cheng</surname><given-names>W.-C.</given-names></name><name><surname>Wong</surname><given-names>C.-H.</given-names></name></person-group>
<article-title>Iminosugar <italic>C</italic>-Glycoside Analogues of &#x003b1;- d -GlcNAc-1-Phosphate: Synthesis and Bacterial Transglycosylase Inhibition</article-title>
<source>J. Org. Chem.</source>
<year>2014</year>
<volume>79</volume>
<fpage>8629</fpage>
<lpage>8637</lpage>
<pub-id pub-id-type="doi">10.1021/jo501340s</pub-id>
<pub-id pub-id-type="pmid">25137529</pub-id></element-citation></ref><ref id="B163-antibiotics-05-00012"><label>163.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perlstein</surname><given-names>D.L.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>T.S.</given-names></name><name><surname>Kahne</surname><given-names>D.E.</given-names></name><name><surname>Walker</surname><given-names>S.</given-names></name></person-group>
<article-title>The direction of glycan chain elongation by peptidoglycan glycosyltransferases</article-title>
<source>J. Am. Chem. Soc.</source>
<year>2007</year>
<volume>129</volume>
<fpage>12674</fpage>
<lpage>12675</lpage>
<pub-id pub-id-type="doi">10.1021/ja075965y</pub-id>
<pub-id pub-id-type="pmid">17914829</pub-id></element-citation></ref><ref id="B164-antibiotics-05-00012"><label>164.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fraipont</surname><given-names>C.</given-names></name><name><surname>Sapunaric</surname><given-names>F.</given-names></name><name><surname>Zervosen</surname><given-names>A.</given-names></name><name><surname>Auger</surname><given-names>G.</given-names></name><name><surname>Devreese</surname><given-names>B.</given-names></name><name><surname>Lioux</surname><given-names>T.</given-names></name><name><surname>Blanot</surname><given-names>D.</given-names></name><name><surname>Mengin-Lecreulx</surname><given-names>D.</given-names></name><name><surname>Herdewijn</surname><given-names>P.</given-names></name><name><surname>Van Beeumen</surname><given-names>J.</given-names></name><etal/></person-group>
<article-title>Glycosyl transferase activity of the <italic>Escherichia coli</italic> penicillin-binding protein 1b: Specificity profile for the substrate</article-title>
<source>Biochemistry</source>
<year>2006</year>
<volume>45</volume>
<fpage>4007</fpage>
<lpage>4013</lpage>
<pub-id pub-id-type="doi">10.1021/bi051055m</pub-id>
<pub-id pub-id-type="pmid">16548528</pub-id></element-citation></ref><ref id="B165-antibiotics-05-00012"><label>165.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shih</surname><given-names>H.-W.</given-names></name><name><surname>Chang</surname><given-names>Y.-F.</given-names></name><name><surname>Li</surname><given-names>W.-J.</given-names></name><name><surname>Meng</surname><given-names>F.-C.</given-names></name><name><surname>Huang</surname><given-names>C.-Y.</given-names></name><name><surname>Ma</surname><given-names>C.</given-names></name><name><surname>Cheng</surname><given-names>T.-J.R.</given-names></name><name><surname>Wong</surname><given-names>C.-H.</given-names></name><name><surname>Cheng</surname><given-names>W.-C.</given-names></name></person-group>
<article-title>Effect of the peptide moiety of Lipid II on bacterial transglycosylase</article-title>
<source>Angew. Chem. Int. Ed. Engl.</source>
<year>2012</year>
<volume>51</volume>
<fpage>10123</fpage>
<lpage>10126</lpage>
<pub-id pub-id-type="doi">10.1002/anie.201204038</pub-id>
<pub-id pub-id-type="pmid">22952114</pub-id></element-citation></ref><ref id="B166-antibiotics-05-00012"><label>166.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McPherson</surname><given-names>D.C.</given-names></name><name><surname>Popham</surname><given-names>D.L.</given-names></name></person-group>
<article-title>Peptidoglycan synthesis in the absence of class A penicillin-binding proteins in Bacillus subtilis</article-title>
<source>J. Bacteriol.</source>
<year>2003</year>
<volume>185</volume>
<fpage>1423</fpage>
<lpage>1431</lpage>
<pub-id pub-id-type="doi">10.1128/JB.185.4.1423-1431.2003</pub-id>
<pub-id pub-id-type="pmid">12562814</pub-id></element-citation></ref><ref id="B167-antibiotics-05-00012"><label>167.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arbeloa</surname><given-names>A.</given-names></name><name><surname>Segal</surname><given-names>H.</given-names></name><name><surname>Hugonnet</surname><given-names>J.E.</given-names></name><name><surname>Josseaume</surname><given-names>N.</given-names></name><name><surname>Dubost</surname><given-names>L.</given-names></name><name><surname>Brouard</surname><given-names>J.P.</given-names></name><name><surname>Gutmann</surname><given-names>L.</given-names></name><name><surname>Mengin-Lecreulx</surname><given-names>D.</given-names></name><name><surname>Arthur</surname><given-names>M.</given-names></name></person-group>
<article-title>Role of class A penicillin-binding proteins in PBP5-mediated beta-lactam resistance in Enterococcus faecalis</article-title>
<source>J. Bacteriol.</source>
<year>2004</year>
<volume>186</volume>
<fpage>1221</fpage>
<lpage>1228</lpage>
<pub-id pub-id-type="doi">10.1128/JB.186.5.1221-1228.2004</pub-id>
<pub-id pub-id-type="pmid">14973044</pub-id></element-citation></ref><ref id="B168-antibiotics-05-00012"><label>168.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Welzel</surname><given-names>P.</given-names></name></person-group>
<article-title>Syntheses around the transglycosylation step in peptidoglycan biosynthesis</article-title>
<source>Chem Rev</source>
<year>2005</year>
<volume>105</volume>
<fpage>4610</fpage>
<lpage>4660</lpage>
<pub-id pub-id-type="doi">10.1021/cr040634e</pub-id>
<pub-id pub-id-type="pmid">16351056</pub-id></element-citation></ref><ref id="B169-antibiotics-05-00012"><label>169.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fuse</surname><given-names>S.</given-names></name><name><surname>Tsukamoto</surname><given-names>H.</given-names></name><name><surname>Yuan</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>T.-S.A.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Bolla</surname><given-names>M.</given-names></name><name><surname>Walker</surname><given-names>S.</given-names></name><name><surname>Sliz</surname><given-names>P.</given-names></name><name><surname>Kahne</surname><given-names>D.</given-names></name></person-group>
<article-title>Functional and structural analysis of a key region of the cell wall inhibitor moenomycin</article-title>
<source>ACS Chem. Biol.</source>
<year>2010</year>
<volume>5</volume>
<fpage>701</fpage>
<lpage>711</lpage>
<pub-id pub-id-type="doi">10.1021/cb100048q</pub-id>
<pub-id pub-id-type="pmid">20496948</pub-id></element-citation></ref><ref id="B170-antibiotics-05-00012"><label>170.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ostash</surname><given-names>B.</given-names></name><name><surname>Walker</surname><given-names>S.</given-names></name></person-group>
<article-title>Moenomycin family antibiotics: Chemical synthesis, biosynthesis, and biological activity</article-title>
<source>Nat. Prod. Rep.</source>
<year>2010</year>
<volume>27</volume>
<fpage>1594</fpage>
<lpage>1617</lpage>
<pub-id pub-id-type="doi">10.1039/c001461n</pub-id>
<pub-id pub-id-type="pmid">20730219</pub-id></element-citation></ref><ref id="B171-antibiotics-05-00012"><label>171.</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Huber</surname><given-names>G.</given-names></name></person-group>
<article-title>Moenomycin and Related Phosphorus-Containing Antibiotics</article-title>
<source>Mechanism of Action of Antibacterial Agents</source>
<person-group person-group-type="editor"><name><surname>Hahn</surname><given-names>F.</given-names></name></person-group>
<publisher-name>Springer-Verlag Berlin</publisher-name>
<publisher-loc>Berlin/Heidelberg, Germany</publisher-loc>
<year>1979</year>
<fpage>135</fpage>
<lpage>153</lpage>
</element-citation></ref><ref id="B172-antibiotics-05-00012"><label>172.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pfaller</surname><given-names>M.A.</given-names></name></person-group>
<article-title>Flavophospholipol use in animals: Positive implications for antimicrobial resistance based on its microbiologic properties</article-title>
<source>Diagn. Microbiol. Infect. Dis.</source>
<year>2006</year>
<volume>56</volume>
<fpage>115</fpage>
<lpage>121</lpage>
<pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2006.03.014</pub-id>
<pub-id pub-id-type="pmid">16698216</pub-id></element-citation></ref><ref id="B173-antibiotics-05-00012"><label>173.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>H.</given-names></name><name><surname>van Heijenoort</surname><given-names>Y.</given-names></name><name><surname>Tamura</surname><given-names>T.</given-names></name><name><surname>Mizoguchi</surname><given-names>J.</given-names></name><name><surname>Hirota</surname><given-names>Y.</given-names></name><name><surname>van Heijenoort</surname><given-names>J.</given-names></name></person-group>
<article-title><italic>In vitro</italic> peptidoglycan polymerization catalysed by penicillin binding protein 1b of <italic>Escherichia coli</italic> K-12</article-title>
<source>FEBS Lett.</source>
<year>1980</year>
<volume>110</volume>
<fpage>245</fpage>
<lpage>249</lpage>
<pub-id pub-id-type="doi">10.1016/0014-5793(80)80083-4</pub-id>
<pub-id pub-id-type="pmid">6989636</pub-id></element-citation></ref><ref id="B174-antibiotics-05-00012"><label>174.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Di Berardino</surname><given-names>M.</given-names></name><name><surname>Dijkstra</surname><given-names>A.</given-names></name><name><surname>Stuber</surname><given-names>D.</given-names></name><name><surname>Keck</surname><given-names>W.</given-names></name><name><surname>Gubler</surname><given-names>M.</given-names></name></person-group>
<article-title>The monofunctional glycosyltransferase of <italic>Escherichia coli</italic> is a member of a new class of peptidoglycan-synthesising enzymes</article-title>
<source>FEBS Lett.</source>
<year>1996</year>
<volume>392</volume>
<fpage>184</fpage>
<lpage>188</lpage>
<pub-id pub-id-type="doi">10.1016/0014-5793(96)00809-5</pub-id>
<pub-id pub-id-type="pmid">8772200</pub-id></element-citation></ref><ref id="B175-antibiotics-05-00012"><label>175.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Butaye</surname><given-names>P.</given-names></name><name><surname>Devriese</surname><given-names>L.A.</given-names></name><name><surname>Haesebrouck</surname><given-names>F.</given-names></name></person-group>
<article-title>Influence of different medium components on the <italic>in vitro</italic> activity of the growth-promoting antibiotic flavomycin against enterococci</article-title>
<source>J. Antimicrob. Chemother.</source>
<year>2000</year>
<volume>46</volume>
<fpage>713</fpage>
<lpage>716</lpage>
<pub-id pub-id-type="doi">10.1093/jac/46.5.713</pub-id>
<pub-id pub-id-type="pmid">11062189</pub-id></element-citation></ref><ref id="B176-antibiotics-05-00012"><label>176.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rebets</surname><given-names>Y.</given-names></name><name><surname>Lupoli</surname><given-names>T.</given-names></name><name><surname>Qiao</surname><given-names>Y.</given-names></name><name><surname>Schirner</surname><given-names>K.</given-names></name><name><surname>Villet</surname><given-names>R.</given-names></name><name><surname>Hooper</surname><given-names>D.</given-names></name><name><surname>Kahne</surname><given-names>D.</given-names></name><name><surname>Walker</surname><given-names>S.</given-names></name></person-group>
<article-title>Moenomycin resistance mutations in Staphylococcus aureus reduce peptidoglycan chain length and cause aberrant cell division</article-title>
<source>ACS Chem. Biol.</source>
<year>2014</year>
<volume>9</volume>
<fpage>459</fpage>
<lpage>467</lpage>
<pub-id pub-id-type="doi">10.1021/cb4006744</pub-id>
<pub-id pub-id-type="pmid">24255971</pub-id></element-citation></ref><ref id="B177-antibiotics-05-00012"><label>177.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reed</surname><given-names>P.</given-names></name><name><surname>Veiga</surname><given-names>H.</given-names></name><name><surname>Jorge</surname><given-names>A.M.</given-names></name><name><surname>Terrak</surname><given-names>M.</given-names></name><name><surname>Pinho</surname><given-names>M.G.</given-names></name></person-group>
<article-title>Monofunctional transglycosylases are not essential for Staphylococcus aureus cell wall synthesis</article-title>
<source>J. Bacteriol.</source>
<year>2011</year>
<volume>193</volume>
<fpage>2549</fpage>
<lpage>2556</lpage>
<pub-id pub-id-type="doi">10.1128/JB.01474-10</pub-id>
<pub-id pub-id-type="pmid">21441517</pub-id></element-citation></ref><ref id="B178-antibiotics-05-00012"><label>178.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Derouaux</surname><given-names>A.</given-names></name><name><surname>Sauvage</surname><given-names>E.</given-names></name><name><surname>Terrak</surname><given-names>M.</given-names></name></person-group>
<article-title>Peptidoglycan glycosyltransferase substrate mimics as templates for the design of new antibacterial drugs</article-title>
<source>Front. Immunol.</source>
<year>2013</year>
<volume>4</volume>
<pub-id pub-id-type="doi">10.3389/fimmu.2013.00078</pub-id>
<pub-id pub-id-type="pmid">23543824</pub-id></element-citation></ref><ref id="B179-antibiotics-05-00012"><label>179.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ramachandran</surname><given-names>V.</given-names></name><name><surname>Chandrakala</surname><given-names>B.</given-names></name><name><surname>Kumar</surname><given-names>V.P.</given-names></name><name><surname>Usha</surname><given-names>V.</given-names></name><name><surname>Solapure</surname><given-names>S.M.</given-names></name><name><surname>de Sousa</surname><given-names>S.M.</given-names></name></person-group>
<article-title>Screen for inhibitors of the coupled transglycosylase-transpeptidase of peptidoglycan biosynthesis in <italic>Escherichia coli</italic></article-title>
<source>Antimicrob. Agents Chemother.</source>
<year>2006</year>
<volume>50</volume>
<fpage>1425</fpage>
<lpage>1432</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.50.4.1425-1432.2006</pub-id>
<pub-id pub-id-type="pmid">16569861</pub-id></element-citation></ref><ref id="B180-antibiotics-05-00012"><label>180.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Terrak</surname><given-names>M.</given-names></name><name><surname>Nguyen-Dist&#x000e8;che</surname><given-names>M.</given-names></name></person-group>
<article-title>Kinetic characterization of the monofunctional glycosyltransferase from Staphylococcus aureus</article-title>
<source>J. Bacteriol.</source>
<year>2006</year>
<volume>188</volume>
<fpage>2528</fpage>
<lpage>2532</lpage>
<pub-id pub-id-type="doi">10.1128/JB.188.7.2528-2532.2006</pub-id>
<pub-id pub-id-type="pmid">16547040</pub-id></element-citation></ref><ref id="B181-antibiotics-05-00012"><label>181.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blanchaert</surname><given-names>B.</given-names></name><name><surname>Wyseure</surname><given-names>T.</given-names></name><name><surname>Breukink</surname><given-names>E.</given-names></name><name><surname>Adams</surname><given-names>E.</given-names></name><name><surname>Declerck</surname><given-names>P.</given-names></name><name><surname>Van Schepdael</surname><given-names>A.</given-names></name></person-group>
<article-title>Development of a liquid chromatography/mass spectrometry assay for the bacterial transglycosylation reaction through measurement of Lipid II</article-title>
<source>Electrophoresis</source>
<year>2015</year>
<pub-id pub-id-type="doi">10.1002/elps.201500201</pub-id>
<pub-id pub-id-type="pmid">26333884</pub-id></element-citation></ref><ref id="B182-antibiotics-05-00012"><label>182.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cheng</surname><given-names>T.J.</given-names></name><name><surname>Sung</surname><given-names>M.T.</given-names></name><name><surname>Liao</surname><given-names>H.Y.</given-names></name><name><surname>Chang</surname><given-names>Y.F.</given-names></name><name><surname>Chen</surname><given-names>C.W.</given-names></name><name><surname>Huang</surname><given-names>C.Y.</given-names></name><name><surname>Chou</surname><given-names>L.Y.</given-names></name><name><surname>Wu</surname><given-names>Y.D.</given-names></name><name><surname>Chen</surname><given-names>Y.H.</given-names></name><name><surname>Cheng</surname><given-names>Y.S.</given-names></name><etal/></person-group>
<article-title>Domain requirement of moenomycin binding to bifunctional transglycosylases and development of high-throughput discovery of antibiotics</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>2008</year>
<volume>105</volume>
<fpage>431</fpage>
<lpage>436</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0710868105</pub-id>
<pub-id pub-id-type="pmid">18182485</pub-id></element-citation></ref><ref id="B183-antibiotics-05-00012"><label>183.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cheng</surname><given-names>T.-J.R.</given-names></name><name><surname>Wu</surname><given-names>Y.-T.</given-names></name><name><surname>Yang</surname><given-names>S.-T.</given-names></name><name><surname>Lo</surname><given-names>K.-H.</given-names></name><name><surname>Chen</surname><given-names>S.-K.</given-names></name><name><surname>Chen</surname><given-names>Y.-H.</given-names></name><name><surname>Huang</surname><given-names>W.-I.</given-names></name><name><surname>Yuan</surname><given-names>C.-H.</given-names></name><name><surname>Guo</surname><given-names>C.-W.</given-names></name><name><surname>Huang</surname><given-names>L.-Y.</given-names></name><etal/></person-group>
<article-title>High-throughput identification of antibacterials against methicillin-resistant Staphylococcus aureus (MRSA) and the transglycosylase</article-title>
<source>Bioorg. Med. Chem.</source>
<year>2010</year>
<volume>18</volume>
<fpage>8512</fpage>
<lpage>8529</lpage>
<pub-id pub-id-type="doi">10.1016/j.bmc.2010.10.036</pub-id>
<pub-id pub-id-type="pmid">21075637</pub-id></element-citation></ref><ref id="B184-antibiotics-05-00012"><label>184.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gampe</surname><given-names>C.M.</given-names></name><name><surname>Tsukamoto</surname><given-names>H.</given-names></name><name><surname>Doud</surname><given-names>E.H.</given-names></name><name><surname>Walker</surname><given-names>S.</given-names></name><name><surname>Kahne</surname><given-names>D.</given-names></name></person-group>
<article-title>Tuning the moenomycin pharmacophore to enable discovery of bacterial cell wall synthesis inhibitors</article-title>
<source>J. Am. Chem. Soc.</source>
<year>2013</year>
<volume>135</volume>
<fpage>3776</fpage>
<lpage>3779</lpage>
<pub-id pub-id-type="doi">10.1021/ja4000933</pub-id>
<pub-id pub-id-type="pmid">23448584</pub-id></element-citation></ref><ref id="B185-antibiotics-05-00012"><label>185.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Zuo</surname><given-names>Z.</given-names></name><name><surname>Tang</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Ma.</surname><given-names>X.</given-names></name></person-group>
<article-title>Structure-based virtual screening for glycosyltrasferase51</article-title>
<source>Mol. Simul.</source>
<year>2008</year>
<volume>34</volume>
<fpage>849</fpage>
<lpage>856</lpage>
</element-citation></ref><ref id="B186-antibiotics-05-00012"><label>186.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Chan</surname><given-names>F.-Y.</given-names></name><name><surname>Sun</surname><given-names>N.</given-names></name><name><surname>Lui</surname><given-names>H.-K.</given-names></name><name><surname>So</surname><given-names>P.-K.</given-names></name><name><surname>Yan</surname><given-names>S.-C.</given-names></name><name><surname>Chan</surname><given-names>K.-F.</given-names></name><name><surname>Chiou</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Abagyan</surname><given-names>R.</given-names></name><etal/></person-group>
<article-title>Structure-based design, synthesis, and biological evaluation of isatin derivatives as potential glycosyltransferase inhibitors</article-title>
<source>Chem. Biol. Drug Des.</source>
<year>2014</year>
<volume>84</volume>
<fpage>685</fpage>
<lpage>696</lpage>
<pub-id pub-id-type="doi">10.1111/cbdd.12361</pub-id>
<pub-id pub-id-type="pmid">24890564</pub-id></element-citation></ref><ref id="B187-antibiotics-05-00012"><label>187.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Derouaux</surname><given-names>A.</given-names></name><name><surname>Turk</surname><given-names>S.</given-names></name><name><surname>Olrichs</surname><given-names>N.K.</given-names></name><name><surname>Gobec</surname><given-names>S.</given-names></name><name><surname>Breukink</surname><given-names>E.</given-names></name><name><surname>Amoroso</surname><given-names>A.</given-names></name><name><surname>Offant</surname><given-names>J.</given-names></name><name><surname>Bostock</surname><given-names>J.</given-names></name><name><surname>Mariner</surname><given-names>K.</given-names></name><name><surname>Chopra</surname><given-names>I.</given-names></name><etal/></person-group>
<article-title>Small molecule inhibitors of peptidoglycan synthesis targeting the lipid II precursor</article-title>
<source>Biochem. Pharmacol.</source>
<year>2011</year>
<volume>81</volume>
<fpage>1098</fpage>
<lpage>105</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2011.02.008</pub-id>
<pub-id pub-id-type="pmid">21356201</pub-id></element-citation></ref><ref id="B188-antibiotics-05-00012"><label>188.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sosic</surname><given-names>I.</given-names></name><name><surname>Anderluh</surname><given-names>M.</given-names></name><name><surname>Sova</surname><given-names>M.</given-names></name><name><surname>Gobec</surname><given-names>M.</given-names></name><name><surname>Mlinaric-Rascan</surname><given-names>I.</given-names></name><name><surname>Derouaux</surname><given-names>A.</given-names></name><name><surname>Amoroso</surname><given-names>A.</given-names></name><name><surname>Terrak</surname><given-names>M.</given-names></name><name><surname>Breukink</surname><given-names>E.</given-names></name><name><surname>Gobec</surname><given-names>S.</given-names></name></person-group>
<article-title>Structure-activity relationships of novel tryptamine-based inhibitors of bacterial transglycosylase</article-title>
<source>J. Med. Chem.</source>
<year>2015</year>
<pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b01482</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig id="antibiotics-05-00012-f001" position="float"><label>Figure 1</label><caption><p>Schematic representation of the glycosyltransferase and transpeptidase reactions catalyzed by penicillin-binding proteins.</p></caption><graphic xlink:href="antibiotics-05-00012-g001"/></fig><fig id="antibiotics-05-00012-f002" position="float"><label>Figure 2</label><caption><p>Structure of <italic>E. coli</italic> class A PBP1b [<xref rid="B34-antibiotics-05-00012" ref-type="bibr">34</xref>], class B PBP3 [<xref rid="B32-antibiotics-05-00012" ref-type="bibr">32</xref>], class C PBP4 [<xref rid="B35-antibiotics-05-00012" ref-type="bibr">35</xref>], and class C PBP5 [<xref rid="B36-antibiotics-05-00012" ref-type="bibr">36</xref>]. The TP domains are shown with brown helices and orange strands, the red sphere indicating the position of the active site serine. The PBP1b GT domain is shown with helices colored in lime green and strands in brick color. The GT catalytic centre (Glu233) is shown with a pink sphere.</p></caption><graphic xlink:href="antibiotics-05-00012-g002"/></fig><fig id="antibiotics-05-00012-f003" position="float"><label>Figure 3</label><caption><p>Structures of transpeptidase inhibitors.</p></caption><graphic xlink:href="antibiotics-05-00012-g003"/></fig><fig id="antibiotics-05-00012-f004" position="float"><label>Figure 4</label><caption><p>Superimposition of two structures of <italic>S. aureus</italic> MtgA, PDB 3VMR (yellow) and PDB 3HZS (red). Moenomycin (green) bound to the donor site and a lipid II analog (cyan) bound to the acceptor site are represented in stick. The mobile region between the two sites is highlighted by a circle.</p></caption><graphic xlink:href="antibiotics-05-00012-g004"/></fig><fig id="antibiotics-05-00012-f005" position="float"><label>Figure 5</label><caption><p>Structures of the lipid II substrate and the glycosyltransferase inhibitor moenomycin A and their recent synthetic analogs shown to inhibit GT activity. The compounds are numbered as in the original papers and the references are indicated in square brackets.</p></caption><graphic xlink:href="antibiotics-05-00012-g005"/></fig><fig id="antibiotics-05-00012-f006" position="float"><label>Figure 6</label><caption><p>Structures of small molecule inhibitors of glycosyltrasferases. The compounds are numbered as in the original papers and the references are indicated in square brackets.</p></caption><graphic xlink:href="antibiotics-05-00012-g006"/></fig></floats-group></article>